US20220249482A1 - N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer - Google Patents
N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer Download PDFInfo
- Publication number
- US20220249482A1 US20220249482A1 US17/675,917 US202217675917A US2022249482A1 US 20220249482 A1 US20220249482 A1 US 20220249482A1 US 202217675917 A US202217675917 A US 202217675917A US 2022249482 A1 US2022249482 A1 US 2022249482A1
- Authority
- US
- United States
- Prior art keywords
- amino
- phenyl
- cancer
- pyrimidin
- methanesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 63
- 201000011510 cancer Diseases 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000011282 treatment Methods 0.000 title abstract description 24
- 230000002265 prevention Effects 0.000 title abstract description 18
- 239000004480 active ingredient Substances 0.000 title abstract description 17
- GKFFFOLFBJUEFN-UHFFFAOYSA-N 2-n,4-n-diphenylpyrimidine-2,4-diamine Chemical class C=1C=NC(NC=2C=CC=CC=2)=NC=1NC1=CC=CC=C1 GKFFFOLFBJUEFN-UHFFFAOYSA-N 0.000 title abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 13
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract description 103
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 103
- 230000035772 mutation Effects 0.000 claims abstract description 80
- 150000001875 compounds Chemical class 0.000 claims description 194
- 102000001301 EGF receptor Human genes 0.000 claims description 110
- 108060006698 EGF receptor Proteins 0.000 claims description 110
- 102200048955 rs121434569 Human genes 0.000 claims description 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- 229960005395 cetuximab Drugs 0.000 claims description 23
- -1 KIT Proteins 0.000 claims description 21
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 19
- 102200048928 rs121434568 Human genes 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 17
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 230000003287 optical effect Effects 0.000 claims description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- FJMLHLTVDMXQCW-UHFFFAOYSA-N N-[2-[[5-chloro-2-(2-methoxy-4-piperidin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(C2CCNCC2)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 FJMLHLTVDMXQCW-UHFFFAOYSA-N 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 230000001394 metastastic effect Effects 0.000 claims description 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- WJFFUIAWNSBALS-UHFFFAOYSA-N N-[2-[[2-(2-methoxy-4-piperazin-1-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound C1(=C(C=C(C=C1)N1CCNCC1)OC)NC1=NC(=C(C=N1)C(F)(F)F)NC1=C(NS(=O)(=O)C)C=CC=C1 WJFFUIAWNSBALS-UHFFFAOYSA-N 0.000 claims description 6
- BJALMMZJUQUAAE-UHFFFAOYSA-N N-[2-[[2-[4-[4-(4-acetylpiperazin-1-yl)piperidin-1-yl]-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C(C)=O)OC BJALMMZJUQUAAE-UHFFFAOYSA-N 0.000 claims description 6
- NAJORFDAFHFDAE-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCC(CC1)N(C)C)OC NAJORFDAFHFDAE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- OCGGJNKPTJNJDM-UHFFFAOYSA-N 5-bromo-2-(2-methoxy-4-piperazin-1-ylanilino)-4-[2-(sulfamoylamino)anilino]pyrimidine Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCNCC1)OC)NC1=C(C=CC=C1)NS(N)(=O)=O OCGGJNKPTJNJDM-UHFFFAOYSA-N 0.000 claims description 5
- BMBZARJFOWASOK-UHFFFAOYSA-N 5-bromo-2-(2-methoxy-4-piperidin-4-ylanilino)-4-[2-(sulfamoylamino)anilino]pyrimidine Chemical compound BrC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCNCC1)OC)NC1=C(C=CC=C1)NS(N)(=O)=O BMBZARJFOWASOK-UHFFFAOYSA-N 0.000 claims description 5
- VOZRIRJNGNHIST-UHFFFAOYSA-N 5-chloro-2-(2-methoxy-4-piperazin-1-ylanilino)-4-[2-(sulfamoylamino)anilino]pyrimidine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCNCC1)OC)NC1=C(C=CC=C1)NS(N)(=O)=O VOZRIRJNGNHIST-UHFFFAOYSA-N 0.000 claims description 5
- KYBURVUSHWYVCL-UHFFFAOYSA-N 5-chloro-2-(2-methoxy-4-piperidin-4-ylanilino)-4-[2-(sulfamoylamino)anilino]pyrimidine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCNCC1)OC)NC1=C(C=CC=C1)NS(N)(=O)=O KYBURVUSHWYVCL-UHFFFAOYSA-N 0.000 claims description 5
- CLGWUCNXOBLWFM-UHFFFAOYSA-N CZC-25146 Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1NS(C)(=O)=O CLGWUCNXOBLWFM-UHFFFAOYSA-N 0.000 claims description 5
- SGUQSUILSYWLIQ-UHFFFAOYSA-N N-[2-[[2-(2-methoxy-4-piperidin-4-ylanilino)-5-methylpyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1C)NC1=C(C=C(C=C1)C1CCNCC1)OC SGUQSUILSYWLIQ-UHFFFAOYSA-N 0.000 claims description 5
- WRXVQCLYNNRXNO-UHFFFAOYSA-N N-[2-[[2-(2-methoxy-4-piperidin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1)NC1=C(C=C(C=C1)C1CCNCC1)OC WRXVQCLYNNRXNO-UHFFFAOYSA-N 0.000 claims description 5
- ODBFMVYBQSBSGU-UHFFFAOYSA-N N-[2-[[2-[4-(4-aminopiperidin-1-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound C1(=C(C=C(C=C1)N1CCC(CC1)N)OC)NC1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 ODBFMVYBQSBSGU-UHFFFAOYSA-N 0.000 claims description 5
- VAANZFXFCPBDJN-UHFFFAOYSA-N N-[2-[[5-bromo-2-(2-methoxy-4-piperidin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound O(C)C1=C(NC2=NC(=C(C=N2)Br)NC2=C(NS(=O)(=O)C)C=CC=C2)C=CC(C2CCNCC2)=C1 VAANZFXFCPBDJN-UHFFFAOYSA-N 0.000 claims description 5
- OAMFBPFNPBIRSI-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(1-methylpiperidin-4-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(C2CCN(CC2)C)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 OAMFBPFNPBIRSI-UHFFFAOYSA-N 0.000 claims description 5
- NBDBQWQCAHCHKG-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(4-piperazin-1-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)N1CCC(CC1)N1CCNCC1)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 NBDBQWQCAHCHKG-UHFFFAOYSA-N 0.000 claims description 5
- MPISIZFSGAZROV-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC MPISIZFSGAZROV-UHFFFAOYSA-N 0.000 claims description 5
- VPDQSKQSKQMWOI-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-[4-(methylamino)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(N2CCC(CC2)NC)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 VPDQSKQSKQMWOI-UHFFFAOYSA-N 0.000 claims description 5
- HAHYBCMZKYAKPL-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-[1-(2-hydroxyethyl)piperidin-4-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)C1CCN(CC1)CCO)OC HAHYBCMZKYAKPL-UHFFFAOYSA-N 0.000 claims description 5
- AQOBZRDHNGYBNF-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-[1-[1-(2-hydroxyethyl)piperidin-4-yl]piperidin-4-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)C1CCN(CC1)C1CCN(CC1)CCO)OC AQOBZRDHNGYBNF-UHFFFAOYSA-N 0.000 claims description 5
- ZNOQPCJDZQZAIC-UHFFFAOYSA-N N-[2-[[5-methoxy-2-(2-methoxy-4-piperidin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(C2CCNCC2)C=C1OC)C1=NC(=C(OC)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 ZNOQPCJDZQZAIC-UHFFFAOYSA-N 0.000 claims description 5
- WMYXHXVJYBMKDM-UHFFFAOYSA-N [2-[[5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]phenyl]sulfamoylcarbamic acid Chemical compound CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5NS(=O)(=O)NC(=O)O)Cl)OC WMYXHXVJYBMKDM-UHFFFAOYSA-N 0.000 claims description 5
- ROBLKZXSKKIRJX-UHFFFAOYSA-N [2-[[5-chloro-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]sulfamoylcarbamic acid Chemical compound CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4NS(=O)(=O)NC(=O)O)Cl)OC ROBLKZXSKKIRJX-UHFFFAOYSA-N 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- TZCLDPSTOOMNDB-UHFFFAOYSA-N N-[1-[4-[[5-chloro-4-[2-(methanesulfonamido)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidin-4-yl]acetamide Chemical compound N(C1=CC=C(N2CCC(CC2)NC(=O)C)C=C1OC)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 TZCLDPSTOOMNDB-UHFFFAOYSA-N 0.000 claims description 4
- GFXBLHRLLKARCC-UHFFFAOYSA-N N-[2-[[2-[4-(1-acetylpiperidin-4-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)C1CCN(CC1)C(=O)C)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 GFXBLHRLLKARCC-UHFFFAOYSA-N 0.000 claims description 4
- YAXGAKLMDJDPLF-UHFFFAOYSA-N N-[2-[[2-[4-[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)C1CCN(CC1)C1CCN(CC1)C(=O)C)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 YAXGAKLMDJDPLF-UHFFFAOYSA-N 0.000 claims description 4
- WFXLLKTWXVMWQT-UHFFFAOYSA-N N-[2-[[2-[4-[4-(1-acetylpiperidin-4-yl)piperazin-1-yl]-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)N1CCN(CC1)C1CCN(CC1)C(=O)C)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 WFXLLKTWXVMWQT-UHFFFAOYSA-N 0.000 claims description 4
- IMPYDMBLVWLTOI-UHFFFAOYSA-N N-[2-[[5-chloro-2-(2-methoxy-4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)N1CCNCC1)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 IMPYDMBLVWLTOI-UHFFFAOYSA-N 0.000 claims description 4
- QLOZCEXTSVOFQC-UHFFFAOYSA-N N-[2-[[5-chloro-2-(2-methoxy-5-methyl-4-piperidin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C(C)=C1)C1CCNCC1)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 QLOZCEXTSVOFQC-UHFFFAOYSA-N 0.000 claims description 4
- ATHZZWBANOJUOA-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound C1(=C(C=C(C=C1)N1CCN(CC1)C)OC)NC1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 ATHZZWBANOJUOA-UHFFFAOYSA-N 0.000 claims description 4
- ZDVUGMNGSNJJHP-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(4-morpholin-4-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(N2CCC(N3CCOCC3)CC2)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 ZDVUGMNGSNJJHP-UHFFFAOYSA-N 0.000 claims description 4
- STIHECNZUQAXIG-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(4-piperidin-4-ylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(N2CCN(CC2)C2CCNCC2)C=C1)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 STIHECNZUQAXIG-UHFFFAOYSA-N 0.000 claims description 4
- HOMBUEPXSDZARQ-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(N2CCC(N3CCCC3)CC2)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 HOMBUEPXSDZARQ-UHFFFAOYSA-N 0.000 claims description 4
- IYRAVFSBUZWXNC-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)C1CCN(CC1)C1CCN(CC1)C)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 IYRAVFSBUZWXNC-UHFFFAOYSA-N 0.000 claims description 4
- LDFKKQRRCNWVQN-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)N1CCN(CC1)C1CCN(CC1)C)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 LDFKKQRRCNWVQN-UHFFFAOYSA-N 0.000 claims description 4
- WFHKANLTOXOHFH-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-[4-(2-methoxyethylamino)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(N2CCC(NCCOC)CC2)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 WFHKANLTOXOHFH-UHFFFAOYSA-N 0.000 claims description 4
- DCXDPULBNSHOAG-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-[4-(2-hydroxyethylamino)piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(N2CCC(NCCO)CC2)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 DCXDPULBNSHOAG-UHFFFAOYSA-N 0.000 claims description 4
- CTUYJNXFAUWSJB-BGYRXZFFSA-N N-[2-[[5-chloro-2-[4-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCC(CC1)N1C[C@H](N[C@H](C1)C)C)OC CTUYJNXFAUWSJB-BGYRXZFFSA-N 0.000 claims description 4
- NJEOVELELZRZAG-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-[4-[2-(dimethylamino)ethylamino]piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=CC=C(N2CCC(NCCN(C)C)CC2)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 NJEOVELELZRZAG-UHFFFAOYSA-N 0.000 claims description 4
- KRXROXSPQRVKGS-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-[4-[4-(2-hydroxyethyl)piperazin-1-yl]piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(N2CCC(CC2)N2CCN(CC2)CCO)C=C1)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 KRXROXSPQRVKGS-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- UBIQSIHMZZCANG-UHFFFAOYSA-N tert-butyl 4-[4-[4-[[5-chloro-4-[2-(methanesulfonamido)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]piperidine-1-carboxylate Chemical compound N(C1=C(OC)C=C(N2CCN(CC2)C2CCN(CC2)C(=O)OC(C)(C)C)C=C1)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)C)C=CC=C1 UBIQSIHMZZCANG-UHFFFAOYSA-N 0.000 claims description 4
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010007281 Carcinoid tumour of the stomach Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010061825 Duodenal neoplasm Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 3
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims description 3
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 claims description 3
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims description 3
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010062038 Lip neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- DTZKMEPLXTWROE-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(1-piperidin-4-ylpiperidin-4-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound N(C1=C(OC)C=C(C=C1)C1CCN(CC1)C1CCNCC1)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 DTZKMEPLXTWROE-UHFFFAOYSA-N 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 206010054184 Small intestine carcinoma Diseases 0.000 claims description 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
- 206010046392 Ureteric cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 208000004064 acoustic neuroma Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000000312 duodenum cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 201000011587 gastric lymphoma Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010235 heart cancer Diseases 0.000 claims description 3
- 208000024348 heart neoplasm Diseases 0.000 claims description 3
- 208000006359 hepatoblastoma Diseases 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000006721 lip cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 201000003175 male breast cancer Diseases 0.000 claims description 3
- 208000010907 male breast carcinoma Diseases 0.000 claims description 3
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 201000000349 mediastinal cancer Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000009612 pediatric lymphoma Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 201000003437 pleural cancer Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 208000017901 rectal neuroendocrine tumor G1 Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011096 spinal cancer Diseases 0.000 claims description 3
- 208000014618 spinal cord cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 3
- KZZLHIQRHCJDBY-UHFFFAOYSA-N tert-butyl 4-[1-[4-[[5-chloro-4-[2-(methanesulfonamido)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidin-4-yl]piperazine-1-carboxylate Chemical compound N(C1=C(OC)C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C(=O)OC(C)(C)C)C1=NC(=C(Cl)C=N1)NC1=C(NS(=O)(=O)C)C=CC=C1 KZZLHIQRHCJDBY-UHFFFAOYSA-N 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 14
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 229910003827 NRaRb Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 38
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 description 123
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 77
- 238000005160 1H NMR spectroscopy Methods 0.000 description 75
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 62
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 61
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
- 239000000203 mixture Substances 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 32
- 239000003814 drug Substances 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- 0 [1*]S(=O)(=O)Cc1ccccc1Nc1nc(Nc2cc([3*])c(C)cc2O[4*])ncc1[2*] Chemical compound [1*]S(=O)(=O)Cc1ccccc1Nc1nc(Nc2cc([3*])c(C)cc2O[4*])ncc1[2*] 0.000 description 23
- 239000007787 solid Substances 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 229910001868 water Inorganic materials 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 230000003833 cell viability Effects 0.000 description 16
- 230000036541 health Effects 0.000 description 16
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 229950004272 brigatinib Drugs 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000002253 acid Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- NNPPMTNAJDCUHE-UHFFFAOYSA-N CC(C)C Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 235000013376 functional food Nutrition 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 7
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- YLNRCLFODARCHN-UHFFFAOYSA-N n-[2-[(2,5-dichloropyrimidin-4-yl)amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl YLNRCLFODARCHN-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 4
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 4
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 4
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
- 229940077388 benzenesulfonate Drugs 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- 239000004210 ether based solvent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 229940049920 malate Drugs 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 4
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 4
- 229940049953 phenylacetate Drugs 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 229950009215 phenylbutanoic acid Drugs 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 230000001235 sensitizing effect Effects 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- IWKHHOSJKSVLCT-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate Chemical compound C1=C(N)C(OC)=CC(C2CCN(CC2)C(=O)OC(C)(C)C)=C1 IWKHHOSJKSVLCT-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940071104 xylenesulfonate Drugs 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- BRRNUXSNANEKEO-UHFFFAOYSA-N 4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxyaniline Chemical compound C1=C(N)C(OC)=CC(N2CCC3(CC2)OCCO3)=C1 BRRNUXSNANEKEO-UHFFFAOYSA-N 0.000 description 3
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 3
- XDYQILYENWMGAA-UHFFFAOYSA-N 8-(3-methoxy-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC3(CC2)OCCO3)=C1 XDYQILYENWMGAA-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IOKIPRUVARDNST-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1 IOKIPRUVARDNST-UHFFFAOYSA-N 0.000 description 3
- SGDDUBYNWHPHMO-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.Cc1cnc(Cl)nc1Nc1ccccc1CS(C)(=O)=O Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.Cc1cnc(Cl)nc1Nc1ccccc1CS(C)(=O)=O SGDDUBYNWHPHMO-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- IYYADOWCGHWEDH-UHFFFAOYSA-N N-[2-[[5-chloro-2-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCC2(OCCO2)CC1)OC)NC1=C(C=CC=C1)NS(=O)(=O)C IYYADOWCGHWEDH-UHFFFAOYSA-N 0.000 description 3
- OUHIAKNHAJQWNR-UHFFFAOYSA-N NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCOCC1)OC Chemical compound NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCOCC1)OC OUHIAKNHAJQWNR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229960003278 osimertinib Drugs 0.000 description 3
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- YCGQMVSKEKKWCT-UHFFFAOYSA-N tert-butyl 4-[4-[[4-(2-aminoanilino)-5-chloropyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-1-carboxylate Chemical compound NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)C1CCN(CC1)C(=O)OC(C)(C)C)OC YCGQMVSKEKKWCT-UHFFFAOYSA-N 0.000 description 3
- BPAGZVKXKUJJAP-UHFFFAOYSA-N tert-butyl 4-[4-[[5-chloro-4-(2-nitroanilino)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-1-carboxylate Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)C1CCN(CC1)C(=O)OC(C)(C)C)OC)NC1=C(C=CC=C1)[N+](=O)[O-] BPAGZVKXKUJJAP-UHFFFAOYSA-N 0.000 description 3
- HJKNHVRQUQFMPT-UHFFFAOYSA-N tert-butyl 4-[4-[[5-chloro-4-[2-[(2-methylpropan-2-yl)oxycarbonylsulfamoylamino]anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)C1CCN(CC1)C(=O)OC(C)(C)C)OC HJKNHVRQUQFMPT-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- PZVSRJZDEMTYLK-UHFFFAOYSA-N 1-(3-methoxy-4-nitrophenyl)-n,n-dimethylpiperidin-4-amine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC(CC2)N(C)C)=C1 PZVSRJZDEMTYLK-UHFFFAOYSA-N 0.000 description 2
- STOCRCLYMPKTEC-UHFFFAOYSA-N 1-(4-amino-3-methoxyphenyl)-n,n-dimethylpiperidin-4-amine Chemical compound C1=C(N)C(OC)=CC(N2CCC(CC2)N(C)C)=C1 STOCRCLYMPKTEC-UHFFFAOYSA-N 0.000 description 2
- OFRMASLPWOMYHN-UHFFFAOYSA-N 1-[3-methoxy-4-[[6-(2-propan-2-ylsulfonylanilino)-7H-purin-2-yl]amino]phenyl]piperidin-4-ol Chemical group COc1cc(ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2[nH]cnc2n1)N1CCC(O)CC1 OFRMASLPWOMYHN-UHFFFAOYSA-N 0.000 description 2
- XIPWYJVUFSUEOD-UHFFFAOYSA-N 2-[4-(4-amino-3-methoxyphenyl)piperidin-1-yl]ethyl acetate Chemical compound C1(OC)=C(N)C=CC(C2CCN(CC2)CCOC(=O)C)=C1 XIPWYJVUFSUEOD-UHFFFAOYSA-N 0.000 description 2
- ZSOOICWRUHUCRR-UHFFFAOYSA-N 2-[4-[4-(4-amino-3-methoxyphenyl)piperidin-1-yl]piperidin-1-yl]ethyl acetate Chemical compound NC1=CC=C(C2CCN(CC2)C2CCN(CC2)CCOC(=O)C)C=C1OC ZSOOICWRUHUCRR-UHFFFAOYSA-N 0.000 description 2
- YAMGYZKPMODVIX-UHFFFAOYSA-N 2-methoxy-4-(1-methylpiperidin-4-yl)aniline Chemical compound C1=C(N)C(OC)=CC(C2CCN(C)CC2)=C1 YAMGYZKPMODVIX-UHFFFAOYSA-N 0.000 description 2
- BNEFAEMCPOUQPF-UHFFFAOYSA-N 4-N-(2-aminophenyl)-5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound C1(Cl)=C(N=C(N=C1)NC1=CC=C(N2CC[C@H](N3CCN(CC3)C)CC2)C=C1OC)NC1=CC=CC=C1N BNEFAEMCPOUQPF-UHFFFAOYSA-N 0.000 description 2
- BRLZIJUMYJEWOO-UHFFFAOYSA-N 4-N-(2-aminophenyl)-5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]pyrimidine-2,4-diamine Chemical compound O(C)C1=C(NC2=NC(=C(Cl)C=N2)NC2=C(N)C=CC=C2)C=CC(N2CCC(CC2)N(C)C)=C1 BRLZIJUMYJEWOO-UHFFFAOYSA-N 0.000 description 2
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 2
- AXCUBDZAOCNSKR-UHFFFAOYSA-N 5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-nitrophenyl)pyrimidine-2,4-diamine Chemical compound N(C1=CC=C(N2CCC(CC2)N2CCN(CC2)C)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(N(=O)=O)C=CC=C1 AXCUBDZAOCNSKR-UHFFFAOYSA-N 0.000 description 2
- AXGKAJDIZNOZFP-UHFFFAOYSA-N 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-nitrophenyl)pyrimidine-2,4-diamine Chemical compound N(C1=CC=C(N2CCC(CC2)N(C)C)C=C1OC)C1=NC(=C(Cl)C=N1)NC1=C(N(=O)=O)C=CC=C1 AXGKAJDIZNOZFP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- JKMVNVDEZOBEEC-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCOCC1)OC)NC1=C(C=CC=C1)[N+](=O)[O-] Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCOCC1)OC)NC1=C(C=CC=C1)[N+](=O)[O-] JKMVNVDEZOBEEC-UHFFFAOYSA-N 0.000 description 2
- 229910020323 ClF3 Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000003749 KINOMEscan Methods 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- CEMYNXIJZMEHGQ-UHFFFAOYSA-N N-[2-[(2-chloro-5-methoxypyrimidin-4-yl)amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1OC)Cl CEMYNXIJZMEHGQ-UHFFFAOYSA-N 0.000 description 2
- RHEYEGYRLXRYEZ-UHFFFAOYSA-N N-[2-[[2-(2-methoxy-4-piperidin-4-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound C1(=C(OC)C=C(C=C1)C1CCNCC1)NC1=NC(=C(C=N1)C(F)(F)F)NC1=C(NS(=O)(=O)C)C=CC=C1 RHEYEGYRLXRYEZ-UHFFFAOYSA-N 0.000 description 2
- PZUSGJSWIAGQIP-UHFFFAOYSA-N N-[2-[[5-chloro-2-[2-methoxy-4-(4-oxopiperidin-1-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound C1(OC)=C(NC2=NC(=C(C=N2)Cl)NC2=C(NS(=O)(=O)C)C=CC=C2)C=CC(N2CCC(=O)CC2)=C1 PZUSGJSWIAGQIP-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- IAOXZLAUYRRAPL-UHFFFAOYSA-N n-[2-[(2-chloro-5-methylpyrimidin-4-yl)amino]phenyl]methanesulfonamide Chemical compound CC1=CN=C(Cl)N=C1NC1=CC=CC=C1NS(C)(=O)=O IAOXZLAUYRRAPL-UHFFFAOYSA-N 0.000 description 2
- JTEPJYFSTBIBKE-UHFFFAOYSA-N n-[2-[(2-chloropyrimidin-4-yl)amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1NC1=CC=NC(Cl)=N1 JTEPJYFSTBIBKE-UHFFFAOYSA-N 0.000 description 2
- XBYQJSWVVIKANG-UHFFFAOYSA-N n-[2-[(5-bromo-2-chloropyrimidin-4-yl)amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1NC1=NC(Cl)=NC=C1Br XBYQJSWVVIKANG-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- AGDVHTFXQBURDM-UHFFFAOYSA-N tert-butyl 4-[4-[[4-(2-aminoanilino)-5-bromopyrimidin-2-yl]amino]-3-methoxyphenyl]piperazine-1-carboxylate Chemical compound NC1=C(C=CC=C1)NC1=NC(=NC=C1Br)NC1=C(C=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C)OC AGDVHTFXQBURDM-UHFFFAOYSA-N 0.000 description 2
- SAKNXDACNXIMKU-UHFFFAOYSA-N tert-butyl 4-[4-[[4-(2-aminoanilino)-5-bromopyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-1-carboxylate Chemical compound N(C1=C(C=C(C2CCN(C(=O)OC(C)(C)C)CC2)C=C1)OC)C1=NC(=C(C=N1)Br)NC1=C(N)C=CC=C1 SAKNXDACNXIMKU-UHFFFAOYSA-N 0.000 description 2
- GPJKVESIEDMGHY-UHFFFAOYSA-N tert-butyl 4-[4-[[4-(2-aminoanilino)-5-chloropyrimidin-2-yl]amino]-3-methoxyphenyl]piperazine-1-carboxylate Chemical compound NC1=C(C=CC=C1)NC1=NC(=NC=C1Cl)NC1=C(C=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C)OC GPJKVESIEDMGHY-UHFFFAOYSA-N 0.000 description 2
- BIRXSTUAYPDEHD-UHFFFAOYSA-N tert-butyl 4-[4-[[5-bromo-4-(2-nitroanilino)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazine-1-carboxylate Chemical compound C1(=C(C=C(C=C1)N1CCN(C(=O)OC(C)(C)C)CC1)OC)NC1=NC(=C(C=N1)Br)NC1=C(N(=O)=O)C=CC=C1 BIRXSTUAYPDEHD-UHFFFAOYSA-N 0.000 description 2
- DFPPRPQZSUQLHR-UHFFFAOYSA-N tert-butyl 4-[4-[[5-bromo-4-(2-nitroanilino)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-1-carboxylate Chemical compound N(C1=CC=C(C2CCN(C(=O)OC(C)(C)C)CC2)C=C1OC)C1=NC(=C(Br)C=N1)NC1=C(N(=O)=O)C=CC=C1 DFPPRPQZSUQLHR-UHFFFAOYSA-N 0.000 description 2
- SWAFAJYITUOOAK-UHFFFAOYSA-N tert-butyl 4-[4-[[5-bromo-4-[2-[(2-methylpropan-2-yl)oxycarbonylsulfamoylamino]anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazine-1-carboxylate Chemical compound O(C)C1=C(NC2=NC(=C(Br)C=N2)NC2=C(NS(=O)(=O)NC(=O)OC(C)(C)C)C=CC=C2)C=CC(N2CCN(C(=O)OC(C)(C)C)CC2)=C1 SWAFAJYITUOOAK-UHFFFAOYSA-N 0.000 description 2
- ZPSUOZCTWZPRCZ-UHFFFAOYSA-N tert-butyl 4-[4-[[5-bromo-4-[2-[(2-methylpropan-2-yl)oxycarbonylsulfamoylamino]anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-1-carboxylate Chemical compound C1(=C(OC)C=C(C=C1)C1CCN(C(=O)OC(C)(C)C)CC1)NC1=NC(=C(C=N1)Br)NC1=C(NS(=O)(=O)NC(=O)OC(C)(C)C)C=CC=C1 ZPSUOZCTWZPRCZ-UHFFFAOYSA-N 0.000 description 2
- MEPFOSKGMUPWJS-UHFFFAOYSA-N tert-butyl 4-[4-[[5-chloro-4-(2-nitroanilino)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazine-1-carboxylate Chemical compound C1(=C(OC)C=C(C=C1)N1CCN(C(=O)OC(C)(C)C)CC1)NC1=NC(=C(C=N1)Cl)NC1=C(N(=O)=O)C=CC=C1 MEPFOSKGMUPWJS-UHFFFAOYSA-N 0.000 description 2
- MMPLCZXWKNXOMG-UHFFFAOYSA-N tert-butyl 4-[4-[[5-chloro-4-[2-[(2-methylpropan-2-yl)oxycarbonylsulfamoylamino]anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazine-1-carboxylate Chemical compound C1(=C(C=C(C=C1)N1CCN(C(=O)OC(C)(C)C)CC1)OC)NC1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)NC(=O)OC(C)(C)C)C=CC=C1 MMPLCZXWKNXOMG-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- HMZSSVSGZFQLHH-UHFFFAOYSA-N tert-butyl N-[1-(4-amino-3-methoxyphenyl)piperidin-4-yl]-N-methylcarbamate Chemical compound C1=C(N)C(OC)=CC(N2CCC(CC2)N(C)C(=O)OC(C)(C)C)=C1 HMZSSVSGZFQLHH-UHFFFAOYSA-N 0.000 description 2
- GYBCQJWEYHJPAQ-UHFFFAOYSA-N tert-butyl N-[[2-[[5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]phenyl]sulfamoyl]carbamate Chemical compound N(C1=CC=C(N2CCC(CC2)N2CCN(CC2)C)C=C1OC)C1=NC(=C(C=N1)Cl)NC1=C(NS(=O)(=O)NC(=O)OC(C)(C)C)C=CC=C1 GYBCQJWEYHJPAQ-UHFFFAOYSA-N 0.000 description 2
- HHMYAFHZBTWYOU-UHFFFAOYSA-N tert-butyl N-[[2-[[5-chloro-2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]phenyl]sulfamoyl]carbamate Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C=C1)N1CCC(CC1)N(C)C)OC)NC1=C(C=CC=C1)NS(=O)(=O)NC(OC(C)(C)C)=O HHMYAFHZBTWYOU-UHFFFAOYSA-N 0.000 description 2
- WJGXUQWOEIKACI-UHFFFAOYSA-N tert-butyl n-[1-(3-methoxy-4-nitrophenyl)piperidin-4-yl]-n-methylcarbamate Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC(CC2)N(C)C(=O)OC(C)(C)C)=C1 WJGXUQWOEIKACI-UHFFFAOYSA-N 0.000 description 2
- UTONXENUMXLKRA-UHFFFAOYSA-N tert-butyl n-[1-(3-methoxy-4-nitrophenyl)piperidin-4-yl]carbamate Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC(CC2)NC(=O)OC(C)(C)C)=C1 UTONXENUMXLKRA-UHFFFAOYSA-N 0.000 description 2
- ZZGVFYRZUYTWHJ-UHFFFAOYSA-N tert-butyl n-[1-(4-amino-3-methoxyphenyl)piperidin-4-yl]carbamate Chemical compound C1=C(N)C(OC)=CC(N2CCC(CC2)NC(=O)OC(C)(C)C)=C1 ZZGVFYRZUYTWHJ-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- ZDHUOHXJOTTYGN-UHFFFAOYSA-N 2,5-dichloro-N-(2-nitrophenyl)pyrimidin-4-amine Chemical compound C1(Cl)=C(NC2=C(N(=O)=O)C=CC=C2)N=C(N=C1)Cl ZDHUOHXJOTTYGN-UHFFFAOYSA-N 0.000 description 1
- HHYWBYQFVVVMDV-UHFFFAOYSA-N 2-[4-[4-(4-amino-3-methoxyphenyl)-3,6-dihydro-2H-pyridin-1-yl]piperidin-1-yl]ethyl acetate Chemical compound C(C)(=O)OCCN1CCC(CC1)N1CCC(=CC1)C1=CC(=C(C=C1)N)OC HHYWBYQFVVVMDV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 1
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- OXGIDQZERSLESF-UHFFFAOYSA-N 4-(3-methoxy-4-nitrophenyl)-1,2,3,6-tetrahydropyridine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(C=2CCNCC=2)=C1 OXGIDQZERSLESF-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- MXYHDEBQHQRVMA-UHFFFAOYSA-N C.CC(C)C.CC(C)C1CCCCC1 Chemical compound C.CC(C)C.CC(C)C1CCCCC1 MXYHDEBQHQRVMA-UHFFFAOYSA-N 0.000 description 1
- UGRKJFPLJFYGPZ-UHFFFAOYSA-N CC(C)C.CC(C)C1CCCCC1 Chemical compound CC(C)C.CC(C)C1CCCCC1 UGRKJFPLJFYGPZ-UHFFFAOYSA-N 0.000 description 1
- OLPKIXDYVSIHFE-UHFFFAOYSA-N CCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4CS(C)(=O)=O)n3)c(OC)c2)CC1 Chemical compound CCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4CS(C)(=O)=O)n3)c(OC)c2)CC1 OLPKIXDYVSIHFE-UHFFFAOYSA-N 0.000 description 1
- ZGPQWSRWQSLBBR-UHFFFAOYSA-N CCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4CS(C)(=O)=O)n3)c(OC)c2)CC1.COc1cc(F)ccc1[N+](=O)[O-].COc1cc(N2CCC(N(C)C(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(N2CCC(N(C)C(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-] Chemical compound CCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4CS(C)(=O)=O)n3)c(OC)c2)CC1.COc1cc(F)ccc1[N+](=O)[O-].COc1cc(N2CCC(N(C)C(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(N2CCC(N(C)C(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-] ZGPQWSRWQSLBBR-UHFFFAOYSA-N 0.000 description 1
- AZPUYUVONHTYKA-UHFFFAOYSA-N COCCCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4CS(C)(=O)=O)n3)c(OC)c2)CC1 Chemical compound COCCCC1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4CS(C)(=O)=O)n3)c(OC)c2)CC1 AZPUYUVONHTYKA-UHFFFAOYSA-N 0.000 description 1
- MVHUBYSCVXJDPG-UHFFFAOYSA-N COc1cc(C2=CCN(C3CCN(C(=O)OC(C)(C)C)CC3)CC2)ccc1[N+](=O)[O-].COc1cc(C2=CCN(C3CCN(CCOC(C)=O)CC3)CC2)ccc1[N+](=O)[O-].COc1cc(C2=CCNCC2)ccc1[N+](=O)[O-].COc1cc(C2CCN(C3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(C3CCN(CCOC(C)=O)CC3)CC2)ccc1N Chemical compound COc1cc(C2=CCN(C3CCN(C(=O)OC(C)(C)C)CC3)CC2)ccc1[N+](=O)[O-].COc1cc(C2=CCN(C3CCN(CCOC(C)=O)CC3)CC2)ccc1[N+](=O)[O-].COc1cc(C2=CCNCC2)ccc1[N+](=O)[O-].COc1cc(C2CCN(C3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(C3CCN(CCOC(C)=O)CC3)CC2)ccc1N MVHUBYSCVXJDPG-UHFFFAOYSA-N 0.000 description 1
- YJRCAJCROQQRSD-UHFFFAOYSA-N COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(C2CCN(C)CC2)ccc1N.COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(C2CCN(C)CC2)ccc1N.COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 YJRCAJCROQQRSD-UHFFFAOYSA-N 0.000 description 1
- FVBLYFPFGYDCSM-UHFFFAOYSA-N COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(C2CCN(CCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(CCOC(C)=O)CC2)ccc1N Chemical compound COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(C2CCN(CCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(CCOC(C)=O)CC2)ccc1N FVBLYFPFGYDCSM-UHFFFAOYSA-N 0.000 description 1
- FSIZFPUDKFUOBT-UHFFFAOYSA-N COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2N)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Br Chemical compound COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2N)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Br FSIZFPUDKFUOBT-UHFFFAOYSA-N 0.000 description 1
- LPBOGQOIWPMBCA-UHFFFAOYSA-N COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2N)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(N2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Br Chemical compound COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2N)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Br)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(N2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Br LPBOGQOIWPMBCA-UHFFFAOYSA-N 0.000 description 1
- DQVFDFKATLRYNA-UHFFFAOYSA-N COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl Chemical compound COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl DQVFDFKATLRYNA-UHFFFAOYSA-N 0.000 description 1
- RAPHDHWTGRJBNO-UHFFFAOYSA-N COc1cc(C2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 RAPHDHWTGRJBNO-UHFFFAOYSA-N 0.000 description 1
- GONSUZYGOCFOJX-UHFFFAOYSA-N COc1cc(C2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 GONSUZYGOCFOJX-UHFFFAOYSA-N 0.000 description 1
- GIWKTZWDZNWHNY-UHFFFAOYSA-N COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 GIWKTZWDZNWHNY-UHFFFAOYSA-N 0.000 description 1
- JVIVETSXTLMODJ-UHFFFAOYSA-N COc1cc(C2CCN(C3CCN(C(C)=O)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C3CCN(C(C)=O)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 JVIVETSXTLMODJ-UHFFFAOYSA-N 0.000 description 1
- MCXMSBJZXYEITN-UHFFFAOYSA-N COc1cc(C2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 MCXMSBJZXYEITN-UHFFFAOYSA-N 0.000 description 1
- GCBVVTLZTZRVPQ-UHFFFAOYSA-N COc1cc(C2CCN(C3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 GCBVVTLZTZRVPQ-UHFFFAOYSA-N 0.000 description 1
- RHZCEDORMGEGBS-UHFFFAOYSA-N COc1cc(C2CCN(C3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(C3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 RHZCEDORMGEGBS-UHFFFAOYSA-N 0.000 description 1
- JKBKOIOEFVYUOK-UHFFFAOYSA-N COc1cc(C2CCN(CCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCN(CCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 JKBKOIOEFVYUOK-UHFFFAOYSA-N 0.000 description 1
- RNOIRLKSWGDGDG-UHFFFAOYSA-N COc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 RNOIRLKSWGDGDG-UHFFFAOYSA-N 0.000 description 1
- ZQPSJLCDFXQTPC-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1 ZQPSJLCDFXQTPC-UHFFFAOYSA-N 0.000 description 1
- XGYVCNZZJDOPOY-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.CS(=O)(=O)Cc1ccccc1Nc1nc(Cl)ncc1Br Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.CS(=O)(=O)Cc1ccccc1Nc1nc(Cl)ncc1Br XGYVCNZZJDOPOY-UHFFFAOYSA-N 0.000 description 1
- MKTZBWJEKUAZNY-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1 MKTZBWJEKUAZNY-UHFFFAOYSA-N 0.000 description 1
- FKZJIRSVTBPGNH-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 FKZJIRSVTBPGNH-UHFFFAOYSA-N 0.000 description 1
- LRRMPQFHBDLDRF-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 LRRMPQFHBDLDRF-UHFFFAOYSA-N 0.000 description 1
- XGEPSJNPFWAJNE-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1nccc(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1nccc(Nc2ccccc2CS(C)(=O)=O)n1 XGEPSJNPFWAJNE-UHFFFAOYSA-N 0.000 description 1
- ATCJBLXQMVRDPQ-UHFFFAOYSA-N COc1cc(C2CCNCC2)ccc1Nc1nccc(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.CS(=O)(=O)Cc1ccccc1Nc1ccnc(Cl)n1 Chemical compound COc1cc(C2CCNCC2)ccc1Nc1nccc(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.CS(=O)(=O)Cc1ccccc1Nc1ccnc(Cl)n1 ATCJBLXQMVRDPQ-UHFFFAOYSA-N 0.000 description 1
- BWZUGKMZDBKCKK-UHFFFAOYSA-N COc1cc(F)ccc1[N+](=O)[O-].COc1cc(N2CCC(CC(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(N2CCC(CC(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-].COc1cc(N2CCC(CC(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(F)ccc1[N+](=O)[O-].COc1cc(N2CCC(CC(=O)OC(C)(C)C)CC2)ccc1N.COc1cc(N2CCC(CC(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-].COc1cc(N2CCC(CC(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 BWZUGKMZDBKCKK-UHFFFAOYSA-N 0.000 description 1
- BDEJDTVLHXQGEM-UHFFFAOYSA-N COc1cc(F)ccc1[N+](=O)[O-].COc1cc(N2CCC(N(C)C)CC2)ccc1N.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1[N+](=O)[O-] Chemical compound COc1cc(F)ccc1[N+](=O)[O-].COc1cc(N2CCC(N(C)C)CC2)ccc1N.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1[N+](=O)[O-] BDEJDTVLHXQGEM-UHFFFAOYSA-N 0.000 description 1
- IEENILHZYQGJQM-UHFFFAOYSA-N COc1cc(N2CCC(CC(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(CC(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 IEENILHZYQGJQM-UHFFFAOYSA-N 0.000 description 1
- NUWNMHRPIZVNEA-UHFFFAOYSA-N COc1cc(N2CCC(CCCN(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(CCCN(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 NUWNMHRPIZVNEA-UHFFFAOYSA-N 0.000 description 1
- AEDFSQUWJOUMQM-UHFFFAOYSA-N COc1cc(N2CCC(CCCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(CCCO)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 AEDFSQUWJOUMQM-UHFFFAOYSA-N 0.000 description 1
- SPPODSQUOBMPAA-UHFFFAOYSA-N COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(=O)(=O)NC(=O)OC(C)(C)C)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl Chemical compound COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(=O)(=O)NC(=O)OC(C)(C)C)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl SPPODSQUOBMPAA-UHFFFAOYSA-N 0.000 description 1
- GADFUWBKXVLULD-UHFFFAOYSA-N COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 GADFUWBKXVLULD-UHFFFAOYSA-N 0.000 description 1
- ATQFDBMMONWKRU-UHFFFAOYSA-N COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 ATQFDBMMONWKRU-UHFFFAOYSA-N 0.000 description 1
- DJZQNWNRWQPLSR-UHFFFAOYSA-N COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 DJZQNWNRWQPLSR-UHFFFAOYSA-N 0.000 description 1
- RLNVXBUHHIEULW-UHFFFAOYSA-N COc1cc(N2CCC(N3CC(C)NC(C)C3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CC(C)NC(C)C3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 RLNVXBUHHIEULW-UHFFFAOYSA-N 0.000 description 1
- CXBGALNSQMIMQB-UHFFFAOYSA-N COc1cc(N2CCC(N3CCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 CXBGALNSQMIMQB-UHFFFAOYSA-N 0.000 description 1
- KHHJNOAKQGLDQT-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(C(=O)OC(C)(C)C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCN(C(=O)OC(C)(C)C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 KHHJNOAKQGLDQT-UHFFFAOYSA-N 0.000 description 1
- CLFJHGWYEWUSEM-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(C(C)=O)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCN(C(C)=O)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 CLFJHGWYEWUSEM-UHFFFAOYSA-N 0.000 description 1
- ZLCBROWMUJMIEV-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1N.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1N.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 ZLCBROWMUJMIEV-UHFFFAOYSA-N 0.000 description 1
- LWCSYTDFJUTMHH-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(=O)(=O)NC(=O)OC(C)(C)C)n1.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(N)c(Nc2ccccc2N)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl Chemical compound COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(=O)(=O)NC(=O)OC(C)(C)C)n1.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(N)c(Nc2ccccc2N)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl LWCSYTDFJUTMHH-UHFFFAOYSA-N 0.000 description 1
- PFYUCAKTSLQMSG-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 PFYUCAKTSLQMSG-UHFFFAOYSA-N 0.000 description 1
- IGMJKFPWRPDZFR-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 IGMJKFPWRPDZFR-UHFFFAOYSA-N 0.000 description 1
- RGZMVAOBYXEGGV-UHFFFAOYSA-N COc1cc(N2CCC(N3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 RGZMVAOBYXEGGV-UHFFFAOYSA-N 0.000 description 1
- CUVGJGJTYKLUKL-UHFFFAOYSA-N COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 CUVGJGJTYKLUKL-UHFFFAOYSA-N 0.000 description 1
- QIOMOKXENMAZLA-UHFFFAOYSA-N COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 QIOMOKXENMAZLA-UHFFFAOYSA-N 0.000 description 1
- AFBHHVLIKDQVKC-UHFFFAOYSA-N COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl Chemical compound COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl AFBHHVLIKDQVKC-UHFFFAOYSA-N 0.000 description 1
- AUKCVEIYIRDTKB-UHFFFAOYSA-N COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 AUKCVEIYIRDTKB-UHFFFAOYSA-N 0.000 description 1
- VKRSSFJGYLRWDH-UHFFFAOYSA-N COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1Nc1nc(Cl)ncc1Cl Chemical compound COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1Nc1nc(Cl)ncc1Cl VKRSSFJGYLRWDH-UHFFFAOYSA-N 0.000 description 1
- SKDHJCOYYLVRBA-UHFFFAOYSA-N COc1cc(N2CCN(C3CCN(C(=O)OC(C)(C)C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCN(C3CCN(C(=O)OC(C)(C)C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 SKDHJCOYYLVRBA-UHFFFAOYSA-N 0.000 description 1
- VKMSIADLKBTITB-UHFFFAOYSA-N COc1cc(N2CCN(C3CCN(C(C)=O)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCN(C3CCN(C(C)=O)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 VKMSIADLKBTITB-UHFFFAOYSA-N 0.000 description 1
- JTYCQADBJCDIQF-UHFFFAOYSA-N COc1cc(N2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 JTYCQADBJCDIQF-UHFFFAOYSA-N 0.000 description 1
- MTAIUIJQWUNQPF-UHFFFAOYSA-N COc1cc(N2CCN(C3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCN(C3CCNCC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 MTAIUIJQWUNQPF-UHFFFAOYSA-N 0.000 description 1
- WWFWSRITLFKYFD-UHFFFAOYSA-N COc1cc(N2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1 Chemical compound COc1cc(N2CCNCC2)ccc1Nc1ncc(Br)c(Nc2ccccc2CS(N)(=O)=O)n1 WWFWSRITLFKYFD-UHFFFAOYSA-N 0.000 description 1
- NQAXWRCTQNUENY-UHFFFAOYSA-N COc1cc(N2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1 NQAXWRCTQNUENY-UHFFFAOYSA-N 0.000 description 1
- KYOUGCVJAOBGBG-UHFFFAOYSA-N COc1cc(N2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.Cc1cnc(Cl)nc1Nc1ccccc1CS(C)(=O)=O Chemical compound COc1cc(N2CCNCC2)ccc1Nc1ncc(C)c(Nc2ccccc2CS(C)(=O)=O)n1.CS(=O)(=O)Cc1ccccc1N.Cc1cnc(Cl)nc1Nc1ccccc1CS(C)(=O)=O KYOUGCVJAOBGBG-UHFFFAOYSA-N 0.000 description 1
- AMVYVXUZBBAXSM-UHFFFAOYSA-N COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 AMVYVXUZBBAXSM-UHFFFAOYSA-N 0.000 description 1
- WUGVCWJVGWDDCB-UHFFFAOYSA-N COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 Chemical compound COc1cc(N2CCNCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(N)(=O)=O)n1 WUGVCWJVGWDDCB-UHFFFAOYSA-N 0.000 description 1
- HHPMTXGGDNQEGD-UHFFFAOYSA-N COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 Chemical compound COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1 HHPMTXGGDNQEGD-UHFFFAOYSA-N 0.000 description 1
- KTLMLTUDISQEAG-UHFFFAOYSA-N COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl Chemical compound COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2CS(C)(=O)=O)n1.COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2N)n1.COc1cc(N2CCOCC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2[N+](=O)[O-])n1.O=[N+]([O-])c1ccccc1Nc1nc(Cl)ncc1Cl KTLMLTUDISQEAG-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RIXRQHBQYKZKHP-UHFFFAOYSA-N N-[2-[[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)NC1=NC(=NC=C1C(F)(F)F)Cl RIXRQHBQYKZKHP-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- BGPNDOBOLHJJEE-UHFFFAOYSA-N n-(2-aminophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1N BGPNDOBOLHJJEE-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- RADGPXZWMLVDDP-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate Chemical compound C1=C(N)C(OC)=CC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 RADGPXZWMLVDDP-UHFFFAOYSA-N 0.000 description 1
- XDFRAQNKTYUVKB-UHFFFAOYSA-N tert-butyl 4-[4-(3-methoxy-4-nitrophenyl)-3,6-dihydro-2H-pyridin-1-yl]piperidine-1-carboxylate Chemical compound COC=1C=C(C=CC=1[N+](=O)[O-])C=1CCN(CC=1)C1CCN(CC1)C(=O)OC(C)(C)C XDFRAQNKTYUVKB-UHFFFAOYSA-N 0.000 description 1
- KAJZZLBZXOBEMD-UHFFFAOYSA-N tert-butyl n-chlorosulfonylcarbamate Chemical compound CC(C)(C)OC(=O)NS(Cl)(=O)=O KAJZZLBZXOBEMD-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940087380 vitamin b 12 0.2 mg Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Definitions
- the present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient.
- cancers The occurrence of cancers is related to a number of environmental factors including chemical substances, radiation, virus, and changes of oncogenes, tumor suppressor genes, genes associated with apoptosis and DNA repair and the like. Recently, the molecular mechanism of cancers is to be understood, and thus, this makes a targeted anticancer therapy, which is a new therapy, become available.
- Targeted therapeutic agents are generally prepared to show an effect by targeting molecules that cancer cells characteristically have.
- the molecular targets are genes associated with signal transduction pathway of cancer cells, angiogenesis, cellular matrix, cell cycle regulator, apoptosis and the like.
- An important targeted therapeutic agent used in the current therapy includes signal transduction pathway inhibitors, including tyrosine kinase inhibitors, and angiogenesis inhibitors and the like.
- EGFR epidermal growth factor receptor
- NSCLC non-small cell lung carcinoma
- breast cancer glioma, squamous cell carcinoma of head and neck, colorectal cancer, rectal adenocarcinoma, head and neck cancer, gastric cancer, and prostate cancer
- the activation of the above EGFR-tyrosine kinase causes a persistent cell proliferation, invasion of the surrounding tissue, remote metastasis, and angiogenesis, and increases a cell survival.
- the EGFR which is one of tyrosine kinase receptors of ErbB family (EGFR, HER-2, ErbB-3, and ErbB-4), is a transmembrane tyrosine kinase that has an extracelluar ligand-binding domain and an intracellular domain including a tyrosine kinase domain.
- a tyrosine kinase in a cell is activated, and a signal stimulated by EGFR as such activates phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR, RAS/RAF/MAPK, and JAK/STAT signal transduction pathway (Nat Rev Cancer 2007; 7:169-81).
- PI3K phosphatidylinositol 3-kinase
- EGFR is overexpressed in at least a half of non-small cell lung cancer (NSCLC), and thus, a number of studies have been carried out in which EGFR is a target of a therapy.
- EGFR TKIs tyrosine kinase inhibitors
- TARCEVATM Gefitinib
- TYKERBTM lapatinib
- TYVERBTM lapatinib
- the above EGFR mutation is largely classified into a sensitizing mutation and a resistant mutation, and a deletion of exon 19 and a L858R point mutation of exon 21 are the most important sensitizing mutations and make up about 85 to 90 percent of a sensitizing mutation, and an exon 19 del mutation is more sensitizing to the TKI.
- a T790M point mutation of exon 20 is the most important resistant mutation and is found in at least 50 percent of acquired resistant patients (Clin Cancer Res 2006; 12:6494-6501).
- Somatic mutations identified hitherto include an in-frame deletion in exon 19 or an insertion in exon 20, as well as, a point mutation in which a single nucleic acid residue is modified within an expressed protein (for example, L858R, G719S, G719C, G719A, L861Q) (Fukuoka et al. JCO 2003; Kris et al JAMA 2003; and Shepherd et al NEJM 2004).
- gefitinib/erlotinib in NSCLC patients with a EGFR mutation, a progressive cancer develops in most patients in the end while these patients are receiving a therapy of these drugs.
- a secondary EGFR mutation, T790M was identified, which made gefitinib and erlotinib to be ineffective inhibitors of EGFR kinase activity (Kobayashi et al NEJM 2005 and Pao et al PLOS Medicine 2005).
- the EGFR T790M mutation was found in approximately 50 percent ( 24/48) of tumors derived from patients who acquired a resistance against gefitinib or erlotinib (Kosaka et al CCR 2006; Balak et al CCR 2006; and Engelman et al Science 2007).
- the secondary genetic modification is caused in a position similar to a ‘gatekeeper’ residue and a secondary resistance allele associated with the same in patients to be treated with a kinase inhibitor (for example, T315I within ABL in imatinib resistant CML).
- EGFR_del19 or EGFR_L858R which is an EGFR mutation
- IRESSA and TARCEVA which are therapeutic drugs of the cancers
- an acquired resistance which is a T790M mutation positioned in a gatekeeper of EGFR kinase, occurs to prevent first generation inhibitors of EGFR exerting a medicinal effect. That is, EGFR_del19_T790M or EGFR_L858R_T790M double mutation occurs to prevent conventional therapeutic agents exerting a medicinal effect.
- AZD9291 developed by AstraZeneca, a multinational pharmaceutical company, is the most promising drug. However, it was reported that after approximately ten months passed, another resistance against AZD9291 also occurred to lose the medicinal effect of AZD9291. In particular, it was reported that resistance caused by triple mutation including C797S occurred (Thress et al, Nature Medicine 2015).
- a N2,N4-diphenylpyrimidin-2,4-diamine derivative according to the present invention shows a relatively low inhibition on wild-type EGFR and a high inhibitory ability on EGFR mutation, and thus, can be effectively used for the prevention or treatment of cancer.
- the present invention has been completed.
- R 1 is CH 3 or NH 2 ,
- R 2 is hydrogen, halogen, methoxy, or methyl unsubstituted or substituted with one or more halogens;
- R 3 is hydrogen, halogen, or straight or branched C 1-6 alkyl
- R 4 is straight or branched C 1-6 alkyl
- substituted heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S
- the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of straight or branched C 1-3 alkyl, straight or branched hydroxyC 1-3 alkyl, acetyl, amine unsubstituted or substituted with one or more straight or branched C 1-3 alkyl, and unsubstituted or substituted piperidinyl or piperazinyl
- the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of straight or branched C 1-3 alkyl, straight or branched hydroxyC 1-3 alkyl, acetyl, and straight or branched C 1-5 alkoxycarbonyl
- the present invention provides a method for preparing the compound represented by Formula 1, comprising a step of reacting a compound represented by Formula 2 and a compound represented by Formula 3 to prepare the compound represented by Formula 1, as indicated in Reaction Scheme 1:
- X is halogen
- the present invention provides a pharmaceutical composition for the prevention or treatment of cancer, containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a health functional food for the prevention or amelioration of cancer, containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a method for the prevention or treatment of cancer, comprising a step of administering a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.
- the present invention provides a use of a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof in the prevention or treatment of cancer.
- the N2,N4-diphenylpyrimidin-2,4-diamine derivative according to the present invention shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus, can be effectively used for the treatment of combination administration.
- FIG. 1 is a graph showing a relative cell viability at the time of the administration of brigatinib in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 2 is a graph showing a relative cell viability at the time of the administration of the compound of Example 10 in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 3 is a graph showing a relative cell viability at the time of the administration of the compound of Example 11 in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 4 is a graph showing a relative cell viability at the time of the administration of only cetuximab alone to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 5 shows a sub-signal activity at the time of the administration of brigatinib alone or in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line.
- FIG. 6 shows a sub-signal activity at the time of the administration of the compound of Example 10 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line.
- FIG. 7 shows a sub-signal activity at the time of the administration of the compound of Example 11 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line.
- the present invention provides a compound represented by Formula 1:
- R 1 is CH 3 or NH 2 ,
- R 2 is hydrogen, halogen, methoxy, or methyl unsubstituted or substituted with one or more halogens;
- R 3 is hydrogen, halogen, or straight or branched C 1-6 alkyl
- R 4 is straight or branched C 1-6 alkyl
- substituted heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S
- the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of straight or branched C 1-3 alkyl, straight or branched hydroxyC 1-3 alkyl, acetyl, amine unsubstituted or substituted with one or more straight or branched C 1-3 alkyl, and unsubstituted or substituted piperidinyl or piperazinyl
- the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of straight or branched C 1-3 alkyl, straight or branched hydroxyC 1-3 alkyl, acetyl, and straight or branched C 1-5 alkoxycarbonyl
- R 1 may be CH 3 .
- R 1 may be NH 2 .
- R 2 may be hydrogen, F, Cl, Br, methoxy, or methyl unsubstituted or substituted with one or more fluoro;
- R 3 may be hydrogen, F, Cl, or straight or branched C 1-3 alkyl
- R 4 may be straight or branched C 1-3 alkyl.
- R 2 may be hydrogen, Cl, Br, methyl, CF3, or methoxy
- R 3 may be hydrogen or methyl
- R 4 may be methyl.
- substituted heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S
- substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of methyl, ethyl, hydroxymethyl, hydroxyethyl, acetyl, amine unsubstituted or substituted with one or more methyl, and unsubstituted or substituted piperidinyl or piperazinyl
- the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of methyl, ethyl, hydroxymethyl, hydroxyethyl, acetyl, and tert-butoxy carbonyl.
- substituted heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N and O
- substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, —NH 2 , —N(CH 3 ) 2
- unsubstituted or substituted piperidinyl or piperazinyl and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, and tert-butoxycarbonyl.
- a 1 is CH or N
- a 2 is NH, O, CH—R 5 , or N—R 5 , with the proviso that if A 1 is CH, then A 2 is not CH—R 5 , wherein R 5 is independently hydrogen, methyl, hydroxyethyl, acetyl, —NH 2 , —N(CH 3 ) 2 ,
- R 6 may be independently hydrogen, methyl, hydroxyethyl, acetyl or tert-butoxycarbonyl.
- R 5 is independently hydrogen, methyl, hydroxyethyl, acetyl, —NH 2 , —N(CH 3 ) 2 ,
- R 6 may be independently hydrogen, methyl, hydroxyethyl, acetyl, or tert-butoxycarbonyl.
- R 5 may be hydrogen, methyl, hydroxyethyl, acetyl, —NH 2 , —N(CH 3 ) 2 ,
- R 5 is independently —NH(CH 3 ) or
- R c and R d is independently hydrogen, and R 6 may be methyl.
- Examples of the compound represented by Formula 1 according to the present invention include the following compounds:
- ⁇ 6> 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine;
- the compound represented by Formula 1 of the present invention may be used in form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as a salt.
- the acid addition salt is obtained from inorganic acids, such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid and the like, nontoxic organic acids, such as aliphatic mono- and dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate and alkandioate, aromatic acids, aliphatic and aromatic sulfonic acids and the like, organic acids, such as acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid and the like.
- inorganic acids such as hydrochloric acid,
- Types of such pharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzene sulfonate, toluene sul
- the acid addition salt according to the present invention may be prepared by a conventional method, and, for example, it may be prepared by dissolving the derivative of Formula 1 in an organic solvent, such as methanol, ethanol, acetone, methylene chloride, acetonitrile and the like, adding an organic acid or an inorganic acid, filtering the resulting precipitate, and drying, or it may be prepared by distilling a solvent and an acid in excess amount under reduced pressure, then drying, and crystallizing under an organic solvent.
- an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile and the like
- a pharmaceutically acceptable metal salt may be prepared by using a base.
- An alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an alkali metal hydroxide or alkaline earth metal hydroxide solution in excess amount, filtering the undissolved compound salt, evaporating the filtrate, and drying.
- a sodium, potassium, or calcium salt is pharmaceutically suitable for preparing a metal salt.
- the corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (for example, silver nitrate).
- the present invention includes all the compound represented by Formula 1 and pharmaceutically acceptable salt thereof, as well as, a solvate, an optical isomer, a hydrate and the like that can be prepared therefrom.
- the present invention provides a method for preparing the compound represented by Formula 1, comprising a step of reacting a compound represented by Formula 2 and a compound represented by Formula 3 to prepare the compound represented by Formula 1, as indicated in Reaction Scheme 1:
- X is halogen
- Step 1 is a step of reacting a compound represented by Formula 2 and a compound represented by Formula 3 to prepare the compound represented by Formula 1. Specifically, it is a step of reacting a halogen of a compound represented by Formula 2 and a primary amine of a compound represented by Formula 3 to form the compound represented by Formula 1.
- the reaction in Reaction Scheme 1 above is not particularly limited if the condition of the reaction is a condition under which an amine bond can be formed by binding a halogen and an amine.
- the present invention uses an acid condition, and the acid used in the present invention is, but not limited to, hydrochloric acid.
- a sulfonamide can be introduced before the performance of the reaction of binding a halogen and an amine in Reaction Scheme 1, or a sulfonamide can be introduced after the performance of the reaction of binding a halogen and an amine without the introduction of a sulfonamide.
- Solvents available in Reaction Scheme 1 above include, but are not particularly limited to, lower alcohols including isopropanol, methanol, ethanol, propanol, and butanol; tetrahydrofuran (THF); dioxane; ether solvents including ethyl ether, 1,2-dimethoxyethane and the like; dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonitrile, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalen
- Step 1 a step of reacting a compound represented by Formula 4 and a compound represented by Formula 3 to prepare a compound represented by Formula 5 (Step 1);
- Step 2 a step of reducing the compound represented by Formula 5 obtained in Step 1 above through a reduction reaction to prepare a compound represented by Formula 6 (Step 2);
- Step 3 a step of reacting the compound represented by Formula 6 obtained in Step 2 above with a compound represented by Formula 7 to prepare a compound represented by Formula 8 (Step 3);
- X is halogen
- PG is an amine protecting group selected from the group consisting of t-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), benzyl (Bn), p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), 2,2,2-trichloroethoxycarbonyl (Troc), 2-trimethylsilylethoxycarbonyl (Teoc), and aryloxycarbonyl (Alloc).
- Boc t-butyloxycarbonyl
- Cbz carbobenzyloxy
- Fmoc 9-fluorenylmethyloxycarbonyl
- benzoyl (Bz) benzyl (Bn), p-
- Step 1 above is a step of reacting a compound represented by Formula 4 and a compound represented by Formula 3 to prepare a compound represented by Formula 5. Specifically, it is a step of reacting a halogen of a compound represented by Formula 2 and a primary amine of a compound represented by Formula 3 to form a compound represented by Formula 5.
- the reaction of Step 1 above is not particularly limited if the condition of the reaction is a condition under which an amine bond can be formed by binding a halogen and an amine.
- the present invention uses an acid condition, and the acid used in the present invention is, but not limited to, hydrochloric acid.
- Solvents available in Step 1 above include, but are not particularly limited to, lower alcohols including isopropanol, methanol, ethanol, propanol, and butanol; tetrahydrofuran (THF); dioxane; ether solvents including ethyl ether, 1,2-dimethoxyethane and the like; dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonitrile, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalene-1
- Step 2 above is a step of reducing the compound represented by Formula 5 obtained in Step 1 above through a reduction reaction to prepare a compound represented by Formula 6. Specifically, it is a step of reducing a nitro of a compound represented by Formula 5 to a primary amine through a reduction reaction to form a compound represented by Formula 6.
- the reduction reaction may be carried out by the publicly known method.
- Step 3 above is a step of reacting the compound represented by Formula 6 obtained in Step 2 above with a compound represented by Formula 7 to prepare a compound represented by Formula 8. Specifically, it is a step of reacting a primary amine of a compound represented by Formula 6 with a chloro of tert-butyl chlorosulfonylcarbamate represented by Formula 7 to form a compound represented by Formula 8 in which a sulfonyl group is introduced.
- the compound represented by Formula 7 above may be used either by purchasing as a commercially available product or by preparing by the publicly known method.
- Solvents available in Step 3 above include, but are not particularly limited to, lower alcohols including isopropanol, methanol, ethanol, propanol, and butanol; tetrahydrofuran (THF); dioxane; ether solvents including ethyl ether, 1,2-dimethoxyethane and the like; dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonitrile, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalene-1
- Step 4 above is a step of reacting the compound represented by Formula 8 obtained in Step 3 above to prepare the compound represented by Formula 1. Specifically, it is a step of deprotecting an amine protecting group bound to an amine of sulfonyl in the compound represented by Formula 8 to obtain a compound represented by Formula 1.
- the deprotecting reaction may be carried out by using a conventional deprotecting reaction condition.
- the present invention uses an acid condition, and hydrochloric acid, sulfuric acid, methanesulfonic acid, trifluoroacetic acid and the like may be used as the acid.
- solvents available in the above reaction include tetrahydrofuran, dioxane, dichloromethane, ether solvents, such as 1,2-dimethoxyethane and the like; aromatic hydrocarbon solvents, such as benzene, toluene, xylene and the like; alcohol solvents, such as methanol, ethanol and the like; dimethylformamide (DMF), dimethyl sulfoxide, acetonitrile, water and the like, which may be used alone or in combination herewith.
- tetrahydrofuran dioxane
- dichloromethane ether solvents
- aromatic hydrocarbon solvents such as benzene, toluene, xylene and the like
- alcohol solvents such as methanol, ethanol and the like
- dimethylformamide (DMF) dimethyl sulfoxide, acetonitrile, water and the like, which may be used alone or in combination herewith.
- the present invention provides a pharmaceutical composition for the prevention or treatment of cancer, containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient.
- the cancer is one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testis cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, epithelial ovarian cancer, ovarian seminoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, cholangiocarcinoma, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal and paranasal cavity cancer, non-small cell lung cancer, tongue cancer
- the EGFR mutation may be one or more selected from the group consisting of EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C 797 S, EGFR L858R, EGFR L858R/T790MS, and EGFR L858R/T790M/C 797 S.
- the FLT3 mutation may be one or more selected from the group consisting of FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), and FLT3(R834Q).
- a pharmaceutical composition for the prevention or treatment of cancer containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient can be used either by the administration as an individual therapeutic agent or by the administration in combination with other anticancer agent in use.
- a pharmaceutical composition for the prevention or treatment of cancer containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient can enhance an anticancer effect by the administration in combination with an anticancer agent.
- the compound represented by Formula 1 of the present invention shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a selectively high inhibitory ability on EGFR mutation, and particularly, a high inhibitory ability on EGFR del19/T790M/C 797 S or EGFR L858R/T790M/C 797 S, which is a triple mutation (see Experimental Example 1 and Table 4).
- the compound represented by Formula 1 of the present invention shows a selectively high inhibitory ability on EGFR mutation in Ba/F3 cell line, and particularly, a high inhibitory ability on EGFR del19, which is a single mutation (see Experimental Example 2 and Table 5).
- the compound represented by Formula 1 of the present invention shows a selectively superior inhibitory ability on a kinase associated with cancer, particularly, FLT 3 kinase, which is a kinase associated with hematologic malignancy, and a high inhibitory ability on wild-type FLT3, as well as, FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), FLT3(R834Q), which are mutation forms (see Experimental Example 3 and Table 6).
- the compound represented by Formula 1 of the present invention shows a lower cell viability on Ba/F3 Del19/T790M/C 797 S cell line with EGFR triple mutation when administered alone than a conventional drug, and shows a remarkably decreased cell viability when administered in combination with a conventional drug than when administered alone, and thus, shows a superior cancer cell apoptosis ability on a cell line with EGFR triple mutation even when administered alone, as well as, shows a remarkably elevated anticancer effect when administered in combination with a conventional drug.
- the compound represented by Formula 1 of the present invention shows a cell viability decreased by at least 20% than when administering brigatinib, which is a conventional drug in use, in combination with a conventional drug, and thus, shows a superior anticancer effect than brigatinib (see Experimental Example 4 and FIGS. 1 to 4 ).
- the compound represented by Formula 1 of the present invention shows a concentration-dependent activity in pERK, pAKT, pS6, which is EGFR sub-signal, even when administered alone, as well as, shows a superior activity when administered in combination with a conventional drug.
- the compound represented by Formula 1 of the present invention shows a superior activity than when administering brigatinib, which is a conventional drug in use, in combination with a conventional drug, and thus, shows a superior anticancer effect than brigatinib (see Experimental Example 4 and FIGS. 5 to 7 ).
- the compound represented by Formula 1 according to the present invention shows a high inhibitory ability on EGFR mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation, such as EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C 797 S, EGFR L858R, EGFR L858R/T790MS, EGFR L858R/T790M/C 797 S and the like.
- the compound represented by Formula 1 according to the present invention shows a remarkably superior inhibitory ability on EGFR del19/T790M/C 797 S or EGFR L858R/T790M/C 797 S, which is a triple mutation, and thus, can be effectively used for the treatment of cancer with EGFR del19/T790M/C 797 S or EGFR L858R/T790M/C 797 S.
- the compound represented by Formula 1 according to the present invention shows a high inhibitory ability on FLT 3 and mutation thereof, such as FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), or FLT3(R834Q), and thus, can be effectively used for the treatment of cancer associated with an activity of FLT 3 or a mutation form of FLT 3, particularly hematologic malignancy.
- the compound represented by Formula 1 according to the present invention shows a synergy effect when administered in combination with a conventional drug, and thus, can be effectively used when administered in combination with a conventional drug.
- the compound represented by Formula 1 or pharmaceutically acceptable salt thereof may be administered in various oral and parenteral formulations upon clinical administration. It is prepared by using diluents or excipients, such as fillers, bulking agents, binders, wetting agents, disintegrating agents, surfactants and the like, which are generally used in the formulation.
- Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid formulations are prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin and the like to one or more compounds.
- lubricants such as magnesium stearate, talc and the like are also used.
- Liquid formulations for oral administration include suspensions, oral solutions, emulsions, syrups and the like.
- simple diluents such as water and liquid paraffin, which are commonly used
- various excipients for example wetting agents, sweetening agents, perfuming agents, preservatives and the like may be included.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions.
- Propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, injectable ester, such as ethyl oleate and the like can be used as non-aqueous solvents, suspending solvents.
- a pharmaceutical composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient may be parenterally administered, and parenteral administration is by infusion methods of subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
- the compound represented by Formula 1 or pharmaceutically acceptable salt thereof is mixed with a stabilizer or buffer in water to prepare a solution or suspension, and it may be manufactured in an ampoule or vial unit dosage form.
- the composition may be sterilized and/or contain preservatives, stabilizers, wetting agents or emulsifying accelerators, adjuvants, such as salts and/or buffers for regulating osmotic pressure and the like, and other therapeutically useful substances, and may be formulated according to a conventional method of mixing, granulation, or coating method.
- Formulations for oral administration include, for example, tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs, troches and the like. These formulations contain, in addition to an active ingredient, diluents (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine) and glidants (for example, silica, talc, stearic acid and magnesium or calcium salt thereof, and/or polyethylene glycol).
- diluents for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine
- glidants for example, silica, talc, stearic acid and magnesium or calcium salt thereof, and/or polyethylene glycol.
- the tablets may contain binders, such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidine and the like, and may contain, where appropriate, disintegrating agents, such as starch, agar, alginic acid or sodium salt thereof and the like, or effervescent mixtures and/or absorbents, colorants, flavoring agents, and sweetening agents.
- binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidine and the like
- disintegrating agents such as starch, agar, alginic acid or sodium salt thereof and the like, or effervescent mixtures and/or absorbents, colorants, flavoring agents, and sweetening agents.
- the present invention provides a health functional food for the prevention or amelioration of cancer, containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient.
- the cancer is one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testis cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, epithelial ovarian cancer, ovarian seminoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, cholangiocarcinoma, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal and paranasal cavity cancer, non-small cell lung cancer, tongue cancer, a
- the compound represented by Formula 1 according to the present invention shows a high inhibitory ability on EGFR mutation, and thus, can be added to health functional foods, such as foods, beverages and the like, as a health functional food composition for the prevention or amelioration of cancer, particularly cancer with EGFR mutation.
- the compound represented by Formula 1 according to the present invention may be added to foods as it is, or may be used with other foods or food ingredients, and may be appropriately used according to conventional methods.
- the mixing amount of the active ingredient may be suitably determined depending on the purpose of use thereof (for the prevention or amelioration).
- the amount of the compound in health foods may be added in 0.1 to 90 parts by weight of a total weight of foods.
- the amount may be less than the above range in case of long-term ingestion for health and hygiene, or for health regulation, and the active ingredient may be also used in amount more than the above range because there is no problem in regard to safety.
- the health functional beverage composition of the present invention may contain, in addition to the above compound as an essential ingredient in the indicated ratio, other ingredients, which are not particularly limited.
- the health functional beverage composition of the present invention may contain various flavoring agents or natural carbohydrates and the like as additional ingredients, as conventional beverages have.
- natural carbohydrates are conventional sugars, such as monosaccharides, for example glucose, fructose and the like; disaccharides, for example maltose, sucrose and the like; and polysaccharides, for example dextrin, cyclodextrin and the like, and sugar alcohols, such as xylitol, sorbitol, erythritol and the like.
- natural flavoring agents thaumatin, stevia extract (for example, rebaudioside A, glycyrrhizin and the like) and synthetic flavoring agents (saccharin, aspartame and the like) can be effectively used.
- the ratio of the natural carbohydrate is generally about 1 to 20 g per 100 g of the composition of the present invention, preferably about 5 to 12 g.
- the compound represented by Formula 1 of the present invention may contain, in addition to those described above, various nutrients, vitamins, minerals (electrolytes), flavoring agents, such as synthetic flavoring agents and natural flavoring agents and the like, colorants and enhancers (cheese, chocolate and the like), pectic acids and salts thereof, alginic acids and salts thereof, organic acids, protective colloidal thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages and the like.
- the compound represented by Formula 1 of the present invention may contain fruit flesh for the preparation of natural fruit juice and fruit juice beverage and vegetable beverage.
- the present invention provides a method for the prevention or treatment of cancer, comprising a step of administering a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.
- the present invention provides a use of a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof in the prevention or treatment of cancer.
- Example 1 The compounds of Example 1 and 2 were prepared according to Reaction Example 1 below.
- N-(2-aminophenyl)methanesulfonamide (18.6 mg, 0.1 mmol), 2,4,5-trichloropyrimidine (14 ⁇ L, 0.12 mmol), and DIPEA (diisopropyl ethyl amine, 38 ⁇ L, 0.22 mmol) were mixed with isopropyl alcohol (1 mL). The above reaction mixture was stirred overnight at 60° C. The above mixture was concentrated under reduced pressure.
- Step 2 Preparation of N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 3 was prepared according to Reaction Example 2 below.
- Step 1 Preparation of N-(2-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide
- Step 2 Preparation of N-(2-((5-bromo-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 4 was prepared according to Reaction Example 3 below.
- Step 2 Preparation of N-(2-((5-methoxy-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 5 was prepared according to Reaction Example 4 below.
- Step 1 Preparation of N-(2-((2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- Step 2 Preparation of N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 6 was prepared according to Reaction Example 5 below.
- Step 1 Preparation of tert-butyl 4-(4-((5-chloro-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine-1-carboxylate
- Step 2 Preparation of tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine-1-carboxylate
- Step 3 Preparation of tert-butyl 4-(4-((4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate
- Step 4 Preparation of 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine
- Example 7 The compound of Example 7 was prepared according to Reaction Example 6 below.
- Step 1 Preparation of tert-butyl 4-(4-((5-bromo-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate
- Step 2 Preparation of tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-bromopyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine-1-carboxylate
- Step 3 Preparation of tert-butyl 4-(4-((5-bromo-4-((2-((N-(tert-butoxy carbonyl)sulfamoyl)amino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate
- Step 4 Preparation of 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine
- the compound of Example 8 was prepared according to Reaction Example 7 below.
- Step 2 Preparation of N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino))-5-methylpyrimidin-4-ylamino)phenyl)methanesulfonamide
- Example 9 The compound of Example 9 was prepared according to Reaction Example 8 below.
- Step 2 Preparation of N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 10 was prepared according to Reaction Example 9 below.
- the compound of Example 11 was prepared according to Reaction Example 10 below.
- the reaction tube containing DMF (30 mL) of a mixture of 4-fluoro-2-methoxy-1-nitrobenzene (5.00 g, 29.22 mmol), N,N-dimethylpiperidin-4-amine (6.53 g, 35.06 mmol), and K 2 CO 3 (6.06 g, 43.83 mmol) was sealed with a Teflon-lined cap, and the above reaction mixture was stirred for 2 hours at 90° C. The above mixture was concentrated under reduced pressure. The above reaction mixture was diluted in ethyl acetate (300 mL), washed with water (100 mL), and then, washed with brine (100 mL).
- Step 3 Preparation of N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 12 was prepared according to Reaction Example 11 below.
- Step 2 Preparation of N-(2-((5-chloro-2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 13 was prepared according to Reaction Example 12 below.
- Step 1 Preparation of 2-(4-(4-amino-3-methoxyphenyl)piperidin-1-yl)ethyl acetate
- Step 2 Preparation of N-(2-((5-chloro-2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 14 was prepared according to Reaction Example 13 below.
- Step 1 Preparation of tert-butyl 4-(4-(3-methoxy-4-nitrophenyl)-3,6-dihydropyridin-1(2H)-yl)piperidine-1-carboxylate
- Step 2 Preparation of 2-(4-(4-(4-amino-3-methoxyphenyl)-3,6-dihydropyridin-1-(2H)-yl)piperidin-1-yl)ethyl acetate
- Step 3 Preparation of 2-(4-(4-amino-3-methoxyphenyl)-[1,4′-bipiperidin]-1′-yl)ethyl acetate
- Step 4 Preparation of N-(2-((5-chloro-2-((4-(1′-(2-hydroxyethyl)-[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 15 was prepared according to Reaction Example 14 below.
- R 6 H indicates the compound of Example 16
- R 6 CH 3 indicates the compound of Example 17
- R 6 Ac indicates the compound of Example 18.
- N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (24.4 mg, 0.04 mmol), 1-boc-4-piperidone (16.9 mg, 0.08 mmol), a dichloromethane 1 M solution (120 ⁇ L, 0.12 mmol) of acetic acid, and 1,2-dichloroethane (1 mL) of triethylamine (10 ⁇ L, 0.04 mmol) were stirred for 1 hour at ambient temperature, and then, sodium triacetoxyborohydride (12.7 mg, 0.06 mmol) was added.
- the compound produced after the performance of Step 6 is the compound of Example 21
- the compound produced after the performance of Step 7 is the compound of Example 22.
- Step 1 Preparation of 8-(3-methoxy-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane
- Step 3 Preparation of N-(2-((5-chloro-2-((2-methoxy-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- Step 4 Preparation of N-(2-((5-chloro-2-((2-methoxy-4-(4-oxopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the resulting unpurified product was diluted with water, basified (pH ⁇ 8) with a 5 N NaOH aqueous solution, and then, extracted with dichloromethane.
- the above organic layer was separated, washed with water and brine, then, dried over Na 2 SO 4 , and evaporated under reduced pressure to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-oxopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (100 mg, 72%) as a white solid.
- Step 5 Preparation of N-(2-((2-((4-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 28 was prepared according to Reaction Example 18 below.
- Example 29 The compound of Example 29 was prepared according to Reaction Example 19 below.
- Step 1 Preparation of tert-butyl 4-(4-((5-chloro-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate
- Step 2 Preparation of tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate
- Step 3 Preparation of tert-butyl 4-(4-((4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate
- Step 4 Preparation of 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine
- the compound of Example 30 was prepared according to Reaction Example 20 below.
- Step 1 Preparation of tert-butyl 4-(4-((5-bromo-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate
- Step 2 Preparation of tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-bromopyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate
- Step 3 Preparation of tert-butyl 4-(4-((5-bromo-4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate
- Step 4 Preparation of 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine
- the compound of Example 31 was prepared according to Reaction Example 21 below.
- Step 1 Preparation of N-(2-((2-chloro-5-(trifluoromethyppyrimidin-4-yl)amino)phenyl)methanesulfonamide
- Step 2 Preparation of N-(2-((2-((2-methoxy-4-(piperazin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 32 was prepared according to Reaction Example 22 below.
- Step 1 Preparation of 5-chloro-N 2 -(2-methoxy-4-morpholinophenyl)-N 4 -(2-nitrophenyl)pyrimidin-2,4-diamine
- Step 2 Preparation of N 4 -(2-aminophenyl)-5-chloro-N 2 -(2-methoxy-4-morpholinophenyl)pyrimidin-2,4-diamine
- Step 3 Preparation of N-(2-((5-chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- the compound of Example 36 was prepared according to Reaction Example 23 below.
- Step 1 Preparation of 5-chloro-N2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-N4-(2-nitrophenyl)pyrimidin-2,4-diamine
- Step 2 Preparation of N4-(2-aminophenyl)-5-chloro-N2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)pyrimidin-2,4-diamine
- Step 3 Preparation of tert-butyl (N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate
- Step 4 Preparation of (N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate
- the compound of Example 37 was prepared according to Reaction Example 24 below.
- Step 1 Preparation of 5-chloro-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N4-(2-nitrophenyl)pyrimidin-2,4-diamine
- Step 2 Preparation of N4-(2-aminophenyl)-5-chloro-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidin-2,4-diamine
- Step 3 Preparation of tert-butyl (N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate
- Step 4 Preparation of (N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate
- the compound produced after the performance of Step 3 is the compound of Example 38
- the compound produced after the performance of Step 4 is the compound of Example 39.
- Step 1 Preparation of tert-butyl (1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)carbamate
- Step 2 Preparation of tert-butyl (1-(4-amino-3-methoxy phenyl)piperidin-4-yl)carbamate
- Step 3 Preparation of N-(2-((2-((4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide
- Example 40 The compound of Example 40 was prepared according to Reaction Example 26 below.
- Step 1 Preparation of tert-butyl (1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)(methyl)carbamate
- Step 2 Preparation of tert-butyl (1-(4-amino-3-methoxyphenyl)piperidin-4-yl)(methyl)carbamate
- Step 3 Preparation of N-(2-((5-chloro-2-((2-methoxy-4-(4-(methylamino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide
- Example 41, 42, and 43 were prepared according to Reaction Example 27 below.
- R represents a substance reacting with a starting material
- the measurement of an activity on wild-type and EGFR mutation enzyme of the compound of the present invention was experimented by utilizing the HTRF system sold by Cisbio, as follow. Wild-type EGFR and EGFR del19, EGFR del19/T790M mutation enzyme were used by purchasing the recombinant proteins provided by Carna Biosciences, and EGFR del19/T790M/C 797 S mutation enzyme was used as an enzyme source by purchasing the proteins provided by SignalChem.
- the composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl 2 , 3 mM KCl, 0.01% Tween 20, 0.1% BSA, 1 mM DTT.
- the enzymatic reaction was carried out hereto by using the peptide substrate labeled with ATP of 50 mM concentration and biotin of 0.5 mM concentration.
- the analysis of an EGFR activity inhibitory effect of the compound was carried out in accordance with the analysis reaction recipe below.
- Component 1 4 ml of EGFR wild-type or mutation enzyme
- Component 3 4 ml of peptide labeled with ATP and biotin
- the enzymatic reaction was initiated by mixing Component 1 and Component 2 first, and then, adding component 3. After the reaction for 2 hours at 37° C., 10 ml of a measurement solution consisting of streptavidin-XL665 provided by Cisbio and anti-phosphotyrosine antibody labeled with europium was added to the enzymatic reaction solution and reacted for 1 hour at ambient temperature. Finally, the ratio of fluorescence values at 615 nm and 665 nm was obtained by using the Envision equipment of Perkin-Elmer, and the enzymatic activity was quantitatively measured, and the inhibitory ability of the compound was confirmed. The measurement values measured at the seven concentrations of the compound were analyzed by using the Prism program (version 5.01, Graphpad Software, Inc.), and IC 50 value of the compound was calculated, which is an inhibitory ability indicator.
- the measurement of an activity on wild-type and mutation Ba/F3 EGFR cell line of the compound of the present invention was experimented by utilizing the CellTiter-Glo system sold by Promega, as follow.
- the CellTiter-Glo assay is a method for measuring the ATP present in cells in cell culture conditions to determine the cell viability.
- Ba/F3 EGFR wild-type and Ba/F3 EGFR del19, Ba/F3 EGFR del19/T790M, Ba/F3 del19/T790M/C 797 S mutation cell lines were used by purchasing the cell lines provided by Crown Bioscience, Inc.
- Ba/F3 EGFR wild-type and Ba/F3 EGFR del19, Ba/F3 EGFR del19/T790M, Ba/F3 del19/T790M/C 797 S mutation cell lines were cultured in 37° C., 5% CO 2 incubator by adding puromycine 1 ug to RPMI containing 10% FBS, 1% penicillin-streptomycin.
- 2500 cells/90 ul was cultured by passage in 96 well cell culture plate, and after 24 hours, treated with the compound represented by Formula 1 in concentrations of 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 ( ⁇ M). After the reaction of 72 hours, the plate treated with the compound was allowed to stand for 30 minutes at ambient temperature, and then, was further treated with 100 ⁇ l of the reagent, and was shaked for 10 minutes at ambient temperature. Finally, the ratio of fluorescence values at 570 nm was obtained by using the equipment and quantitatively measured, and the inhibitory ability of the compound was confirmed. The measurement values measured at the eight concentrations of the compound were analyzed by using the Prism program (version 5.01, Graphpad Software, Inc.), and IC 50 value of the compound was calculated, which is an inhibitory ability indicator.
- the example compounds according to the present invention showed a high inhibitory ability on EGFR mutation including EGFR del19/T790M/C 797 S, which is a triple mutation.
- the example compounds according to the present invention show a relatively weak activity inhibitory ability on wild-type EGFR in Ba/F3 cell line and a selectively high inhibitory ability on EGFR mutation including EGFR del19/T790M/C 797 S, which is a triple mutation.
- FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N 841 I), FLT3(R834Q) was measured.
- KINOMEscan method consists of the following processes. T7 bacteriophage labeled with FLT kinase was cultured by the infection to E. coli derived from BL21. After the infection of E. coli in the condition of 0.4 of MOI (multiplicity of infection), it was cultured for 90 to 150 minutes at 32° C. to lyse E. coli. The cell debris was removed by centrifugation and filtration, and the kinase protein present in the supernatant was secured. Additionally, the kinase protein was labeled with DNA for the qPCR measurement.
- the magnetic beads labeled with streptavidin were treated with the standard compound labeled with biotin and reacted for 30 minutes.
- the resulting beads were used as affinity beads for the measurement of a kinase activity.
- the binding reaction was initiated with mixing a kinase protein, the affinity beads bound with a ligand, and the compound.
- the used buffer solution was 20% SeaBlock, 0.17 ⁇ PBS, 0.05% Tween 20, 6 mM DTT. All the reactions were carried out in volume of 20 ul at a 384 well plate. After the reaction for 1 hour at ambient temperature, the beads were washed with the solution consisting of 1 ⁇ PBS, 0.05 Tween 20.
- the kinase bound with the beads was eluted by using 1 ⁇ PBS, 0.05 Tween 20, 0.5 uM standard compound unlabeled with biotin.
- the affinity of the compound to be tested was indirectly measured by quantifying the eluted kinase by qPCR.
- the compounds of Examples 10 and 11 of the present invention showed a selectively superior inhibitory ability on FLT 3 kinase in comparison with FLT 1 and FLT 4, and also showed a high inhibitory ability on wild-type FLT3, as well as, FLT3 mutation forms, such as FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N 841 I), FLT3(R834Q).
- cetuximab to be used in single therapy or combination therapy with anticancer chemotherapy in metastatic colorectal cancer, metastatic squamous epithelium head and neck cancer and the like was used to evaluate the cell activity according to the combination administration.
- brigatinib was used as a control drug, and each of 30 nM of brigatinib, 30 nM of the compound of Example 10 according to the present invention, and 15 nM of the compound of Example 11 was administered to Ba/F3 Del19/T790M/C 797 S cell line in combination with 10 ⁇ g of cetuximab, which is a monoclonal antibody.
- the relative cell viability was measured and shown in FIGS. 1 to 4 .
- FIG. 1 is a graph showing a relative cell viability at the time of the administration of brigatinib in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 2 is a graph showing a relative cell viability at the time of the administration of the compound of Example 10 in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 3 is a graph showing a relative cell viability at the time of the administration of the compound of Example 11 in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 4 is a graph showing a relative cell viability at the time of the administration of only cetuximab alone to Ba/F3 Del19/T790M/C 797 S cell line (calculated by sigmaplot's t-test (**P ⁇ 0.001, *P>0.01)).
- FIG. 5 shows a sub-signal activity at the time of the administration of brigatinib alone or in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line.
- FIG. 6 shows a sub-signal activity at the time of the administration of the compound of Example 10 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line.
- FIG. 7 shows a sub-signal activity at the time of the administration of the compound of Example 11 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C 797 S cell line.
- the compounds of Examples 10 and 11 of the present invention show a lower cell viability by at least 30% on Ba/F3 Del19/T790M/C 797 S cell line when administered alone than cetuximab, and show a cell viability decreased by at least 50% when administered in combination with cetuximab than when administered alone, and thus, show a superior cancer cell apoptosis ability on a cell line with EGFR triple mutation even when administered alone, as well as, show a remarkably elevated anticancer effect when administered in combination with a conventional drug.
- the compounds of Examples 10 and 11 of the present invention show a cell viability decreased by at least 20% than when administering brigatinib, which is a conventional drug in use, in combination with cetuximab, and thus, show a superior anticancer effect than brigatinib.
- the compounds of Examples 10 and 11 of the present invention show a concentration-dependent activity in pERK, pAKT, pS6, which is EGFR sub-signal, even when administered alone, as well as, show a superior activity when administered in combination with cetuximab.
- the compounds of Examples 10 and 11 of the present invention show a superior activity than when administering brigatinib, which is a conventional drug in use, in combination with cetuximab, and thus, show a superior anticancer effect than brigatinib.
- the compound represented by Formula 1 according to the present invention shows a high inhibitory ability on EGFR mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation, such as EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C 797 S, EGFR L858R, EGFR L858R/T790MS, EGFR L858R/T790M/C 797 S and the like.
- the compound represented by Formula 1 according to the present invention shows a remarkably superior inhibitory ability on EGFR del19/T790M/C 797 S or EGFR L858R/T790M/C 797 S, which is a triple mutation, and thus, can be effectively used for the treatment of cancer with EGFR del19/T790M/C 797 S or EGFR L858R/T790M/C 797 S.
- the compound represented by Formula 1 according to the present invention shows a high inhibitory ability on FLT 3 and mutation thereof, such as FLT3(D 835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N 841 I), or FLT3(R834Q), and thus, can be effectively used for the treatment of cancer associated with an activity of FLT 3 or a mutation form of FLT 3, particularly hematologic malignancy.
- the compound represented by Formula 1 according to the present invention shows a synergy effect when administered in combination with a conventional drug, and thus, can be effectively used when administered in combination with a conventional drug.
- the powders were prepared by mixing the above ingredients and filling into an airtight bag.
- the tablets were prepared by mixing the above ingredients and then tableting according to conventional methods for manufacturing tablets.
- the capsules were prepared by mixing the above ingredients and then filling into gelatin capsules according to conventional methods for manufacturing capsules.
- the injections were prepared by containing the above ingredients in contents set forth above according to conventional methods for manufacturing injections.
- Vitamin A acetate 70 mg Vitamin E 1.0 mg Vitamin 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 mg Vitamin C 10 mg Biotin 10 mg Nicotinamide 1.7 mg Folic acid 50 mg Calcium pantothenate 0.5 mg Mineral mixture q.s. Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium dihydrogen phosphate 15 mg Calcium hydrogen phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg
- the ingredients relatively suitable for health foods were mixed according to the preferred examples, but the mixing ratio can be optionally modified in practice.
- the above ingredients were mixed and then prepared into granules, and may be used in the preparation of health food compositions according to conventional methods.
- the above ingredients were mixed, then stirred and heated at 85° C. for about 1 hour, and then the resulting solution was filtered, obtained in a sterilized container, sealed, sterilized, then stored in a refrigerator, and used in the preparation of health beverage compositions.
- the ingredients relatively suitable for favorite beverages were mixed according to the preferred examples, but the mixing ratio can be optionally modified in practice according to regional and ethnic preference, such as a demand class, demand country, purpose of use and the like.
- the N2,N4-diphenylpyrimidin-2,4-diamine derivative according to the present invention can be effectively used for the treatment of cancer, particularly cancer with EGFR mutation or cancer with FLT3 or a mutation thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.
Description
- The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient.
- The occurrence of cancers is related to a number of environmental factors including chemical substances, radiation, virus, and changes of oncogenes, tumor suppressor genes, genes associated with apoptosis and DNA repair and the like. Recently, the molecular mechanism of cancers is to be understood, and thus, this makes a targeted anticancer therapy, which is a new therapy, become available.
- Targeted therapeutic agents are generally prepared to show an effect by targeting molecules that cancer cells characteristically have. The molecular targets are genes associated with signal transduction pathway of cancer cells, angiogenesis, cellular matrix, cell cycle regulator, apoptosis and the like. An important targeted therapeutic agent used in the current therapy includes signal transduction pathway inhibitors, including tyrosine kinase inhibitors, and angiogenesis inhibitors and the like.
- It has been found that a protein tyrosine kinase plays an important role in a number of malignant tumors. In particular, it is known that epidermal growth factor receptor (EGFR), which is a receptor tyrosine kinase of ErbB family, is abnormally activated in a number of epithelial cell tumors including non-small cell lung carcinoma (NSCLC), breast cancer, glioma, squamous cell carcinoma of head and neck, colorectal cancer, rectal adenocarcinoma, head and neck cancer, gastric cancer, and prostate cancer; and the activation of the above EGFR-tyrosine kinase causes a persistent cell proliferation, invasion of the surrounding tissue, remote metastasis, and angiogenesis, and increases a cell survival.
- Specifically, the EGFR, which is one of tyrosine kinase receptors of ErbB family (EGFR, HER-2, ErbB-3, and ErbB-4), is a transmembrane tyrosine kinase that has an extracelluar ligand-binding domain and an intracellular domain including a tyrosine kinase domain. If a ligand binds to a receptor forming homodimer or heterodimer, a tyrosine kinase in a cell is activated, and a signal stimulated by EGFR as such activates phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR, RAS/RAF/MAPK, and JAK/STAT signal transduction pathway (Nat Rev Cancer 2007; 7:169-81).
- In particular, EGFR is overexpressed in at least a half of non-small cell lung cancer (NSCLC), and thus, a number of studies have been carried out in which EGFR is a target of a therapy. EGFR TKIs (tyrosine kinase inhibitors), which inhibit an activity of EGFR tyrosine kinase, have been developed, and representative drugs include Gefitinib (IRESSA™) erlotinib (TARCEVA™), lapatinib (TYKERB™, TYVERB™).
- On the other hand, it was reported that, in 2004, an activating mutation of EGFR is correlated with a response to gefitinib therapy in non-small cell lung cancer (NSCLC) (Science [2004] Vol. 304, 1497-500 and New England Journal of Medicine [2004] Vol. 350, 2129-39).
- Specifically, it is known that the above EGFR mutation is largely classified into a sensitizing mutation and a resistant mutation, and a deletion of
exon 19 and a L858R point mutation of exon 21 are the most important sensitizing mutations and make up about 85 to 90 percent of a sensitizing mutation, and anexon 19 del mutation is more sensitizing to the TKI. On the other hand, it is known that a T790M point mutation of exon 20 is the most important resistant mutation and is found in at least 50 percent of acquired resistant patients (Clin Cancer Res 2006; 12:6494-6501). - Somatic mutations identified hitherto include an in-frame deletion in
exon 19 or an insertion in exon 20, as well as, a point mutation in which a single nucleic acid residue is modified within an expressed protein (for example, L858R, G719S, G719C, G719A, L861Q) (Fukuoka et al. JCO 2003; Kris et al JAMA 2003; and Shepherd et al NEJM 2004). - Despite an early clinical effect of gefitinib/erlotinib in NSCLC patients with a EGFR mutation, a progressive cancer develops in most patients in the end while these patients are receiving a therapy of these drugs. In an early study of recurred samples, a secondary EGFR mutation, T790M, was identified, which made gefitinib and erlotinib to be ineffective inhibitors of EGFR kinase activity (Kobayashi et al NEJM 2005 and Pao et al PLOS Medicine 2005). It has been proved in the follow-up study that the EGFR T790M mutation was found in approximately 50 percent ( 24/48) of tumors derived from patients who acquired a resistance against gefitinib or erlotinib (Kosaka et al CCR 2006; Balak et al CCR 2006; and Engelman et al Science 2007). The secondary genetic modification is caused in a position similar to a ‘gatekeeper’ residue and a secondary resistance allele associated with the same in patients to be treated with a kinase inhibitor (for example, T315I within ABL in imatinib resistant CML).
- It has been known for a long time that EGFR_del19 or EGFR_L858R, which is an EGFR mutation, is a major cause of non-small cell lung cancer and head and neck cancer, and IRESSA and TARCEVA, which are therapeutic drugs of the cancers, were developed and are currently used in clinical trials. However, when such drugs were administered for cancer patients, an acquired resistance caused by an EGFR secondary mutation based on the structure of the drug was observed. In addition, it was found that this was actually a major cause of drug resistance. If first generation inhibitors of EGFR have been used for about ten months in average, an acquired resistance, which is a T790M mutation positioned in a gatekeeper of EGFR kinase, occurs to prevent first generation inhibitors of EGFR exerting a medicinal effect. That is, EGFR_del19_T790M or EGFR_L858R_T790M double mutation occurs to prevent conventional therapeutic agents exerting a medicinal effect.
- On the basis of these facts, it is imperative to develop the second generation and third generation drugs having a superior medicinal effect and a new structure.
- For the last five years, various third generation new drug candidates showing an effect on an EGFR T790M double mutation are under development, and clinical studies are in progress. AZD9291 developed by AstraZeneca, a multinational pharmaceutical company, is the most promising drug. However, it was reported that after approximately ten months passed, another resistance against AZD9291 also occurred to lose the medicinal effect of AZD9291. In particular, it was reported that resistance caused by triple mutation including C797S occurred (Thress et al, Nature Medicine 2015).
- Thus, there is a need for the development of an inhibitor showing a higher inhibition on EGFR of specific activating or resistant mutant form while showing a relatively low inhibition on WT EGFR.
- Thus, while the prevent inventors were trying to develop a cancer therapeutic agent inhibiting an EGFR multiple mutation, the prevent inventors found that a N2,N4-diphenylpyrimidin-2,4-diamine derivative according to the present invention shows a relatively low inhibition on wild-type EGFR and a high inhibitory ability on EGFR mutation, and thus, can be effectively used for the prevention or treatment of cancer. On the basis of the above findings, the present invention has been completed.
- It is an object of the present invention to provide a N2,N4-diphenylpyrimidin-2,4-diamine derivative, an optical isomer thereof or a pharmaceutically acceptable salt thereof.
- It is another object of the present invention to provide a method for preparing the N2,N4-diphenylpyrimidin-2,4-diamine derivative.
- It is another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of cancer, containing the N2,N4-diphenylpyrimidin-2,4-diamine derivative, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- It is another object of the present invention to provide a health functional food composition for the prevention or amelioration of cancer, containing the N2,N4-diphenylpyrimidin-2,4-diamine derivative, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- In order to accomplish the above objects,
- the present invention provides a compound represented by Formula 1:
- in which,
- R1 is CH3 or NH2,
- R2 is hydrogen, halogen, methoxy, or methyl unsubstituted or substituted with one or more halogens;
- R3 is hydrogen, halogen, or straight or branched C1-6alkyl;
- R4 is straight or branched C1-6alkyl; and
- is an unsubstituted or substituted 5- to 7-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of straight or branched C1-3alkyl, straight or branched hydroxyC1-3alkyl, acetyl, amine unsubstituted or substituted with one or more straight or branched C1-3alkyl, and unsubstituted or substituted piperidinyl or piperazinyl, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of straight or branched C1-3alkyl, straight or branched hydroxyC1-3alkyl, acetyl, and straight or branched C1-5alkoxycarbonyl,
- an optical isomer thereof or a pharmaceutically acceptable salt thereof.
- In addition, the present invention provides a method for preparing the compound represented by
Formula 1, comprising a step of reacting a compound represented by Formula 2 and a compound represented byFormula 3 to prepare the compound represented byFormula 1, as indicated in Reaction Scheme 1: - in which, R1, R2, R3, R4, and
- are as defined in Formula 1 above; and
- X is halogen.
- Furthermore, the present invention provides a pharmaceutical composition for the prevention or treatment of cancer, containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient.
- In addition, the present invention provides a health functional food for the prevention or amelioration of cancer, containing the compound represented by Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient.
- In addition, the present invention provides a method for the prevention or treatment of cancer, comprising a step of administering a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.
- In addition, the present invention provides a use of a pharmaceutical composition or a health functional food composition containing the compound represented by Formula 1 or pharmaceutically acceptable salt thereof in the prevention or treatment of cancer.
- The N2,N4-diphenylpyrimidin-2,4-diamine derivative according to the present invention shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus, can be effectively used for the treatment of combination administration.
-
FIG. 1 is a graph showing a relative cell viability at the time of the administration of brigatinib in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 2 is a graph showing a relative cell viability at the time of the administration of the compound of Example 10 in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 3 is a graph showing a relative cell viability at the time of the administration of the compound of Example 11 in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 4 is a graph showing a relative cell viability at the time of the administration of only cetuximab alone to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 5 shows a sub-signal activity at the time of the administration of brigatinib alone or in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line. -
FIG. 6 shows a sub-signal activity at the time of the administration of the compound of Example 10 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line. -
FIG. 7 shows a sub-signal activity at the time of the administration of the compound of Example 11 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line. - Hereinafter, the present invention will be described in detail.
- The present invention provides a compound represented by Formula 1:
- in which,
- R1 is CH3 or NH2,
- R2 is hydrogen, halogen, methoxy, or methyl unsubstituted or substituted with one or more halogens;
- R3 is hydrogen, halogen, or straight or branched C1-6alkyl;
- R4 is straight or branched C1-6alkyl; and
- is an unsubstituted or substituted 5- to 7-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of straight or branched C1-3alkyl, straight or branched hydroxyC1-3alkyl, acetyl, amine unsubstituted or substituted with one or more straight or branched C1-3alkyl, and unsubstituted or substituted piperidinyl or piperazinyl, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of straight or branched C1-3alkyl, straight or branched hydroxyC1-3alkyl, acetyl, and straight or branched C1-5alkoxycarbonyl,
- an optical isomer thereof or a pharmaceutically acceptable salt thereof.
- R1 may be CH3.
- R1 may be NH2.
- R2 may be hydrogen, F, Cl, Br, methoxy, or methyl unsubstituted or substituted with one or more fluoro;
- R3 may be hydrogen, F, Cl, or straight or branched C1-3alkyl; and
- R4 may be straight or branched C1-3alkyl.
- R2 may be hydrogen, Cl, Br, methyl, CF3, or methoxy;
- R3 may be hydrogen or methyl; and
- R4 may be methyl.
- is unsubstituted or substituted 5- or 6-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of methyl, ethyl, hydroxymethyl, hydroxyethyl, acetyl, amine unsubstituted or substituted with one or more methyl, and unsubstituted or substituted piperidinyl or piperazinyl, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of methyl, ethyl, hydroxymethyl, hydroxyethyl, acetyl, and tert-butoxy carbonyl.
- is unsubstituted or substituted 5- or 6-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, —NH2, —N(CH3)2, and unsubstituted or substituted piperidinyl or piperazinyl, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, and tert-butoxycarbonyl.
- wherein A1 is CH or N, and A2 is NH, O, CH—R5, or N—R5, with the proviso that if A1 is CH, then A2 is not CH—R5, wherein R5 is independently hydrogen, methyl, hydroxyethyl, acetyl, —NH2, —N(CH3)2,
- and R6 may be independently hydrogen, methyl, hydroxyethyl, acetyl or tert-butoxycarbonyl.
- wherein R5 is independently hydrogen, methyl, hydroxyethyl, acetyl, —NH2, —N(CH3)2,
- and R6 may be independently hydrogen, methyl, hydroxyethyl, acetyl, or tert-butoxycarbonyl.
- wherein R5 may be hydrogen, methyl, hydroxyethyl, acetyl, —NH2, —N(CH3)2,
- wherein R5 is independently —NH(CH3) or
- wherein Rc and Rd is independently hydrogen, and R6 may be methyl.
- Examples of the compound represented by
Formula 1 according to the present invention include the following compounds: - <1> N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <2> N-(2-((5-chloro-2-((2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <3> N-(2-((5-bromo-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <4> N-(2-((5-methoxy-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <5> N-(2-((2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <6> 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine;
- <7> 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine;
- <8> N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino))-5-methylpyrimidin-4-ylamino)phenyl)methanesulfonamide;
- <9> N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <10> N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <11> N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <12> N-(2-((5-chloro-2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <13> N-(2-((5-chloro-2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <14> N-(2-((5-chloro-2-((4-(1′-(2-hydroxyethyl)-[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <15> N-(2-((2-((4-(1-acetylpiperidin-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <16> N-(2-((2-((4-([1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-ylamino)phenyl)methanesulfonamide;
- <17> N-(2-((5-chloro-2-((2-methoxy-4-(1′-methyl-[1,4′-bipiperidin]-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <18> N-(2-((2-((4-(1′-acetyl-[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <19> N-(2-((2-((4-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <20> tert-butyl 4-(1-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate;
- <21> N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <22> N-(2-((5-chloro-2-((4-(4-(4-(2-hydroxyethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <23> N-(2-((5-chloro-2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <24> N-(2-((2-((4-(4-(1-acetylpiperidin-4-yl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <25> N-(2-((5-chloro-2-((2-methoxy-4-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <26> tert-butyl 4-(4-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)piperidine-1-carboxylate;
- <27> N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <28> N-(2-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <29> 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine;
- <30> 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine;
- <31> N-(2-((2-((2-methoxy-4-(piperazin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <32> N-(2-((5-chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <33> N-(2-((5-chloro-2-((4-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)piperidin-1-yl)-2-methoxy phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <34> N-(2-((5-chloro-2-((2-methoxy-4-(4-morpholinopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <35> N-(2-((5-chloro-2-((2-methoxy-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <36> (N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate;
- <37> (N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate;
- <38> N-(2-((2-((4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <39> N-(1-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)acetamide;
- <40> N-(2-((5-chloro-2-((2-methoxy-4-(4-(methylamino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <41> N-(2-((5-chloro-2-((4-(4-((2-hydroxyethyl)amino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
- <42> N-(2-((5-chloro-2-((2-methoxy-4-(4-((2-methoxyethyl)amino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide; and
- <43> N-(2-((5-chloro-2-((4-(4-((2-(dimethylamino)ethyl)amino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide.
- The compound represented by
Formula 1 of the present invention may be used in form of a pharmaceutically acceptable salt, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as a salt. The acid addition salt is obtained from inorganic acids, such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid and the like, nontoxic organic acids, such as aliphatic mono- and dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate and alkandioate, aromatic acids, aliphatic and aromatic sulfonic acids and the like, organic acids, such as acetate, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid and the like. Types of such pharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. - The acid addition salt according to the present invention may be prepared by a conventional method, and, for example, it may be prepared by dissolving the derivative of
Formula 1 in an organic solvent, such as methanol, ethanol, acetone, methylene chloride, acetonitrile and the like, adding an organic acid or an inorganic acid, filtering the resulting precipitate, and drying, or it may be prepared by distilling a solvent and an acid in excess amount under reduced pressure, then drying, and crystallizing under an organic solvent. - In addition, a pharmaceutically acceptable metal salt may be prepared by using a base. An alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an alkali metal hydroxide or alkaline earth metal hydroxide solution in excess amount, filtering the undissolved compound salt, evaporating the filtrate, and drying. In this case, a sodium, potassium, or calcium salt is pharmaceutically suitable for preparing a metal salt. In addition, the corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (for example, silver nitrate).
- Furthermore, the present invention includes all the compound represented by
Formula 1 and pharmaceutically acceptable salt thereof, as well as, a solvate, an optical isomer, a hydrate and the like that can be prepared therefrom. - In addition, the present invention provides a method for preparing the compound represented by Formula 1, comprising a step of reacting a compound represented by Formula 2 and a compound represented by Formula 3 to prepare the compound represented by Formula 1, as indicated in Reaction Scheme 1:
- in which, is as defined in
Formula 1 ofclaim 1; and - X is halogen.
- Hereinafter, the preparation method represented by
Reaction Scheme 1 above will be described in detail. - In a method for preparing the compound according to the present invention represented by
Reaction Scheme 1 above,Step 1 is a step of reacting a compound represented by Formula 2 and a compound represented byFormula 3 to prepare the compound represented byFormula 1. Specifically, it is a step of reacting a halogen of a compound represented by Formula 2 and a primary amine of a compound represented byFormula 3 to form the compound represented byFormula 1. - The reaction in
Reaction Scheme 1 above is not particularly limited if the condition of the reaction is a condition under which an amine bond can be formed by binding a halogen and an amine. - The present invention uses an acid condition, and the acid used in the present invention is, but not limited to, hydrochloric acid.
- In addition, as in the preparation method of Reaction Scheme 2 below, a sulfonamide can be introduced before the performance of the reaction of binding a halogen and an amine in
Reaction Scheme 1, or a sulfonamide can be introduced after the performance of the reaction of binding a halogen and an amine without the introduction of a sulfonamide. - Solvents available in
Reaction Scheme 1 above include, but are not particularly limited to, lower alcohols including isopropanol, methanol, ethanol, propanol, and butanol; tetrahydrofuran (THF); dioxane; ether solvents including ethyl ether, 1,2-dimethoxyethane and the like; dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonitrile, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, acetonitrile and the like, which may be used alone or in combination herewith. A lower alcohol solvent is used in the present invention, but not limited hereto. - In addition, the compound represented by
Formula 1 according to the present invention, wherein R1 is NH2, may be prepared by the preparation method comprising - a step of reacting a compound represented by Formula 4 and a compound represented by
Formula 3 to prepare a compound represented by Formula 5 (Step 1); - a step of reducing the compound represented by Formula 5 obtained in
Step 1 above through a reduction reaction to prepare a compound represented by Formula 6 (Step 2); - a step of reacting the compound represented by
Formula 6 obtained in Step 2 above with a compound represented by Formula 7 to prepare a compound represented by Formula 8 (Step 3); and - a step of reacting the compound represented by Formula 8 obtained in Step 3 above to prepare the compound represented by Formula 1 (Step 4), as indicated in Reaction Scheme 2:
- in which, R2, R3, R4, and
- are as defined in
Formula 1 above; - X is halogen; and
- PG is an amine protecting group selected from the group consisting of t-butyloxycarbonyl (Boc), carbobenzyloxy (Cbz), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), benzyl (Bn), p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), 2,2,2-trichloroethoxycarbonyl (Troc), 2-trimethylsilylethoxycarbonyl (Teoc), and aryloxycarbonyl (Alloc).
- Hereinafter, the preparation method represented by Reaction Scheme 2 above will be described in detail.
- In the preparation method represented by Reaction Scheme 2 above according to the present invention,
Step 1 above is a step of reacting a compound represented by Formula 4 and a compound represented byFormula 3 to prepare a compound represented by Formula 5. Specifically, it is a step of reacting a halogen of a compound represented by Formula 2 and a primary amine of a compound represented byFormula 3 to form a compound represented by Formula 5. - The reaction of
Step 1 above is not particularly limited if the condition of the reaction is a condition under which an amine bond can be formed by binding a halogen and an amine. - The present invention uses an acid condition, and the acid used in the present invention is, but not limited to, hydrochloric acid.
- Solvents available in
Step 1 above include, but are not particularly limited to, lower alcohols including isopropanol, methanol, ethanol, propanol, and butanol; tetrahydrofuran (THF); dioxane; ether solvents including ethyl ether, 1,2-dimethoxyethane and the like; dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonitrile, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, acetonitrile and the like, which may be used alone or in combination herewith. A lower alcohol solvent is used in the present invention, but not limited hereto. - In the preparation method represented by Reaction Scheme 2 above according to the present invention, Step 2 above is a step of reducing the compound represented by Formula 5 obtained in
Step 1 above through a reduction reaction to prepare a compound represented byFormula 6. Specifically, it is a step of reducing a nitro of a compound represented by Formula 5 to a primary amine through a reduction reaction to form a compound represented byFormula 6. - The reduction reaction may be carried out by the publicly known method.
- In the preparation method represented by Reaction Scheme 2 above according to the present invention,
Step 3 above is a step of reacting the compound represented byFormula 6 obtained in Step 2 above with a compound represented by Formula 7 to prepare a compound represented by Formula 8. Specifically, it is a step of reacting a primary amine of a compound represented byFormula 6 with a chloro of tert-butyl chlorosulfonylcarbamate represented by Formula 7 to form a compound represented by Formula 8 in which a sulfonyl group is introduced. - In this case, the compound represented by Formula 7 above may be used either by purchasing as a commercially available product or by preparing by the publicly known method.
- In the present invention, it is prepared by using chlorosulfonyl isocyanate and t-butanol, but not limited hereto.
- Solvents available in
Step 3 above include, but are not particularly limited to, lower alcohols including isopropanol, methanol, ethanol, propanol, and butanol; tetrahydrofuran (THF); dioxane; ether solvents including ethyl ether, 1,2-dimethoxyethane and the like; dimethylformamide (DMF), dimethyl sulfoxide (DMSO), methylene chloride, dichloroethane, water, acetonitrile, benzene sulfonate, toluene sulfonate, chlorobenzene sulfonate, xylene sulfonate, ethyl acetate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methane sulfonate, propane sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, acetonitrile and the like, which may be used alone or in combination herewith. - In the preparation method represented by Reaction Scheme 2 above according to the present invention, Step 4 above is a step of reacting the compound represented by Formula 8 obtained in
Step 3 above to prepare the compound represented byFormula 1. Specifically, it is a step of deprotecting an amine protecting group bound to an amine of sulfonyl in the compound represented by Formula 8 to obtain a compound represented byFormula 1. - The deprotecting reaction may be carried out by using a conventional deprotecting reaction condition.
- The present invention uses an acid condition, and hydrochloric acid, sulfuric acid, methanesulfonic acid, trifluoroacetic acid and the like may be used as the acid.
- In addition, solvents available in the above reaction include tetrahydrofuran, dioxane, dichloromethane, ether solvents, such as 1,2-dimethoxyethane and the like; aromatic hydrocarbon solvents, such as benzene, toluene, xylene and the like; alcohol solvents, such as methanol, ethanol and the like; dimethylformamide (DMF), dimethyl sulfoxide, acetonitrile, water and the like, which may be used alone or in combination herewith.
- Furthermore, the present invention provides a pharmaceutical composition for the prevention or treatment of cancer, containing the compound represented by
Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient. - In this case, the cancer is one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testis cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, epithelial ovarian cancer, ovarian seminoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, cholangiocarcinoma, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal and paranasal cavity cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, renal cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal tumor, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsillar cancer, squamous cell cancer, adenocarcinoma of lung, lung cancer, squamous cell lung cancer, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleura cancer, hematologic malignancy, and thymic cancer, and the cancer may be a cancer with a mutation expressed on one or more selected from the group consisting of EGFR, ALK, FAK, FLT3, JAK3, KIT, and PLK4.
- In this case, the EGFR mutation may be one or more selected from the group consisting of EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C797S, EGFR L858R, EGFR L858R/T790MS, and EGFR L858R/T790M/C797S.
- In this case, the FLT3 mutation may be one or more selected from the group consisting of FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), and FLT3(R834Q).
- A pharmaceutical composition for the prevention or treatment of cancer, containing the compound represented by
Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient can be used either by the administration as an individual therapeutic agent or by the administration in combination with other anticancer agent in use. - A pharmaceutical composition for the prevention or treatment of cancer, containing the compound represented by
Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient can enhance an anticancer effect by the administration in combination with an anticancer agent. - The compound represented by
Formula 1 of the present invention shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a selectively high inhibitory ability on EGFR mutation, and particularly, a high inhibitory ability on EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S, which is a triple mutation (see Experimental Example 1 and Table 4). - The compound represented by
Formula 1 of the present invention shows a selectively high inhibitory ability on EGFR mutation in Ba/F3 cell line, and particularly, a high inhibitory ability on EGFR del19, which is a single mutation (see Experimental Example 2 and Table 5). - The compound represented by
Formula 1 of the present invention shows a selectively superior inhibitory ability on a kinase associated with cancer, particularly,FLT 3 kinase, which is a kinase associated with hematologic malignancy, and a high inhibitory ability on wild-type FLT3, as well as, FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), FLT3(R834Q), which are mutation forms (see Experimental Example 3 and Table 6). - It can be seen that the compound represented by
Formula 1 of the present invention shows a lower cell viability on Ba/F3 Del19/T790M/C797S cell line with EGFR triple mutation when administered alone than a conventional drug, and shows a remarkably decreased cell viability when administered in combination with a conventional drug than when administered alone, and thus, shows a superior cancer cell apoptosis ability on a cell line with EGFR triple mutation even when administered alone, as well as, shows a remarkably elevated anticancer effect when administered in combination with a conventional drug. In particular, it can be seen that the compound represented byFormula 1 of the present invention shows a cell viability decreased by at least 20% than when administering brigatinib, which is a conventional drug in use, in combination with a conventional drug, and thus, shows a superior anticancer effect than brigatinib (see Experimental Example 4 andFIGS. 1 to 4 ). - It can be seen that the compound represented by
Formula 1 of the present invention shows a concentration-dependent activity in pERK, pAKT, pS6, which is EGFR sub-signal, even when administered alone, as well as, shows a superior activity when administered in combination with a conventional drug. In particular, it can be seen that the compound represented byFormula 1 of the present invention shows a superior activity than when administering brigatinib, which is a conventional drug in use, in combination with a conventional drug, and thus, shows a superior anticancer effect than brigatinib (see Experimental Example 4 andFIGS. 5 to 7 ). - Therefore, the compound represented by
Formula 1 according to the present invention shows a high inhibitory ability on EGFR mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation, such as EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C797S, EGFR L858R, EGFR L858R/T790MS, EGFR L858R/T790M/C797S and the like. In particular, the compound represented byFormula 1 according to the present invention shows a remarkably superior inhibitory ability on EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S, which is a triple mutation, and thus, can be effectively used for the treatment of cancer with EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S. - In addition, the compound represented by
Formula 1 according to the present invention shows a high inhibitory ability onFLT 3 and mutation thereof, such as FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), or FLT3(R834Q), and thus, can be effectively used for the treatment of cancer associated with an activity ofFLT 3 or a mutation form ofFLT 3, particularly hematologic malignancy. - In addition, the compound represented by
Formula 1 according to the present invention shows a synergy effect when administered in combination with a conventional drug, and thus, can be effectively used when administered in combination with a conventional drug. - The compound represented by
Formula 1 or pharmaceutically acceptable salt thereof may be administered in various oral and parenteral formulations upon clinical administration. It is prepared by using diluents or excipients, such as fillers, bulking agents, binders, wetting agents, disintegrating agents, surfactants and the like, which are generally used in the formulation. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid formulations are prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin and the like to one or more compounds. Furthermore, in addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid formulations for oral administration include suspensions, oral solutions, emulsions, syrups and the like. In addition to simple diluents, such as water and liquid paraffin, which are commonly used, various excipients, for example wetting agents, sweetening agents, perfuming agents, preservatives and the like may be included. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions. Propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, injectable ester, such as ethyl oleate and the like can be used as non-aqueous solvents, suspending solvents. - A pharmaceutical composition containing the compound represented by
Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient may be parenterally administered, and parenteral administration is by infusion methods of subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection. - In this case, in order to formulate the formulations for parenteral administration, the compound represented by
Formula 1 or pharmaceutically acceptable salt thereof is mixed with a stabilizer or buffer in water to prepare a solution or suspension, and it may be manufactured in an ampoule or vial unit dosage form. The composition may be sterilized and/or contain preservatives, stabilizers, wetting agents or emulsifying accelerators, adjuvants, such as salts and/or buffers for regulating osmotic pressure and the like, and other therapeutically useful substances, and may be formulated according to a conventional method of mixing, granulation, or coating method. - Formulations for oral administration include, for example, tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs, troches and the like. These formulations contain, in addition to an active ingredient, diluents (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine) and glidants (for example, silica, talc, stearic acid and magnesium or calcium salt thereof, and/or polyethylene glycol). The tablets may contain binders, such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidine and the like, and may contain, where appropriate, disintegrating agents, such as starch, agar, alginic acid or sodium salt thereof and the like, or effervescent mixtures and/or absorbents, colorants, flavoring agents, and sweetening agents.
- In addition, the present invention provides a health functional food for the prevention or amelioration of cancer, containing the compound represented by
Formula 1, optical isomer thereof, or pharmaceutically acceptable salt thereof as an active ingredient. - The cancer is one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testis cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, epithelial ovarian cancer, ovarian seminoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, cholangiocarcinoma, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal and paranasal cavity cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, renal cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal tumor, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsillar cancer, squamous cell cancer, adenocarcinoma of lung, lung cancer, squamous cell lung cancer, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleura cancer, and thymic cancer; and more preferably, the cancer may be a cancer with mutation on one or more selected from the group consisting of EGFR, ALK, FAK, FLT3, JAK3, KIT, and PLK4.
- The compound represented by
Formula 1 according to the present invention shows a high inhibitory ability on EGFR mutation, and thus, can be added to health functional foods, such as foods, beverages and the like, as a health functional food composition for the prevention or amelioration of cancer, particularly cancer with EGFR mutation. - The compound represented by
Formula 1 according to the present invention may be added to foods as it is, or may be used with other foods or food ingredients, and may be appropriately used according to conventional methods. The mixing amount of the active ingredient may be suitably determined depending on the purpose of use thereof (for the prevention or amelioration). Generally, the amount of the compound in health foods may be added in 0.1 to 90 parts by weight of a total weight of foods. However, the amount may be less than the above range in case of long-term ingestion for health and hygiene, or for health regulation, and the active ingredient may be also used in amount more than the above range because there is no problem in regard to safety. - In addition, the health functional beverage composition of the present invention may contain, in addition to the above compound as an essential ingredient in the indicated ratio, other ingredients, which are not particularly limited. The health functional beverage composition of the present invention may contain various flavoring agents or natural carbohydrates and the like as additional ingredients, as conventional beverages have. Examples of the aforementioned natural carbohydrates are conventional sugars, such as monosaccharides, for example glucose, fructose and the like; disaccharides, for example maltose, sucrose and the like; and polysaccharides, for example dextrin, cyclodextrin and the like, and sugar alcohols, such as xylitol, sorbitol, erythritol and the like. As flavoring agents in addition to those described above, natural flavoring agents (thaumatin, stevia extract (for example, rebaudioside A, glycyrrhizin and the like) and synthetic flavoring agents (saccharin, aspartame and the like) can be effectively used. The ratio of the natural carbohydrate is generally about 1 to 20 g per 100 g of the composition of the present invention, preferably about 5 to 12 g.
- Furthermore, the compound represented by
Formula 1 of the present invention may contain, in addition to those described above, various nutrients, vitamins, minerals (electrolytes), flavoring agents, such as synthetic flavoring agents and natural flavoring agents and the like, colorants and enhancers (cheese, chocolate and the like), pectic acids and salts thereof, alginic acids and salts thereof, organic acids, protective colloidal thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages and the like. Besides, the compound represented byFormula 1 of the present invention may contain fruit flesh for the preparation of natural fruit juice and fruit juice beverage and vegetable beverage. - In addition, the present invention provides a method for the prevention or treatment of cancer, comprising a step of administering a pharmaceutical composition or a health functional food composition containing the compound represented by
Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof. - In addition, the present invention provides a use of a pharmaceutical composition or a health functional food composition containing the compound represented by
Formula 1 or pharmaceutically acceptable salt thereof in the prevention or treatment of cancer. - Hereinafter, the present invention will be described in detail through the Examples and Experimental Examples.
- However, the following Examples and Experimental Examples are only illustrations of the present invention, and the contents of the present invention are not limited to the following Examples and Experimental Examples.
- The compounds of Example 1 and 2 were prepared according to Reaction Example 1 below.
- In which, R3=H indicates the compound of Example 1, and R3=CH3 indicates the compound of Example 2.
- N-(2-aminophenyl)methanesulfonamide (18.6 mg, 0.1 mmol), 2,4,5-trichloropyrimidine (14 μL, 0.12 mmol), and DIPEA (diisopropyl ethyl amine, 38 μL, 0.22 mmol) were mixed with isopropyl alcohol (1 mL). The above reaction mixture was stirred overnight at 60° C. The above mixture was concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (CH2Cl2/EtOAc, 5:1) to obtain N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (15 mg, white solid) in a yield of 42%.
- 1H NMR (300 MHz, CDCl3) δ 8.38 (br s, 1 H), 8.24 (s, 1 H), 8.05 (d, J=7.5 Hz, 1 H), 7.46-7.37 (m, 2 H), 7.31-7.29 (m, 1 H), 6.56 (s, 1 H), 3.08 (s, 3 H); LC-MS calcd for C11H10Cl2N4O2S 332.0, found 333.0 (M+H+)
- To n-butanol (1 mL) of N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (5.0 mg, 0.015 mmol) and tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate (5.0 mg, 0.016 mmol) was added a dioxane solution (0.15 mL, 0.012 mmol) of 0.08 N HCl. The above reaction mixture was stirred overnight at 95° C. The above mixture was concentrated under reduced pressure, and the residue was purified by prep-HPLC to obtain N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (2.2 mg, white solid) in a yield of 30%.
- 1H NMR (500 MHz, CD3OD) δ 8.12 (s, 1 H), 7.81 (d, J=8.8 Hz, 1 H), 7.63-7.60 (m, 1 H), 7.54-7.52 (m, 1 H), 7.41-7.36 (m, 2 H), 6.93 (s, 1 H), 6.70 (d, J=7.5 Hz, 1 H), 3.90 (s, 3 H), 3.53 (d, J=12.6 Hz, 2 H), 3.18-3.13 (m, 2 H), 2.96 (s, 3 H), 2.93-2.88 (m, 1 H), 2.11-2.08 (m, 2 H), 1.95-1.88 (m, 2 H); LC-MS calcd for C23H27ClN6O3S 502.2, found 503.2 (M+H+)
- The same manner as in Example 1 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (28 mg, 30%).
- 1H NMR (300 MHz, CD3OD) δ 8.16 (s, 1 H), 7.74 (d, J=7.8 Hz, 1 H), 7.57 (dd, J=7.8, 1.5 Hz, 1 H), 7.43 (td, J=7.8, 1.5 Hz, 1 H), 7.36 (td, J=7.8, 1.5 Hz, 1 H), 7.32 (s, 1 H), 6.91 (s, 1 H), 3.89 (s, 3 H), 3.55 (d, J=12.6 Hz, 2 H), 3.27-3.14 (m, 3 H), 2.97 (s, 3 H), 2.16 (s, 3 H), 2.00-1.97 (m, 4 H); LC-MS calcd for C24H29ClN6OS 516.2, found 516.8 (M+H+)
- The compound of Example 3 was prepared according to Reaction Example 2 below.
- The same manner as in
Step 1 of Example 1 above was performed to obtain N-(2-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (25 mg, 30%). - 1H NMR (300 MHz, CDCl3) δ 8.35 (s, 1 H), 8.03 (dd, J=8.3, 1.0 Hz, 1 H), 7.46-7.38 (m, 2 H), 7.31-7.26 (m, 1 H), 6.57 (s, 1 H), 3.08 (s, 3 H); LC-MS calcd for C11H10BrClN4O2S 375.9, found 376.9 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-bromo-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (13 mg, 37%).
- 1H NMR (300 MHz, CD3OD) δ 8.11 (s, 1 H), 7.65 (d, J=7.5 Hz, 1 H), 7.42 (dd, J=7.8, 1.3 Hz, 1 H), 7.33-7.21 (m, 3 H), 6.85 (s, 1 H), 6.61 (d, J=7.9 Hz, 1 H), 3.77 (s, 3 H), 3.43 (d, J=12.7 Hz, 2 H), 3.08-3.01 (m, 2 H), 2.86 (s, 3 H), 2.83-2.77 (m, 1 H), 1.99-1.80 (m, 4 H); LC-MS calcd for C23H27BrN6O3S 546.1, found 546.7 (M+H+)
- The compound of Example 4 was prepared according to Reaction Example 3 below.
- The same manner as in
Step 1 of Example 1 above was performed to obtain N-(2-((2-chloro-5-methoxypyrimidin-4-yl)amino)phenyl)methanesulfonamide (6 mg, 8%). - 1H NMR (300 MHz, CDCl3) δ 7.98-7.95 (m, 2 H), 7.79 (s, 1 H), 7.45 (dd, J=7.9, 0.8 Hz, 1 H), 7.38 (td, J=7.4, 1.0 Hz, 1 H), 6.67 (s, 1 H), 4.02 (s, 3 H), 3.08 (s, 3 H); LC-MS calcd for C12H13ClN4O3S 328.0, found 328.9 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-methoxy-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (5.5 mg, 58%).
- 1H NMR (300 MHz, CD3OD) δ 7.87-7.84 (m, 1 H), 7.53 (s, 1 H), 7.51-7.45 (m, 2 H), 7.39-7.34 (m, 2 H), 6.98 (d, J=1.5 Hz, 1 H), 6.78 (dd, J=8.3, 1.5 Hz, 1 H), 3.99 (s, 3 H), 3.89 (s, 3 H), 3.55-3.51 (m, 2 H), 3.20-3.11 (m, 2 H), 2.97 (s, 3 H), 2.94-2.90 (m, 1 H), 2.21-1.90 (m, 4 H); LC-MS calcd for C24H30N6O4S 498.2, found 498.8 (M+H+)
- The compound of Example 5 was prepared according to Reaction Example 4 below.
- The same manner as in
Step 1 of Example 1 above was performed to obtain N-(2-((2-chloro-5-(trifluoromethyppyrimidin-4-yl)amino)phenyl)methanesulfonamide (199 mg, 18%). - 1H NMR (300 MHz, CDCl3) δ 8.47 (s, 1 H), 8.23 (br s, 1 H), 7.92 (d, J=7.8 Hz, 1 H), 7.46-7.28 (m, 3 H), 6.27 (br s, 1 H), 3.05 (s, 3 H); LC-MS calcd for C12H10ClF3N4O2S 366.0, found 366.8 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (15 mg, 31%).
- 1H NMR (300 MHz, CD3OD) δ 8.38 (s, 1 H), 7.60 (d, J=7.8 Hz, 1 H), 7.48 (dd, J=7.8, 1.8 Hz, 1 H), 7.42-7.29 (m, 3 H), 6.89 (s, 1 H), 6.60 (br s, 1 H), 3.83 (s, 3 H), 3.49 (dd, J=10.2, 3.3 Hz, 2 H), 3.11 (td, J=12.9, 3.3 Hz, 2 H), 2.89-2.85 (m, 4 H), 2.04-1.81 (m, 4 H); LC-MS calcd for C24H27F3N6OS 536.2, found 536.8 (M+H+)
- The compound of Example 6 was prepared according to Reaction Example 5 below.
- To n-butanol (10 mL) of 2,5-dichloro-N-(2-nitrophenyl)pyrimidin-4-amine (1.0 g, 3.5 mmol) and tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate (1.1 g, 3.5 mmol) was added a 1,4-dioxane solution (0.7 mL, 2.8 mmol) of 4 N HCl. The above reaction mixture was stirred overnight at 95° C. The above reactant was concentrated under reduced pressure. To the residual solution concentrated under reduced pressure was added CH2Cl2 (10 mL), and di-tert-butyl dicarbonate (1.2 g, 5.3 mmol) and Et3N (0.98 mL, 7.0 mmol) were added at 0° C. and stirred overnight at ambient temperature. The above mixture was diluted in methylene chloride (200 mL), was washed with a saturated NaHCO3 aqueous solution (100 mL), and then, was washed with water (100 mL). The above organic layer was dried over anhydrous MgSO4 and concentrated under vacuum to obtain tert-butyl 4-(4-((5-chloro-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine-1-carboxylate (1.0 g) in a yield of 57%.
- 1H NMR (300 MHz, CDCl3) δ 10.61 (s, 1 H), 8.95 (d, J=8.5 Hz, 1 H), 8.29 (dd, J=8.4, 1.4 Hz, 1 H), 8.23 (s, 1 H), 8.15 (d, J=8.1 Hz, 1 H), 7.67-7.61 (m, 1 H), 7.50 (s, 1 H), 7.22-7.17 (m, 1 H), 6.81-6.77 (m, 2 H), 4.31-4.25 (m, 2 H), 3.92 (s, 3 H), 2.83 (t, J=12.2 Hz, 2 H), 2.65 (dt, J=12.1, 3.4 Hz, 1 H), 1.88-1.84 (m, 2 H), 1.72-7.62 (m, 2 H), 1.51 (s, 9 H); LC-MS calcd for C27H31ClN6O5 554.2, found 555.0 (M+H+)
- Tert-butyl 4-(4-((5-chloro-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate (1.4 g, 2.4 mmol) obtained in
Step 1 above, iron powder (0.68 g, 12 mmol), and NH4Cl (0.65 g, 12 mmol) were added to THF/H2O (1:1, 24 mL). The above reaction mixture was stirred for 1 hour at 60° C. After completion of the reaction, the above reaction mixture was filtered through celite and concentrated under vacuum. The above residue was washed with water and filtered to obtain tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate (0.50 g) in a yield of 53% without a separate purification process. - LC-MS calcd for C27H33ClN6O3 524.2, found 525.0 (M+H+)
- To an anhydrous methylene chloride (1 mL) solution of chlorosulfonyl isocyanate (8.7 μL, 0.1 mmol) was added dropwise anhydrous methylene chloride (1 mL) of t-butanol (9.5 uL, 0.1 mmol) at 0° C. The above mixture was stirred for 30 minutes at 0° C., and Et3N (16 uL, 0.11 mmol) was added and stirred for 30 minutes at 0° C. The above reaction solution was added slowly at 0° C. to a methylene chloride (1 mL) solution of tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate (26 mg, 0.05 mmol) obtained in Step 2 above. The above mixture was stirred for 3 hours at ambient temperature. The above reaction mixture was diluted in methylene chloride (20 mL) and washed with water (10 mL). The above organic layer was dried over anhydrous MgSO4 and concentrated under vacuum. The residue was purified by silica gel flash column chromatography (CH2Cl2/EtOAc, 5:1) to obtain tert-butyl 4-(4-((4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate (17 mg, white solid) in a yield of 49%.
- 1H NMR (300 MHz, (CD3)2SO) δ 8.13 (s, 1 H), 7.97-7.92 (m, 1 H), 7.89-7.85 (m, 1 H), 7.71 (d, J=7.8 Hz, 1 H), 7.26-7.13 (m, 3 H), 6.88 (s, 1 H), 6.67 (d, J=8.3 Hz, 1 H), 4.08 (d, J=12.3 Hz, 2 H), 3.80 (s, 3 H), 2.86-2.72 (m, 2 H), 2.68-2.58 (m, 1 H), 1.74 (d, J=12.3 Hz, 2 H), 1.57-1.46 (m, 2 H), 1.42 (s, 9 H), 1.39 (s, 9 H); LC-MS calcd for C32H42ClN7O7S 703.3, found 704.8 (M+H+)
- CH2Cl2/trifluoroacetic acid (1:1, 1 mL) of tert-butyl 4-(4-((4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate (4 mg, 0.006 mmol) obtained in
Step 3 above was stirred for 2 hours at ambient temperature. To the above reaction mixture was added 1,4-dioxane (10 μL) of 4 N HCl. The above reaction mixture was concentrated under vacuum to obtain 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine (4.2 mg, white solid) in a quantitative yield. - 1H NMR (300 MHz, CD3OD) δ 8.13 (s, 1 H), 7.83 (d, J=7.6 Hz, 1 H), 7.53 (d, J=8.3 Hz, 2 H), 7.39-7.27 (m, 2 H), 6.98 (s, 1 H), 6.78 (d, J=8.0 Hz, 1 H), 3.89 (s, 3 H), 3.53 (d, J=12.3 Hz, 2 H), 3.16 (t, J=12.0 Hz, 2 H), 2.94 (m, 1 H), 2.12 (m, 2 H), 2.02-1.91 (m, 2 H); LC-MS calcd for C22H26ClN7O3S 503.2, found 503.8 (M+H+)
- The compound of Example 7 was prepared according to Reaction Example 6 below.
- The same manner as in
Step 1 of Example 6 above was performed to obtain tert-butyl 4-(4-((5-bromo-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine-1-carboxylate (68 mg, 58%). - 1H NMR (300 MHz, CDCl3) δ 10.52 (s, 1 H), 8.90 (d, J=8.7 Hz, 1 H), 8.29 (s, 1 H), 8.26 (dd, J=8.4, 1.0 Hz, 1 H), 8.12 (d, J=8.6 Hz, 1 H), 7.62 (t, J=7.5 Hz, 1 H), 7.52 (s, 1 H), 7.18 (t, J=7.5 Hz, 1 H), 6.78-6.76 (m, 2 H), 4.27 (d, J=11.2 Hz, 2 H), 3.91 (s, 3 H), 2.82 (t, J=12.3 Hz, 2 H), 2.68-2.60 (m, 1 H), 1.85 (d, J=12.3 Hz, 2 H), 1.71-1.57 (m, 2 H), 1.50 (s, 9 H); LC-MS calcd for C27H31BrN6O5 598.2, found 599.7 (M+H+)
- The same manner as in Step 2 of Example 6 above was performed to obtain tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-bromopyrimidin-2-yl)amino)-3-methoxy phenyl)piperidine-1-carboxylate (60 mg, 94%).
- LC-MS calcd for C27H33BrN6O3 568.2, found 569.8 (M+H+)
- The same manner as in
Step 3 of Example 6 above was performed to obtain tert-butyl 4-(4-((5-bromo-4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine-1-carboxylate (30 mg, 70%). - 1H NMR (500 MHz, CD3OD) δ 8.12 (s, 1 H), 7.93 (d, J=8.0 Hz, 1 H), 7.80 (d, J=8.1 Hz, 1 H), 7.42 (d, J=8.0 Hz, 1 H), 7.34 (t, J=7.2 Hz, 1 H), 7.27 (t, J=8.1 Hz, 1 H), 6.83 (s, 1 H), 6.61 (d, J=8.0 Hz, 1 H), 4.22 (d, J=13.0 Hz, 2 H), 3.87 (s, 3 H), 2.89-2.86 (m, 2 H), 2.70-2.65 (m, 1 H), 1.81 (d, J=12.3 Hz, 2 H), 1.63-1.57 (m, 2 H), 1.50 (s, 9 H), 1.49 (s, 9 H); LC-MS calcd for C32H42BrN7O7S 747.2, found 749.6 (M+H+)
- The same manner as in Step 4 of Example 6 above was performed to obtain 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine (24 mg, quantitative yield).
- 1H NMR (300 MHz, CD3OD) δ 8.21 (s, 1 H), 7.85-7.83 (m, 1 H), 7.53-7.27 (m, 5 H), 6.99 (s, 1 H), 6.80-6.78 (m, 1 H), 3.89 (s, 3 H), 3.54 (d, J=12.3 Hz, 2 H), 3.21-3.12 (m, 2 H), 2.99-2.90 (m, 1 H), 2.10 (d, J=13.4 Hz, 2 H), 2.02-1.87 (m, 2 H); LC-MS calcd for C22H26BrN7O3S 547.1, found 547.7 (M+H+)
- The compound of Example 8 was prepared according to Reaction Example 7 below.
- The same manner as in
Step 1 of Example 1 above was performed to obtain N-(2-((2-chloro-5-methylpyrimidin-4-yl)amino)phenyl)methanesulfonamide in a yield of 26%. - 1H NMR (300 MHz, CDCl3) δ 9.37 (s, 1 H), 8.62 (s, 1 H), 8.21 (sd, J=0.9 Hz, 1 H), 7.64-7.60 (m, 1 H), 7.49-7.45 (m, 1 H), 7.32-7.24 (m, 2 H), 2.97 (s, 3 H), 2.17 (sd, J=0.9 Hz, 1 H); LC-MS calcd for C12H13ClN4O2S 312.0, found 312.9 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino))-5-methylpyrimidin-4-ylamino)phenyl)methanesulfonamide in a yield of 65%.
- 1H NMR (300 MHz, CD3OD) δ 9.54 (br s, 1 H), 9.49 (br s, 1 H), 9.26 (sd, J=3.6 Hz, 1 H), 8.75 (br s, 1 H), 8.58 (br s, 1 H), 7.89 (s, 1 H), 7.54 (dd, J=8.4, 3.3 Hz, 1 H), 7.45 (dd, J=8.4, 3.0 Hz, 1 H), 7.41-7.35 (m, 1 H), 7.32-7.23 (m, 2 H), 6.88 (s, 1 H), 6.52 (sd, J=5.7 Hz, 1 H), 3.80 (s, 3 H), 3.38 (d, J=12.6 Hz, 2 H), 3.05-2.76 (m, 6 H), 2.18 (s, 3 H), 1.92-1.75 (m, 4 H); LC-MS calcd for C24H30N6O3S 482.2, found 483.0 (M+H+)
- The compound of Example 9 was prepared according to Reaction Example 8 below.
- The same manner as in
Step 1 of Example 1 above was performed to obtain N-(2-((2-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (white solid) in a yield of 47%. - 1H NMR (300 MHz, CDCl3) δ 9.28 (s, 1 H), 9.13 (s, 1 H), 8.12 (d, J=6.0 Hz, 1 H), 7.56-7.44 (m, 2 H), 7.29-7.23 (m, 2 H), 6.67 (d, J=5.7 Hz, 1 H), 2.97 (s, 3 H); LC-MS calcd for C11H11ClN4O2S 298.0, found 298.9 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide in a yield of 65%.
- 1H NMR (300 MHz, CD3OD) δ 10.27 (s, 1 H), 9.74 (s, 1 H), 9.26 (s, 1 H), 8.78 (d, J=10.8 Hz, 1 H), 8.59 (d, J=10.8 Hz, 1 H), 7.96 (d, J=7.2 Hz, 1 H), 7.54-7.46 (m, 3 H), 7.36-7.21 (m, 2 H), 6.93 (s, 1 H), 6.66 (d, J=8.1 Hz, 1 H), 6.47 (br s, 1 H), 3.82 (s, 3 H), 3.39 (d, J=12.6 Hz, 2 H), 3.06-2.95 (m, 5 H), 2.87-2.79 (m, 1 H), 1.95-1.78 (m, 4 H); LC-MS calcd for C23H28N6O3S 468.2, found 469.0 (M+H+)
- The compound of Example 10 was prepared according to Reaction Example 9 below.
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (51.3 mg, 57%).
- 1H NMR (300 MHz, CD3OD) δ 8.10 (s, 1 H), 7.74 (dd, J=7.4, 2.2 Hz, 1 H), 7.53 (dd, J=7.4, 2.1 Hz, 1 H), 7.48 (d, J=8.7 Hz, 1 H), 7.43 (td, J=7.4, 1.9 Hz, 1 H), 7.36 (td, J=7.5, 1.9 Hz, 1 H), 6.92 (sd, J=2.5 Hz, 1 H), 6.67 (dd, J=8.9, 2.5 Hz, 1 H), 3.88 (s, 3 H), 3.82 (d, J=12.4 Hz, 2 H), 3.43 (br s, 4 H), 3.24-3.04 (m, 7 H), 2.96 (s, 3 H), 2.92 (s, 3 H), 2.19 (d, J=12.7, 2 H), 1.99-1.86 (m, 2 H); LC-MS calcd C28H37Cl N8O3S 600.2, found 601.0 (M+H+)
- The compound of Example 11 was prepared according to Reaction Example 10 below.
- The reaction tube containing DMF (30 mL) of a mixture of 4-fluoro-2-methoxy-1-nitrobenzene (5.00 g, 29.22 mmol), N,N-dimethylpiperidin-4-amine (6.53 g, 35.06 mmol), and K2CO3 (6.06 g, 43.83 mmol) was sealed with a Teflon-lined cap, and the above reaction mixture was stirred for 2 hours at 90° C. The above mixture was concentrated under reduced pressure. The above reaction mixture was diluted in ethyl acetate (300 mL), washed with water (100 mL), and then, washed with brine (100 mL). The residue was purified by silica gel flash column chromatography (CH2Cl2/MeOH, 9:1) to obtain 1-(3-methoxy-4-nitrophenyl)-N,N-dimethylpiperidin-4-amine (9.73 g, pale yellow solid) in a yield of 99%.
- 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J=9.4 Hz, 1 H), 6.42 (dd, J=9.4, 2.6 Hz, 1 H), 6.31 (sd, J=2.5 Hz, 1 H), 3.94 (s, 3 H), 3.92 (d, J=13.0 Hz, 2 H), 2.97 (td, J=12.3, 2.8 Hz, 2 H), 2.43-2.33 9 (m, 1 H), 2.30 (s, 6 H), 1.95 (d, J=13.0 Hz, 2 H), 1.58 (qd, J=11.9, 4.0 Hz, 2 H); LC-MS calcd for C14H21N3O3 279.2, found 280.0 (M+H+)
- The same manner as in Step 2 of Example 6 above was performed to obtain 1-(4-amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine (8.50 mg, 96%).
- LC-MS calcd for C14H24N3O 249.2, found 250.0 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (46.7 mg, 57%).
- 1H NMR (300 MHz, CD3OD) δ 8.04 (s, 1 H), 7.77 (d, J=7.5 Hz, 1 H), 7.52 (dd, J=7.5, 2.0 Hz, 1 H), 7.42-7.32 (m, 2 H), 7.25 (d, J=8.7, 1 H), 6.70 (sd, J=2.5 Hz 1 H), 6.50 (d, J=8.7 Hz, 1 H), 3.90 (d, J=12.8 Hz, 2 H), 3.84 (s, 3 H), 3.44-3.34 (m, 1 H), 2.97 (s, 3 H), 2.92-2.82 (m, 8 H), 2.25 (d, J=12.1 Hz, 1 H), 1.93-1.79 (m, 2 H); LC-MS calcd for C25H32ClN7O3S 545.2, found 546.0 (M+H+)
- The compound of Example 12 was prepared according to Reaction Example 11 below.
- To a tetrahydrofuran (18 mL) suspension of lithium tetrahydroaluminate (619.3 mg, 16.3 mmol) was added tetrahydrofuran (18 mL) of tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate (500 mg, 1.63 mmol) at 0° C. The above reaction tube was sealed with a Teflon-lined cap, and the above reaction mixture was stirred for 6 hours at 90° C. The above reaction mixture was cooled, Na2SO410H2O (3 g) was slowly added, and it was stirred for 30 minutes at ambient temperature. The above mixture was filtered and washed with dichloromethane. The above organic layer was dried over anhydrous MgSO4 and concentrated under vacuum to obtain 2-methoxy-4-(1-methylpiperidin-4-yl)aniline (319.4 mg, brown solid) in a yield of 89%.
- 1H NMR (300 MHz, CD3OD) δ 6.68-6.64 (m, 3 H), 3.82 (s, 3 H), 2.98-2.92 (m, 2 H), 2.43-2.34 (m, 1 H), 2.31 (s, 3 H), 2.07-1.98 (m, 2 H), 1.82-1.77 (m, 4 H); LC-MS calcd for C13H20N2O 220.2, found 221.1 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (55.1 mg, 71%).
- 1H NMR (300 MHz, CD3OD) δ 8.12 (s, 1 H), 7.75 (dd, J=7.4, 2.2 Hz, 1 H), 7.52 (d, J=8.6 Hz, 2 H), 7.41-7.31 (m, 2 H), 6.92 (sd, J=1.8 Hz, 1 H), 6.69 (d, J=8.6 Hz, 1 H), 3.87 (s, 3 H), 3.63 (d, J=12.2 Hz 1 H), 3.15 (td, J=12.1, 3.1 Hz, 2 H), 2.94 (s, 3 H), 2.93 (s, 3 H), 2.89-2.82 (m, 1 H), 2.11 (d, J=14.2 Hz, 2 H), 2.03-1.89 (m, 2 H); LC-MS calcd for C24H29ClN6OS 516.2, found 516.9 (M+H+)
- The compound of Example 13 was prepared according to Reaction Example 12 below.
- CH2Cl2/trifluoroacetic acid (1:1, 1 mL) of tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate 30 (300 mg, 0.98 mmol) was stirred for 2 hours at ambient temperature. The above reactant was concentrated under reduced pressure. To an acetonitrile (10 mL) solution of the above residue were added 2-bromoethyl acetate (140 μL, 1.22 mmol) and potassium carbonate (1.00 g, 7.83 mmol) over 4 hours at 95° C. The above mixture was concentrated under reduced pressure. The above reaction mixture was diluted in ethyl acetate (100 mL) and washed with water (50 mL). The residue was purified by silica gel flash column chromatography (CH2Cl2/MeOH, 9:1) to obtain 2-(4-(4-amino-3-methoxyphenyl)piperidin-1-yl)ethyl acetate (125.8 mg, pale yellow oil) in a yield of 44%.
- 1H NMR (300 MHz, CDCl3) δ 6.66 (m, 3 H), 4.23 (t, J=6.1 Hz, 2 H), 3.83 (s, 3 H), 3.68 (br s, 2 H), 3.04 (dt, J=11.3, 2.8 Hz, 2 H), 2.67 (t, J=6.0 Hz, 2 H), 2.40 (tt, J=10.3, 5.1 Hz, 1 H), 2.20-2.10 (m, 2 H), 2.08 (s, 3 H), 1.84-1.75 (m, 4 H); LC-MS calcd C16H24N2O3 292.2, found 293.0 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-chloro-2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (74 mg, 61%).
- 1H NMR (300 MHz, CD3OD) δ 8.12 (s, 1 H), 7.74 (dd, J=7.5, 2.0 Hz, 1 H), 7.54-7.49 (m, 2 H), 7.42-7.31 (m, 2 H), 6.93 (sd, J=1.8 Hz, 1 H), 6.70 (d, J=8.3 Hz, 1 H), 3.94-3.91 (m, 2 H), 3.87 (s, 3 H), 3.74 (d, J=12.5 Hz, 2 H), 3.30-3.28 (m, 2 H), 3.16 (td, J=12.6, 3.6 Hz, 2 H), 2.94 (s, 3 H), 2.92-2.86 (m, 1 H), 2.14-1.97 (m, 4 H); LC-MS calcd C25H31ClN6O4S 546.2, found 547.4 (M+H+)
- The compound of Example 14 was prepared according to Reaction Example 13 below.
- 4-(3-methoxy-4-nitrophenyl)-1,2,3,6-tetrahydropyridine (1.29 g, 5.51 mmol), 1-boc-4-piperidone (2.19 g, 11.01 mmol), dichloromethane 1 M solution (170 μL, 17.62 mmol) of acetic acid, and 1,2-dichloroethane (20 mL) of triethylamine (730 μL, 5.23 mmol) were stirred for 1 hour at ambient temperature, and then, sodium triacetoxyborohydride (1.75 g, 8.26 mmol) was added. The above reaction mixture was stirred overnight at ambient temperature. The above mixture was diluted with methylene chloride (200 mL), washed with a saturated NaHCO3 aqueous solution (100 mL), and then, washed with water (100 mL). The above organic layer was dried over anhydrous MgSO4 and concentrated under vacuum, and the residue was purified by silica gel flash column chromatography (CH2Cl2/MeOH, 9:1) to obtain tert-butyl 4-(4-(3-methoxy-4-nitrophenyl)-3,6-dihydropyridin-1-(2H)-yl)piperidine-1-carboxylate (1.11 g, pale brown solid) in a yield of 50%.
- LC-MS calcd C22H31N3O5 417.2, found 418.0 (M+H+)
- The same manner as in Step 2 of Example 13 above was performed to obtain 2-(4-(4-(4-amino-3-methoxyphenyl)-3,6-dihydropyridin-1-(2H)-yl)piperidin-1-yl)ethyl acetate (536.6 mg, 50%).
- LC-MS calcd C21H29N3O5, 403.2, found 404.1 (M+H+)
- To methanol (10 mL) of 2-(4-(4-(4-amino-3-methoxyphenyl)-3,6-dihydropyridin-1(2H)-yl)piperidin-1-yl)ethyl acetate (536.6 mg, 1.33 mmol) was added 10% Pd/C (palladium on activated charcoal, 141.5 mg, 1.33 mmol). The above reaction mixture was stirred overnight under a hydrogen atmosphere. The filtrate filtered through celite was concentrated under reduced pressure to obtain 2-(4-(4-amino-3-methoxyphenyl)-[1,4′-bipiperidin]-1′-yl)ethyl acetate (399.9 mg, brown gum) in a yield of 80% without a separate purification process.
- LC-MS calcd C21H33N3O3 375.3, found 376.2 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-chloro-2-((4-(1′-(2-hydroxyethyl)-[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (3.4 mg, 4%).
- 1H NMR (300 MHz, CD3OD) δ 8.13 (s, 1 H), 7.38 (d, J=7.8 Hz, 1 H), 7.53 (dd, J=7.8, 1.7 Hz, 1 H), 7.47 (d, J=8.2 Hz, 1 H), 7.43-7.32 (m, 2 H), 6.94 (s, 1 H), 6.70 (d, J=8.4 Hz, 1 H), 3.93-3.84 (m, 7 H), 3.72 (d, J=11.7 Hz, 2 H), 3.62-3.54 (m, 1 H), 3.24-3.13 (m, 4 H), 2.94-2.86 (m, 4 H), 2.48 (d, J=13.0 Hz, 2 H), 2.22-2.06 (m, 7 H); LC-MS calcd C30H40ClN7O4S 629.3, found 630.0 (M+H+)
- The compound of Example 15 was prepared according to Reaction Example 14 below.
- To a dichloromethane (2 mL) solution of N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (40 mg, 0.07 mmol) were added triethylamine (20 μL, 0.14 mmol) and acetic anhydride (10 μL, 0.07 mmol) at 0° C. The above reaction mixture was stirred for 2 hours at ambient temperature. The above mixture was concentrated under reduced pressure, and the residue was purified by prep-HPLC to obtain N-(2-((2-((4-(1-acetylpiperidin-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (12.7 mg, white solid) in a yield of 34%.
- 1H NMR (300 MHz, CD3OD) δ 8.09 (s, 1 H), 7.76 (d, J=7.6 Hz, 1 H), 7.51 (dd, J=7.7, 1.9 Hz, 1 H), 7.43-7.32 (m, 3 H), 6.94 (s, 1 H), 6.70 (d, J=8.2 Hz, 1 H), 4.68 (d, J=13.2 Hz, 1 H), 4.05 (d, J=13.6 Hz, 1 H), 3.86 (s, 3 H), 3.24 (t, J=12.1 Hz 1 H), 2.95 (s, 3 H), 2.87-2.66 (m, 2 H), 2.15 (s, 3 H), 1.88 (t, J=13.7 Hz, 2 H), 1.76-1.51 (m, 2 H); LC-MS calcd for C25H29ClN6O4S 544.2, found 545.0 (M+H+)
- The compounds of Examples 16 to 18 were prepared according to Reaction Example 15 below.
- In which, R6=H indicates the compound of Example 16, R6=CH3 indicates the compound of Example 17, and R6=Ac indicates the compound of Example 18.
- N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (24.4 mg, 0.04 mmol), 1-boc-4-piperidone (16.9 mg, 0.08 mmol), a dichloromethane 1 M solution (120 μL, 0.12 mmol) of acetic acid, and 1,2-dichloroethane (1 mL) of triethylamine (10 μL, 0.04 mmol) were stirred for 1 hour at ambient temperature, and then, sodium triacetoxyborohydride (12.7 mg, 0.06 mmol) was added. The above reaction mixture was stirred overnight at ambient temperature. The above mixture was concentrated under reduced pressure, CH2Cl2/trifluoroacetic acid (1:1, 1 mL) was added, and it was stirred for 2 hours at ambient temperature. The above reaction mixture was concentrated under vacuum, and the residue was purified by prep-HPLC to obtain N-(2-((2-((4-([1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (9.4 mg, red solid) in a yield of 51%.
- 1H NMR (300 MHz, CD3OD) δ 8.10 (s, 1 H), 7.78-7.74 (m, 1 H), 7.53-7.47 (m, 1 H), 7.42-7.36 (m, 2 H), 7.32 (d, J=8.1 Hz, 1 H), 7.12 (sd, J=1.6 Hz, 1 H), 6.99 (dd, J=8.2, 1.6 Hz, 1 H), 4.39 (d, J=13.4 Hz, 1 H), 3.98 (s, 3 H), 3.89-3.78 (m, 1 H), 3.74-3.58 (m, 1 H), 3.52 (d, J=13.0 Hz, 2 H), 3.21 (t, J=13.0 Hz, 2 H), 3.10 (t, J=13.6 Hz, 1 H), 3.03 (s, 3 H), 2.23 (d, J=13.5 Hz, 2 H), 2.08-1.97 (m, 4 H), 1.84-1.71 (m, 2 H); LC-MS calcd C28H36ClN7O3S 585.2, found 586.0 (M+H+)
- The same manner as in
Step 1 of Example 16 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(1′-methyl-[1,4′-bipiperidin]-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (73.3 mg, 88%). - 1H NMR (300 MHz, CD3OD) δ 8.13 (s, 1 H), 7.72 (dd, J=7.8, 1.7 Hz, 1 H), 7.52 (dd, J=7.8, 1.7 Hz, 1 H), 7.45 (d, J=8.2 Hz, 1 H), 7.40 (td, J=7.6, 1.8 Hz, 1 H), 7.34 (td, J=7.7, 1.7 Hz, 1 H), 6.94 (sd, J=1.8 Hz, 1 H), 6.69 (d, J=8.2 Hz, 1 H), 3.87 (s, 3 H), 3.72 (d, J=11.9 Hz, 4 H), 3.66-3.53 (m, 1 H), 3.27-3.09 (m, 4 H), 2.94 (s, 3 H), 2.92 (s, 3 H), 2.91-2.84 (m, 1 H), 2.47 (d, J=13.4 Hz, 2 H), 2.24-2.06 (m, 6 H); LC-MS calcd C29H38ClN7O3S 599.2, found 600.0 (M+H+)
- The same manner as in
Step 1 of Example 16 above was performed to obtain N-(2-((2-((4-(1′-acetyl-[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (40.2 mg, 46%). - 1H NMR (300 MHz, CD3OD) δ 8.11 (s, 1 H), 7.75 (dd, J=7.2, 2.3 Hz, 1 H), 7.55-7.50 (m, 2 H), 7.41-7.32 (m, 2 H), 6.91 (s, 1 H), 6.68 (d, J=9.5 Hz, 1 H), 4.74 (d, J=13.6 Hz, 1 H), 4.13 (d, J=13.9 Hz, 1 H), 3.87 (s, 3 H), 3.67 (d, J=12.1 Hz, 2 H), 3.57-3.49 (m, 1 H), 3.21 (t, J=12.9 Hz, 3 H), 2.94 (s, 3 H), 2.92-2.85 (m, 1 H), 2.68 (t, J=12.7 Hz, 1 H), 2.24-2.17 (m, 7 H), 2.08-1.92 (m, 2 H), 1.85-1.61 (m, 2 H); LC-MS calcd C30H38ClN7O4S 627.2, found 628.0 (M+H+)
- The compounds of Examples 19 to 22 were prepared according to Reaction Example 16 below.
- In which, in the compound produced after the performance of Step 5, R6=Ac indicates the compound of Example 19, and R6=Boc indicates the compound of Example 20, and the compound produced after the performance of
Step 6 is the compound of Example 21, and the compound produced after the performance of Step 7 is the compound of Example 22. - While DMF (75 mL) of 4-fluoro-2-methoxy-1-nitrobenzene (5 g, 29.21 mmol) was stirred at ambient temperature, 1,4-dioxa-8-azaspiro[4.5]decane (5.0 g, 35.0 mmol) and potassium carbonate (8.0 g, 58.0 mmol) were added. The above reaction mixture was stirred overnight at ambient temperature. The above reaction mixture was quenched with cold water and stirred for 15 minutes. The precipitated solid was filtered and dried to obtain 8-(3-methoxy-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane (8.0 g, 94%) as a yellow solid.
- 1H NMR (300 MHz, CDCl3) δ 8.01 (d, J=9.3 Hz, 1 H), 6.45 (dd, J=9.4, 2.6 Hz, 1 H), 6.35 (d, J=2.5 Hz, 1 H), 4.02 (s, 4 H), 3.96 (s, 3 H), 3.72-3.46 (m, 4 H), 2.24-1.72 (m, 4 H).
- To a methanol (15 mL) stirred solution of 8-(3-methoxy-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane (1.0 g, 3.39 mmol) was added 10% Pd/C (palladium on activated charcoal, 36 mg, 0.33 mmol) under an argon atmosphere. The above reaction mixture was stirred for 3 hours at ambient temperature under a hydrogen gas pressure of 1 atm. The above reaction mixture was filtered through celite and concentrated under reduced pressure to obtain 2-methoxy-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)aniline (800 mg, 90%) as a brown solid.
- 1H NMR (300 MHz, CDCl3) δ 6.67-6.50 (m, 3 H), 4.02 (s, 4 H), 3.87 (br s, 3 H), 3.22 (br s, 4 H), 1.95 (br s, 4 H)
- To a n-butanol (5 mL) mixture of N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (200 mg, 0.60 mmol) and 2-methoxy-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)aniline (158 mg, 0.60 mmol) was added a n-butanol solution (3.75 mL, 0.30 mmol) of 0.08 N HCl or TFA (trifluoroacetic acid). The above reaction tube was sealed with a Teflon-lined cap, and the reaction mixture was stirred overnight at 95° C. The above mixture was concentrated under reduced pressure, and the residue was purified by prep-HPLC to obtain N-(2-((5-chloro-2-((2-methoxy-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (150 mg, 40%) as a white solid.
- While methanol (2 ml) of N-(2-((5-chloro-2-((2-methoxy-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (150 mg, 0.267 mmol) was stirred, 6 N HCl (2 ml) was added at ambient temperature. The above reaction mixture was heated at 60° C. for 3 hours. The above reaction mixture was cooled at ambient temperature, and a volatile substance was removed under reduced pressure. The resulting unpurified product was diluted with water, basified (pH ˜8) with a 5 N NaOH aqueous solution, and then, extracted with dichloromethane. The above organic layer was separated, washed with water and brine, then, dried over Na2SO4, and evaporated under reduced pressure to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-oxopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (100 mg, 72%) as a white solid.
- 1H NMR (300 MHz, CDCl3) δ 8.06 (s, 1 H), 7.88-7.65 (m, 3 H), 7.64-7.45 (m, 1 H), 7.43-7.31 (m, 2 H), 6.56 (d, J=2.6 Hz, 1 H), 6.39 (dd, J=8.8, 2.5 Hz, 1 H), 3.86 (s, 3 H), 3.54 (t, J=6.2 Hz, 4 H), 2.96 (s, 3 H), 2.61 (t, J=6.0 Hz, 4 H)
- After N-(2-((2-((4-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (60 mg, 0.11 mmol), 1-acetylpiperazine (28 mg, 0.17 mmol), 1 M solution (220 μL, 0.17 mmol) of dichloromethane of acetic acid, and 1,2-dichloroethane (1 mL) of triethylamine (50 μL, 0.34 mmol) were stirred for 1 hour at ambient temperature, sodium triacetoxyborohydride (49 mg, 0.23 mmol) was added. The above reaction mixture was stirred overnight at ambient temperature. The above mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC to obtain N-(2-((2-((4-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (35 mg, white solid) in a yield of 48%.
- 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1 H), 7.79-7.75 (m, 1 H), 7.72 (dd, J=7.2, 2.3 Hz, 1 H), 7.56-7.52 (m, 2 H), 7.38-7.32 (m, 3 H), 6.51 (br s, 1 H), 6.33 (d, J=8.9 Hz, 1 H), 3.85 (s, 3 H), 3.69-3.61 (m, 4 H), 2.93 (s, 3 H), 2.71 (t, J=11.7 Hz, 4 H), 2.13 (br s, 3 H), 2.03 (s, 4 H), 1.80 (bs, 4 H); LC-MS calcd for C29H37ClN8O4S 628.23, found 627.0 (M−H+)
- The same manner as in Step 5 of Example 19 above was performed to obtain tert-butyl 4-(1-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (52 mg, 63%).
- 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1 H), 7.76 (d, J=9.0 Hz, 1 H), 7.72-7.66 (m, 1 H), 7.57-7.52 (m, 1 H), 7.48 (s, 1 H), 7.38-7.31 (m, 2 H), 7.26 (s, 1 H), 6.50 (br s, 1 H), 6.33 (d, J=8.4 Hz, 1 H), 3.84 (s, 3 H), 3.69-3.54 (m, 6 H), 2.92 (s, 3 H), 2.77-2.62 (m, 6 H), 2.07-1.99 (m, 3 H), 1.83-1.74 (m, 2 H), 1.49 (s, 9H); LC-MS calcd for C32H43ClN8O5S 686.28, found 685.0 (M−H+)
- To a dichloromethane (1 ml) mixture of tert-butyl 4-(1-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (20 mg, 0.03 mmol) was added dioxane (0.014 ml, 0.06 mmol) of 4 N HCl at 0° C. The above reaction mixture was elevated to ambient temperature and stirred for 2 hours. The above reaction mixture was concentrated under reduced pressure to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (20 mg, white solid) in a yield of 88%.
- 1H NMR (300 MHz, CD3OD) δ 8.19 (s, 1 H), 7.70 (d, J=7.9 Hz, 1 H), 7.60-7.56 (m, 1 H), 7.52-7.44 (m, 2 H), 7.45-7.40 (m, 1 H), 7.16 (br s, 1 H), 6.85 (br s, 1 H), 3.94-3.88 (m, 5 H), 3.70-3.66 (m, 8 H), 3.50-3.38 (m, 2 H), 3.00 (s, 3 H), 2.51-2.40 (m, 2 H), 2.34-2.18 (m, 2 H); LC-MS calcd for C27H35ClN8O3S 586.22, found 585.1 (M−H+)
- While DMF (1 mL) of N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (30 mg, 0.05 mmol) was stirred, DIPEA (diisopropylethylamine) (0.017 mL, 0.1 mmol) and 2-iodoethanol (10.9 mg 0.06 mmol) were added at ambient temperature. The above reaction mixture was heated under 80° C. for 30 minutes at MW (microwave). The above reaction mixture was concentrated and purified by HPLC to obtain N-(2-((5-chloro-2-((4-(4-(4-(2-hydroxyethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (20.1 mg, 70%) as a white solid.
- 1H NMR (300 MHz, CD3OD) δ 8.11 (s, 1 H), 7.76 (dd, J=7.4, 2.1 Hz, 1 H), 7.58-7.53 (m, 1 H), 7.49-7.37 (m, 3 H), 6.91 (d, J=2.6 Hz, 1 H), 6.66 (dd, J=8.8, 2.5 Hz, 1 H), 3.92-3.80 (m, 7 H), 3.50 (br s, 4 H), 3.31-3.25 (m, 4 H), 3.12-3.16 (m, 4 H), 2.99 (s, 3 H), 2.23 (d, J=12.4 Hz, 2 H), 1.99-1.87 (m, 2 H); LC-MS calcd for C29H39ClN8O4S 630.25, found 629.1 (M−H+)
- The compounds of Examples 23 and 27 were prepared according to Reaction Example 17 below.
- In which, the compound produced after the performance of
Step 1 is the compound of Example 23, and in the compound produced after the performance of Step 2, R6=Ac indicates the compound of Example 24, R6=Me indicates the compound of Example 25, and R6=Boc indicates the compound of Example 26, and the compound produced after the performance ofStep 3 is the compound of Example 27. - To a n-butanol (1 mL) mixture of N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)methanesulfonamide 2 (100 mg, 0.30 mmol) and tert-butyl 4-(4-amino-3-methoxyphenyl)piperazine-1-carboxylate (92.2 mg, 0.30 mmol) was added a n-butanol solution (3.75 mL, 0.30 mmol) of 0.08 N HCl or TFA (trifluoroacetic acid). The above reaction tube was sealed with a Teflon-lined cap, and the reaction mixture was stirred overnight at 95° C. The above mixture was concentrated under reduced pressure, and the residue was purified by prep-HPLC to obtain N-(2-((5-chloro-2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (150 mg, 82%) as a white solid.
- 1H NMR (500 MHz, CD3OD) δ 8.09 (s, 1 H), 7.82-7.77 (m, 1 H), 7.54 (dd, J=7.9, 1.7 Hz, 1 H), 7.44-7.31 (m, 3 H), 6.74 (d, J=2.5 Hz, 1 H), 6.50 (s, 1 H), 3.87 (s, 3 H), 3.45 (m, 4 H), 3.41 (m, 4 H), 2.98 (s, 3 H)
- The same manner as in Step 4 of Example 19 above was performed to obtain N-(2-((2-((4-(4-(1-acetylpiperidin-4-yl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (60 mg, 64%).
- 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1 H), 7.79 (d, J=8.8 Hz, 1 H), 7.75-7.68 (m, 1 H), 7.60 (s, 1 H), 7.57-7.50 (m, 1 H), 7.37-7.31 (m, 2 H), 6.49 (d, J=2.5 Hz, 1 H), 6.31 (d, J=8.8 Hz, 1 H), 3.84 (s, 3 H), 3.29-3.18 (br s, 4 H), 3.16-3.40 (m, 2 H), 2.94 (s, 3 H), 2.90-2.81 (br s, 4 H), 2.66-2.52 (m, 2 H), 2.13 (s, 3 H), 1.99-1.95 (m, 2 H), 1.59-1.47 (s, 2 H); LC-MS calcd for C29H37ClN8O4S 628.23, found 627.0 (M−H+)
- The same manner as in Step 4 of Example 19 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (29.6 mg, 33%).
- 1H NMR (500 MHz, CD3OD) δ 8.08 (s, 1 H), 7.80 (d, J=7.8 Hz, 1 H), 7.53 (dd, J=7.7, 1.8 Hz, 1 H), 7.40-7.33 (m, 3 H), 6.73 (d, J=2.5 Hz, 1 H), 6.50 (d, J=8.7 Hz, 1 H), 3.87 (s, 3 H), 3.75 (d, J=12.8 Hz, 2 H), 3.62-3.45 (m, 8 H), 3.20-3.12 (m, 2 H), 2.98 (s, 3 H), 2.95 (s, 3 H), 2.56-2.47 (d, J=13.4 Hz, 2 H), 2.20-2.10 (m, 2 H); LC-MS calcd for C28H37ClN8O3S 600.24, found 599.0 (M−H+)
- The same manner as in Step 4 of Example 19 above was performed to obtain tert-butyl 4-(4-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)piperidine-1-carboxylate (16.0 mg, 17%).
- 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1 H), 7.79 (d, J=8.8 Hz, 1 H), 7.74-7.68 (m, 1 H), 7.56-7.51 (m, 2 H), 7.38-7.31 (m, 2 H), 6.49 (d, J=2.5 Hz, 1 H), 6.32 (d, J=9.2 Hz, 1 H), 4.23 (br s, 2 H), 3.84 (s, 3 H), 3.29 (br s, 4 H), 2.94 (br s, 7 H), 2.83-2.67 (m, 4 H), 2.08-2.98 (m, 2 H), 1.49 (s, 9 H); LC-MS calcd for C32H43ClN8O5S 686.28, found 684.9 (M−H+)
- The same manner as in Example 21 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (16 mg, 95%).
- 1H NMR (300 MHz, CD3OD) δ 8.09 (s, 1 H), 7.75 (br s, 1 H), 7.55 (br s, J=7.9, 1.6 Hz, 1 H), 7.48-7.35 (m, 2 H), 7.29 (d, J=8.8 Hz, 1 H), 6.77 (s, 1 H), 6.54 (br s, 1 H), 4.04-3.90 (m, 2 H), 3.88 (s, 3 H), 3.84-3.69 (m, 4 H), 3.66-3.58 (m, 2 H), 3.44-3.34 (m, 2 H), 3.27-3.11 (m, 3 H), 3.00 (s, 3 H), 2.55 (d, J=13.3 Hz, 2 H), 2.29-2.00 (m, 2 H); LC-MS calcd for C27H35ClN8O3S 586.22, found 585.0 (M−H+)
- The compound of Example 28 was prepared according to Reaction Example 18 below.
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (15.0 mg, 19%).
- 1H NMR (300 MHz, CDCl3) δ 8.09 (s, 1 H), 7.78 (d, J=8.8 Hz, 1 H), 7.74-7.68 (m, 1 H), 7.59-7.51 (m, 2 H), 7.38-7.32 (m, 2 H), 6.48 (d, J=2.5 Hz, 1 H), 6.35-6.28 (m, 1 H), 3.85 (s, 3 H), 3.34-3.26 (m, 4 H), 3.02-2.86 (m, 7 H), 2.59 (s, 3 H); LC-MS calcd for C23H28ClN7O3S 517.17, found 515.9 (M−H+)
- The compound of Example 29 was prepared according to Reaction Example 19 below.
- The same manner as in
Step 1 of Example 6 above was performed to obtain tert-butyl 4-(4-((5-chloro-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (1.35 g, 69%). - 1H NMR (300 MHz, CDCl3) δ 10.61 (s, 1 H), 8.95 (dd, J=8.7, 1.3 Hz, 1 H), 8.26 (dd, J=8.5, 1.6 Hz, 1 H), 8.19 (s, 1 H), 8.02 (d, J=8.7 Hz, 1 H), 7.60 (td, J=8.6, 7.9, 1.6 Hz, 1 H), 7.30 (s, 1 H), 7.16 (ddd, J=8.5, 7.2, 1.3 Hz, 1 H), 6.56 (d, J=2.5 Hz, 1 H), 6.50 (dd, J=8.7, 2.5 Hz, 1 H), 3.89 (s, 3 H), 3.71-3.50 (m, 4 H), 3.12-3.08 (m, 4 H), 1.49 (s, 9H); LC-MS calcd for C26H30ClN7O5 555.2, found 555.9 (M+H+)
- The same manner as in Step 2 of Example 6 above was performed to obtain tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (900 mg, 70%).
- LC-MS calcd for C26H32BrN7O3 525.2, found 526.0 (M+H+)
- The same manner as in
Step 3 of Example 6 above was performed to obtain tert-butyl 4-(4-((5-chloro-4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (13.5 mg, 39%). - 1H NMR (500 MHz, CDCl3) δ 8.03-7.90 (m, 3H), 7.87 (d, J=8.7 Hz, 1H), 7.46-7.28 (m, 3H), 7.20 (t, J=7.6 Hz, 1H), 6.50 (s, 1H), 6.34 (d, J=8.8 Hz, 1H), 3.82 (s, 3H), 3.58 (t, J=5.0 Hz, 4H), 3.04 (t, J=5.0 Hz, 4H), 1.48 (s, 18H)
- The same manner as in Step 4 of Example 6 above was performed to obtain 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine (3.6 mg, quantitative yield).
- 1H NMR (300 MHz, CD3OD) δ 8.05 (s, 1 H), 7.93-7.81 (m, 1 H), 7.50 (dd, J=7.7, 1.9 Hz, 1 H), 7.43-7.24 (m, 3 H), 6.73 (s, 1 H), 6.53 (d, J=8.7 Hz, 1 H), 3.85 (s, 3 H), 3.43-3.40 (m, 8 H); LC-MS calcd for C21H25ClN8O3S 504.2, found 504.8 (M+H+)
- The compound of Example 30 was prepared according to Reaction Example 20 below.
- The same manner as in
Step 1 of Example 6 above was performed to obtain tert-butyl 4-(4-((5-bromo-4-((2-nitrophenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (70 mg, 12%). - 1H NMR (300 MHz, CDCl3) δ 10.58 (s, 1 H), 8.86 (d, J=8.8 Hz, 1 H), 8.30-8.25 (m, 2H), 8.04 (s, 1 H), 7.60 (t, J=8.0 Hz, 1 H), 7.19 (t, J=7.8 Hz, 1 H), 6.61 (s, 1H), 3.90 (s, 3 H), 3.69 (br s, 4 H), 3.16 (br s, 4 H), 1.52-1.44 (s, 9 H); LC-MS calcd for C26H30BrN7O5 599.2, found 600.7 (M+H+)
- The same manner as in Step 2 of Example 6 above was performed to obtain tert-butyl 4-(4-((4-((2-aminophenyl)amino)-5-bromopyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (50 mg, 74%).
- LC-MS calcd for C26H33BrN7O3 569.2, found 569.8 (M+H+)
- The same manner as in
Step 3 of Example 6 above was performed to obtain tert-butyl 4-(4-((5-bromo-4-((2-((N-(tert-butoxycarbonyl)sulfamoyl)amino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate (20 mg, 33%). - 1H NMR (300 MHz, CD3OD) δ 8.07 (s, 1 H), 7.94 (d, J=8.0 Hz, 1 H), 7.82 (s, 1 H), 7.66 (d, J=8.7 Hz, 1 H), 7.38 (dd, J=7.7, 1.5 Hz, 1 H), 7.31 (td, J=7.8, 1.7 Hz, 1 H), 7.27-7.19 (m, 1 H), 6.62 (s, 1 H), 6.39 (s, 1 H), 3.84 (s, 3 H), 3.62-3.52 (m, 4 H), 3.09 (br s, 4H), 1.49 (s, 9 H), 1.48 (s, 9 H); LC-MS calcd for C31H41BrN6O7S 748.2, found 748.6 (M+H+)
- The same manner as in Step 4 of Example 6 above was performed to obtain 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine (16.9 mg, quantitative yield).
- 1H NMR (500 MHz, CD3OD) δ 8.13 (s, 1 H), 7.90 (s, 1 H), 7.50 (dd, J=7.7, 1.6 Hz, 1 H), 7.41-7.25 (m, 3 H), 6.74 (d, J=2.5 Hz, 1 H), 6.55 (s, 1 H), 3.85 (s, 3 H), 3.45 (q, J=4.1, 3.6 Hz, 4H), 3.39 (dd, J=6.7, 3.3 Hz, 4H); LC-MS calcd for C21H25BrN8O3S 548.1, found 548.7 (M+H+)
- The compound of Example 31 was prepared according to Reaction Example 21 below.
- The same manner as in
Step 1 of Example 1 above was performed to obtain N-(2-((2-chloro-5-(trifluoromethyppyrimidin-4-yl)amino)phenyl)methanesulfonamide (199 mg, 18%). - 1H NMR (300 MHz, CDCl3) δ 8.47 (s, 1 H), 8.23 (br s, 1 H), 7.92 (d, J=7.8 Hz, 1 H), 7.46-7.28 (m, 3 H), 6.27 (br s, 1 H), 3.05 (s, 3 H); LC-MS calcd for C12H10ClF3N4O2S 366.0, found 366.8 (M+H+)
- The same manner as in Step 2 of Example 1 above was performed to obtain N-(2-((2-((2-methoxy-4-(piperazin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (54.2 mg, 65%).
- 1H NMR (300 MHz, CD3OD) δ 8.32 (br s, 1 H), 7.68 (br s, 1 H), 7.49 (dd, J=7.4, 2.1 Hz, 1 H), 7.43-7.29 (m, 3 H), 6.69 (br s, 1 H), 6.39 (br s, 1 H), 3.85 (s, 3 H), 3.39 (br s, 8 H), 2.93 (s, 3 H); LC-MS calcd for C23H26F3N7O3S 537.2, found 537.8 (M+H+)
- The compound of Example 32 was prepared according to Reaction Example 22 below.
- The same manner as in
Step 1 of Example 6 above was performed to obtain 5-chloro-N2-(2-methoxy-4-morpholinophenyl)-N4-(2-nitrophenyl)pyrimidin-2,4-diamine (125.2 mg, 39%). - 1H NMR (300 MHz, CDCl3) δ 11.08 (s, 1 H), 10.31 (s, 1 H), 8.52 (d, J=7.9 Hz, 1 H), 8.28 (d, J=8.1 Hz, 1 H), 8.10 (s, 1 H), 7.69 (d, J=5.8 Hz, 1 H), 7.57-7.47 (m, 1 H), 7.33-7.30 (m, 1 H), 7.11 (s, 1 H), 6.86 (d, J=7.1 Hz, 1 H), 4.12 (br s, 4 H), 3.87 (s, 3 H), 3.44 (br s, 4 H).
- LC-MS calcd for C21H22ClN6O4 457.1, found 456.9 (M+H+)
- The same manner as in Step 2 of Example 6 above was performed to obtain N4-(2-aminophenyl)-5-chloro-N2-(2-methoxy-4-morpholinophenyl)pyrimidin-2,4-diamine (43.2 mg, 92%).
- LC-MS calcd for C21H24ClN6O2 427.2, found 426.9 (M+H+)
- To dichloromethane (2 mL) of N4-(2-aminophenyl)-5-chloro-N2-(2-methoxy-4-morpholinophenyl)pyrimidin-2,4-diamine (43.2 mg, 0.10 mmol) were added triethylamine (50 μL, 0.40 mmol) and methanesulfonyl chloride (30 μL, 0.30 mmol) at 0° C. The above reaction mixture was stirred overnight at ambient temperature. The above mixture was concentrated under reduced pressure, and the residue was purified by flash column chromatography (CH2Cl2/EtOAc, 5:1) to obtain N-(2-((5-chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (16.1 mg, pale yellow solid) in a yield of 32%.
- 1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1 H), 7.77 (d, J=8.8 Hz, 1 H), 7.70-7.67 (m, 1 H), 7.53-7.50 (m, 1 H), 7.45 (br s, 1 H), 7.34-7.30 (m, 2 H), 7.27 (br s, 1 H), 6.47 (sd, J=2.5 Hz, 1 H), 6.30 (dd, J=8.9, 2.5 Hz, 1 H), 3.88-3.85 (m, 4 H), 3.83 (s, 3 H), 3.10-3.07 (m, 4 H), 2.90 (s, 3 H); LC-MS calcd for C22H26ClN6O4S 505.1, found 504.9 (M+H+)
- The same manner as in Example 19 above was performed to obtain N-(2-((5-chloro-2-((4-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (10.7 mg, 18%).
- 1H NMR (300 MHz, CD3OD) δ 9.65 (s, 1 H), 9.31 (dd, J=7.3, 2.1 Hz, 1 H), 9.14-9.04 (m, 2 H), 9.06-8.95 (m, 1 H), 9.00-8.86 (m, 2 H), 8.44 (sd, J=2.5 Hz, 1 H), 8.20 (dd, J=8.9, 2.5 Hz, 1 H), 5.54 (s, 3 H), 5.41 (d, J=14.7 Hz, 2 H), 5.22-5.02 (m, 3 H), 4.82-4.60 (m, 3 H), 4.52 (s, 3 H), 4.32 (t, J=12.3 Hz, 2 H), 3.76 (d, J=12.6 Hz, 2 H), 3.62-3.40 (m, 2 H), 2.95 (d, J=6.4 Hz, 6H); LC-MS (M+H+) calcd for C29H40ClN8O3S 615.3, found 615.1.
- The same manner as in Example 19 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-morpholinopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (15.3 mg, 27%).
- 1H NMR (300 MHz, CD3OD) δ 8.05 (s, 1 H), 7.77 (d, J=7.7 Hz, 1 H), 7.56-7.48 (m, 1 H), 7.38 (qd, J=7.3, 1.8 Hz, 2 H), 7.25 (d, J=8.7 Hz, 1 H), 6.70 (sd, J=2.5 Hz, 1 H), 6.50 (d, J=8.8 Hz, 1 H), 4.10 (dd, J=19.2, 8.3 Hz, 2 H), 3.92 (d, J=13.2 Hz, 2 H), 3.84 (s, 3 H), 3.81-3.68 (m, 2 H), 3.65-3.48 (m, 2 H), 3.48-3.34 (m, 1 H), 3.29-3.15 (m, 2 H), 2.97 (s, 3 H), 2.93-2.79 (m, 2 H), 2.28 (d, J=12.1 Hz, 2 H), 1.87 (qd, J=12.3, 4.2 Hz, 2 H); LC-MS (M+H+) calcd for C27H35ClN7O4S 588.2, found 588.0
- The same manner as in Example 19 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (7.8 mg, 14%).
- 1H NMR (300 MHz, CD3OD) δ 8.05 (s, 1 H), 7.77 (d, J=7.7 Hz, 1 H), 7.56-7.48 (m, 1 H), 7.38 (qd, J=7.3, 1.8 Hz, 2 H), 7.25 (d, J=8.7 Hz, 1 H), 6.70 (sd, J=2.5 Hz, 1 H), 6.50 (d, J=8.8 Hz, 1 H), 4.10 (dd, J=19.2, 8.3 Hz, 2 H), 3.92 (d, J=13.2 Hz, 2 H), 3.84 (s, 3 H), 3.81-3.68 (m, 2 H), 3.65-3.48 (m, 2 H), 3.48-3.34 (m, 1 H), 3.29-3.15 (m, 2 H), 2.97 (s, 3 H), 2.93-2.79 (m, 2 H), 2.28 (d, J=12.1 Hz, 2 H), 1.87 (qd, J=12.3, 4.2 Hz, 2 H); LC-MS (M+H+) calcd for C27H35ClN7O3S 572.2, found 572.0
- The compound of Example 36 was prepared according to Reaction Example 23 below.
- The same manner as in
Step 1 of Example 6 above was performed to obtain 5-chloro-N2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-N4-(2-nitrophenyl)pyrimidin-2,4-diamine (120 mg, 45%). - 1H NMR (500 MHz, chloroform-d) 10.65 (s, 1 H), 9.00 (dd, J=8.7, 1.3 Hz, 1 H), 8.29 (dd, J=8.5, 1.6 Hz, 1 H), 8.21 (s, 1 H), 8.00 (d, J=8.7 Hz, 1 H), 7.68-7.58 (m, 1 H), 7.23-7.26 (m, 2 H), 7.23-7.14 (m, 1 H), 6.60 (d, J=2.5 Hz, 1 H), 6.54 (dd, J=8.8, 2.6 Hz, 1 H), 3.91 (s, 3 H), 3.70 (d, J=11.8 Hz, 2 H), 2.75 (td, J=12.2, 2.4 Hz, 2 H), 2.41 (bs, 7 H), 2.02 (d, J=12.4 Hz, 2 H), 1.80-1.68 (m, 2 H).
- The same manner as in Step 2 of Example 6 above was performed to obtain N4-(2-aminophenyl)-5-chloro-N2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)pyrimidin-2,4-diamine (90 mg, 85%).
- 1H NMR (500 MHz, chloroform-d) 8.04 (s, 1 H), 7.95 (d, J=8.8 Hz, 1 H), 7.38-7.36 (m, 2 H), 7.19 (td, J=7.7, 1.5 Hz, 1 H), 6.92-6.86 (m, 2 H), 6.77 (s, 1 H), 6.52 (d, J=2.6 Hz, 1 H), 6.33-6.29 (m, 1 H), 3.85 (s, 3 H), 3.84-3.77 (m, 2 H), 3.66-3.57 (m, 3 H), 2.68 (td, J=12.2, 2.3 Hz, 3 H), 2.47-2.38 (bs, 8 H), 2.00 (dd, J=11.9, 3.2 Hz, 2 H), 1.72-1.68 (m, 2 H).
- The same manner as in
Step 3 of Example 6 above was performed to obtain tert-butyl (N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate (62 mg, 48%). - 1H NMR (500 MHz, DMSO-d6) 8.06 (s, 1 H), 7.9-7.88 (m, 1 H), 7.78 (s, 1 H), 7.55 (d, J=8.8 Hz, 1 H), 7.27-7.21 (m, 1 H), 7.12-7.04 (m, 2 H), 6.61 (d, J=2.5 Hz, 1 H), 6.38 (dd, J=8.9, 2.5 Hz, 1 H), 3.78 (s, 3 H), 3.72 (d, J=12.2 Hz, 2 H), 2.66-2.54 (m, 9 H), 1.92 (d, J=12.4 Hz, 2 H), 1.65-1.54 (m, 2 H), 1.36 (s, 9 H).
- The same manner as in Step 4 of Example 6 above was performed to obtain (N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate (30 mg, 60%).
- 1H NMR (300 MHz, Methanol-d4) 8.04 (dd, J=8.0, 1.7 Hz, 1 H), 8.00 (s, 1 H), 7.74 (d, J=8.8 Hz, 1 H), 7.47 (dd, J=7.7, 1.8 Hz, 1 H), 7.33-7.21 (m, 2 H), 6.66 (d, J=2.6 Hz, 1 H), 6.44 (dd, J=8.8, 2.5 Hz, 1 H), 3.86 (s, 3 H), 3.69 (d, J=12.1 Hz, 2 H), 2.75-2.65 (m, 2 H), 2.36 (bs, 7 H), 2.02 (d, J=12.3 Hz, 2 H), 1.66 (dd, J=12.1, 3.8 Hz, 2 H).
- The compound of Example 37 was prepared according to Reaction Example 24 below.
- The same manner as in
Step 1 of Example 6 above was performed to obtain 5-chloro-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N4-(2-nitrophenyl)pyrimidin-2,4-diamine (130 mg, 44%). - 1H NMR (500 MHz, chloroform-d) 10.65 (s, 1 H), 9.00 (dd, J=8.6, 1.3 Hz, 1 H), 8.29 (dd, J=8.5, 1.7 Hz, 1 H), 8.21 (s, 1 H), 7.99 (d, J=8.7 Hz, 1 H), 7.63 (t, J=7.7 Hz, 1 H), 7.29 (s, 1 H), 7.21-7.13 (m, 1 H), 6.59 (d, J=2.5 Hz, 1 H), 6.53 (dd, J=8.8, 2.5 Hz, 1 H), 3.90 (s, 3 H), 3.71 (d, J=11.8 Hz, 2 H), 2.80-2.69 (m, 6 H), 2.64-2.42 (m, 4 H), 2.37 (s, 3 H), 2.00 (d, J=12.4 Hz, 2 H), 1.81-1.70 (m, 2 H).
- The same manner as in Step 2 of Example 6 above was performed to obtain N4-(2-aminophenyl)-5-chloro-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidin-2,4-diamine (110 mg, 89%).
- 1H NMR (500 MHz, chloroform-d) 8.04 (s, 1 H), 7.93 (d, J=8.8 Hz, 1 H), 7.40-7.34 (m, 2 H), 7.18 (td, J=7.6, 1.5 Hz, 1 H), 6.92-6.86 (m, 2 H), 6.76 (s, 1 H), 6.51 (d, J=2.5 Hz, 1 H), 6.32 (d, J=8.8 Hz, 1 H), 3.84 (s, 3 H), 3.81 (bs, 2 H), 3.62 (d, J=11.9 Hz, 3 H), 2.72-2.36 (m, 12 H), 2.34 (s, 3 H), 1.96 (d, J=12.4 Hz, 2 H), 1.77-1.67 (m, 3 H).
- The same manner as in
Step 3 of Example 6 above was performed to obtain tert-butyl (N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate (65 mg, 44%). - 1H NMR (500 MHz, DMSO-d6) 8.83 (s, 1 H), 8.06 (s, 1 H), 7.94 (d, J=8.1 Hz, 1 H), 7.81 (s, 1 H), 7.50 (d, J=8.7 Hz, 1 H), 7.22 (d, J=1.7 Hz, 1 H), 7.14-7.03 (m, 2 H), 6.60 (d, J=2.5 Hz, 1 H), 6.39 (dd, J=8.8, 2.4 Hz, 1 H), 3.77 (s, 3H), 3.69 (d, J=12.1 Hz, 3 H), 2.80-2.58 (m, 10 H), 2.43 (bs, 4 H), 1.85 (d, J=12.0 Hz, 3 H), 1.56-1.47 (m, 2 H), 1.38 (s, 9 H).
- The same manner as in Step 4 of Example 6 above was performed to obtain (N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate (50 mg, 66%).
- 1H NMR (300 MHz, Methanol-d4) δ 8.01 (dd, J=7.9, 1.6 Hz, 1 H), 7.98 (s, 1 H), 7.71 (d, J=8.8 Hz, 1 H), 7.44 (dd, J=7.7, 1.7 Hz, 1 H), 7.23-7.17 (m, 2 H), 6.63 (d, J=2.5 Hz, 1 H), 6.41 (dd, J=8.8, 2.5 Hz, 1 H), 3.83 (s, 3 H), 3.66 (d, J=12.2 Hz, 2 H), 279-2.38 (m, 11 H), 2.30 (s, 3 H), 2.00 (d, J=12.3 Hz, 2 H), 1.736-1.58 (m, 1 H).
- The compounds of Examples 38 and 39 were prepared according to Reaction Example 25 below.
- In which, the compound produced after the performance of
Step 3 is the compound of Example 38, and the compound produced after the performance of Step 4 is the compound of Example 39. - The same manner as in
Step 1 of Example 19 above was performed to obtain tert-butyl (1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)carbamate (400 mg, 78%). - 1H NMR (500 MHz, DMSO-d6) 7.88 (d, J=9.5 Hz, 1 H), 6.89 (d, J=7.8 Hz, 1 H), 6.58 (dd, J=9.5, 2.5 Hz, 1 H), 6.50 (d, J=2.5 Hz, 1 H), 4.01-3.95 (m, 2 H), 3.91 (s, 3 H), 3.59-3.51 (m, 1 H), 3.09-3.00 (m, 2 H), 1.86-1.77 (m, 2 H), 1.44-1.35 (m, 11 H).
- The same manner as in Step 2 of Example 19 above was performed to obtain tert-butyl (1-(4-amino-3-methoxyphenyl)piperidin-4-yl)carbamate (320 mg, 87%).
- 1H NMR (500 MHz, DMSO-d6) 6.85 (d, J=7.8 Hz, 1 H), 6.57-6.51 (m, 2 H), 6.33 (d, J=8.4 Hz, 1 H), 4.87 (bs, 2 H), 3.75 (s, 3 H), 3.41-3.34 (m, 2 H), 2.59 (t, J=11.8 Hz, 2 H), 1.79 (d, J=12.1 Hz, 2 H), 1.56-1.45 (m, 2 H), 1.40 (s, 9 H).
- The same manner as in
Step 3 of Example 19 above was performed to obtain N-(2-((2-((4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide (80 mg, 49%). - 1H NMR (300 MHz, DMSO-d6) 9.31 (s, 1 H), 8.97 (bs, 1 H), 8.16 (s, 1 H), 7.95-7.88 (bs, 2 H), 7.83 (d, J=3.7 Hz, 1 H), 7.47-7.40 (m, 1 H), 7.35 (d, J=8.5 Hz, 1 H), 7.30-7.23 (m, 2 H), 6.66 (d, J=2.3 Hz, 1 H), 6.40 (d, J=8.9 Hz, 1 H), 3.78 (s, 3 H), 3.73 (d, J=12.7 Hz, 2 H), 3.22 (bs, 1 H), 2.97 (s, 3 H), 2.80 (t, J=12.6 Hz, 2 H), 1.97 (d, J=11.9 Hz, 2 H), 1.69-1.54 (m, 1 H).
- The same manner as in Example 15 above was performed to obtain N-(1-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)acetamide (25 mg, 78%).
- 1H NMR (500 MHz, DMSO-d6) 9.28 (s, 1 H), 8.47 (s, 1 H), 8.09 (s, 1 H), 8.01 (d, J=8.1 Hz, 1 H), 7.90 (s, 1 H), 7.84 (d, J=7.7 Hz, 1 H), 7.42 (d, J=8.7 Hz, 1 H), 7.37 (dd, J=7.8, 1.6 Hz, 1 H), 7.24 (d, J=7.9 Hz, 1 H), 7.19 (td, J=7.6, 1.6 Hz, 1 H), 6.61 (d, J=2.5 Hz, 1 H), 6.38 (dd, J=8.7, 2.5 Hz, 1 H), 3.76 (s, 3 H), 3.70 (bs, 1 H), 3.61 (d, J=12.4 Hz, 2 H), 2.96 (s, 3 H), 2.75 (t, J=10.7 Hz, 1 H), 1.86-1.79 (m, 5 H), 1.55-1.44 (m, 2 H).
- The compound of Example 40 was prepared according to Reaction Example 26 below.
- The same manner as in
Step 1 of Example 19 above was performed to obtain tert-butyl (1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)(methyl)carbamate (450 mg, 84%). - 1H NMR (300 MHz, chloroform-d) 8.02 (d, J=9.3 Hz, 1 H), 6.44 (dd, J=9.4, 2.6 Hz, 1 H), 6.34 (d, J=2.5 Hz, 1 H), 4.07-3.98 (m, 2 H), 3.97 (s, 3 H), 3.10-2.96 (m, 2 H), 2.75 (s, 3 H), 1.85-1.76 (m, 2 H), 1.50 (s, 9 H).
- The same manner as in Step 2 of Example 19 above was performed to obtain tert-butyl (1-(4-amino-3-methoxyphenyl)piperidin-4-yl)(methyl)carbamate (400 mg, 96%).
- 1H NMR (300 MHz, chloroform-d) δ 6.66 (d, J=8.3 Hz, 1 H), 6.56 (bs, 1 H), 6.50-6.40 (m, 1 H), 3.86 (s, 3 H), 3.53 (d, J=12.2 Hz, 3 H), 2.80 (s, 3 H), 2.71 (d, J=12.2 Hz, 2 H), 1.99-1.83 (m, 2 H), 1.80-1.69 (m, 2 H), 1.50 (s, 9 H).
- The same manner as in
Step 3 of Example 19 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-(methylamino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (50 mg, 33%). - 1H NMR (300 MHz, DMSO-d6) 8.96 (s, 1H), 8.12 (d, J=7.9 Hz, 1 H), 8.03 (s, 1 H), 7.89 (s, 1 H), 7.48 (d, J=8.7 Hz, 1 H), 7.29-7.19 (m, 1 H), 6.94 (td, J=7.7, 1.6 Hz, 1 H), 6.81 (t, J=7.7 Hz, 1 H), 6.63 (d, J=2.5 Hz, 1 H), 6.46 (dd, J=8.7, 2.5 Hz, 1 H), 3.77 (s, 3 H), 3.71 (d, J=12.6 Hz, 2 H), 2.90-2.81 (m, 1 H), 2.78 (s, 3 H), 2.71 (d, J=12.2 Hz, 2 H), 2.49 (s, 3 H), 1.99 (d, J=12.3 Hz, 2 H), 1.59-1.50 (m, 2 H).
- The compounds of Example 41, 42, and 43 were prepared according to Reaction Example 27 below.
- In which,
- R represents a substance reacting with a starting material,
- the compound wherein R6 is —NH(CH2)2OH is the compound of Example 41,
- the compound wherein R6 is —NH(CH2)2OCH3 is the compound of Example 42, and
- the compound wherein R6 is —NH(CH2)2N(CH3)2 is the compound of Example 43.
- The same manner as in Example 19 above was performed to obtain N-(2-((5-chloro-2-((4-(4-((2-hydroxyethyl)amino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (25 mg, 46%).
- 1H NMR (300 MHz, Methanol-d4) 8.06 (s, 1 H), 7.81 (d, J=7.5 Hz, 1 H), 7.56-7.50 (m, 1 H), 7.44-7.35 (m, 2 H), 7.31 (d, J=8.7 Hz, 1 H), 6.71 (d, J=2.4 Hz, 1 H), 6.51 (d, J=8.7 Hz, 1 H), 3.93-3.81 (m, 7 H), 3.23 (t, J=5.2 Hz, 2 H), 2.99 (s, 3 H), 2.87 (dd, J=13.4, 11.2 Hz, 2 H), 2.25 (d, J=12.4 Hz, 2 H), 1.90-1.73 (m, 2 H).
- The same manner as in Example 19 above was performed to obtain N-(2-((5-chloro-2-((2-methoxy-4-(4-((2-methoxyethyl)amino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (22 mg, 40%).
- 1H NMR (300 MHz, Methanol-d4) 8.06 (s, 1 H), 7.82 (d, J=8.8 Hz, 1 H), 7.56-7.50 (m, 1 H), 7.42-7.35 (m, 2 H), 7.33 (d, J=8.6 Hz, 1 H), 6.70 (d, J=2.5 Hz, 1 H), 6.50 (d, J=8.9 Hz, 1 H), 3.91-3.80 (m, 5 H), 3.73-3.65 (m, 2 H), 3.45 (s, 3 H), 3.32-3.27 (m, 2 H), 2.98 (s, 3 H), 2.85 (t, J=12.0 Hz, 2 H), 2.28-2.19 (m, 2 H), 1.87-1.72 (m, 2 H).
- The same manner as in Example 19 above was performed to obtain N-(2-((5-chloro-2-((4-(4-((2-(dimethylamino)ethyl)amino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide (10 mg, 18%).
- 1H NMR (300 MHz, Methanol-d4) δ 8.07 (s, 1 H), 7.78 (d, J=7.6 Hz, 1 H), 7.54 (dd, J=7.6, 1.9 Hz, 1 H), 7.45-7.41 (m, 1 H), 7.38 (dd, J=7.5, 2.0 Hz, 1 H), 7.28 (d, J=8.7 Hz, 1 H), 6.75 (d, J=2.5 Hz, 1 H), 6.61-6.50 (m, 1 H), 3.90 (d, J=11.7 Hz, 2 H), 3.86 (s, 3 H), 3.643.54 (m, 4 H), 3.50-3.40 (m, 1 H), 3.02 (s, 6 H), 3.00 (s, 4 H), 2.93 (d, J=11.6 Hz, 2 H), 2.28 (d, J=12.4 Hz, 2 H), 194-1.78 (m, 2 H).
- The chemical structures of the compounds prepared in Examples 1-43 were arranged and indicated in Tables 1 to 3 below.
- In order to confirm an inhibitory ability on wild-type EGFR and EGFR mutation of the compound represented by
Formula 1 according to the present invention, the experiment was carried out as described below. The results are shown in Table 4 below. - The measurement of an activity on wild-type and EGFR mutation enzyme of the compound of the present invention was experimented by utilizing the HTRF system sold by Cisbio, as follow. Wild-type EGFR and EGFR del19, EGFR del19/T790M mutation enzyme were used by purchasing the recombinant proteins provided by Carna Biosciences, and EGFR del19/T790M/C797S mutation enzyme was used as an enzyme source by purchasing the proteins provided by SignalChem.
- The composition of the assay buffer used in the activity measurement was 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 7.5 mM MgCl2, 3 mM KCl, 0.01% Tween 20, 0.1% BSA, 1 mM DTT. The enzymatic reaction was carried out hereto by using the peptide substrate labeled with ATP of 50 mM concentration and biotin of 0.5 mM concentration. The analysis of an EGFR activity inhibitory effect of the compound was carried out in accordance with the analysis reaction recipe below.
- Component 1: 4 ml of EGFR wild-type or mutation enzyme
- Component 2: 2 ml of compound solution
- Component 3: 4 ml of peptide labeled with ATP and biotin
- The enzymatic reaction was initiated by mixing
Component 1 and Component 2 first, and then, addingcomponent 3. After the reaction for 2 hours at 37° C., 10 ml of a measurement solution consisting of streptavidin-XL665 provided by Cisbio and anti-phosphotyrosine antibody labeled with europium was added to the enzymatic reaction solution and reacted for 1 hour at ambient temperature. Finally, the ratio of fluorescence values at 615 nm and 665 nm was obtained by using the Envision equipment of Perkin-Elmer, and the enzymatic activity was quantitatively measured, and the inhibitory ability of the compound was confirmed. The measurement values measured at the seven concentrations of the compound were analyzed by using the Prism program (version 5.01, Graphpad Software, Inc.), and IC50 value of the compound was calculated, which is an inhibitory ability indicator. -
TABLE 4 EGFR del19/ EGFR del19/ EGFR wt. EGFR del19 T790M T790M/C797S Example IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 1 2.1 0.020 0.016 0.015 2 0.73 0.012 0.012 0.003 3 0.84 0.018 0.005 0.002 4 nd nd nd 0.72 5 4.3 0.033 0.013 0.014 6 0.39 0.026 0.010 0.011 7 >10 0.079 0.038 0.002 8 nd nd nd 0.36 9 nd nd nd 0.093 10 0.43 0.0007 0.004 0.0002 11 0.28 0.0078 0.0031 0.006 12 1.2 0.022 0.13 0.002 13 1.9 0.013 0.25 0.033 14 1.4 0.006 0.095 0.034 15 nd nd nd 0.33 16 5.4 0.044 0.34 0.023 17 0.6 0.004 0.078 0.012 18 0.97 0.013 0.092 0.03 19 0.7 0.0007 0.069 0.042 20 nd nd nd 0.3 21 0.16 0.0001 0.014 0.005 22 0.26 0.0004 0.031 0.0008 23 2.7 0.025 0.032 0.029 24 0.82 0.003 0.064 0.012 25 0.3 0.0002 0.018 0.009 26 nd nd nd 0.11 27 0.28 0.0003 0.021 0.001 28 0.64 0.0009 0.027 0.009 29 1.2 0.005 0.004 0.007 30 1.8 0.024 0.034 0.003 31 0.58 0.036 0.029 0.007 32 1.3 0.004 0.16 0.014 33 nd nd nd <0.001 34 nd nd nd <0.001 35 0.027 0.0011 0.0083 <0.001 36 nd nd nd 0.0003 37 0.0028 0.0071 0.0027 0.0002 38 nd nd nd 0.0005 39 nd nd nd 0.0003 40 nd nd nd 0.0004 41 nd nd nd 0.0002 42 nd nd nd 0.0003 43 nd nd nd 0.0006 In Table 4 above, nd refers to no data. - As indicated in Table 4 above, it can be seen that all the example compounds of the present invention show a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a selectively high inhibitory ability on EGFR mutation, in particular, and a high inhibitory ability on EGFR del19/T790M/C797S, which is a triple mutation.
- In order to confirm an inhibitory ability on wild-type Ba/F3 EGFR and Ba/F3 EGFR mutation in Ba/F3 cell line of the compound represented by
Formula 1 according to the present invention, the experiment was carried out as described below. The results are shown in Table 5 below. - The measurement of an activity on wild-type and mutation Ba/F3 EGFR cell line of the compound of the present invention was experimented by utilizing the CellTiter-Glo system sold by Promega, as follow. The CellTiter-Glo assay is a method for measuring the ATP present in cells in cell culture conditions to determine the cell viability. Ba/F3 EGFR wild-type and Ba/F3 EGFR del19, Ba/F3 EGFR del19/T790M, Ba/F3 del19/T790M/C797S mutation cell lines were used by purchasing the cell lines provided by Crown Bioscience, Inc. Ba/F3 EGFR wild-type and Ba/F3 EGFR del19, Ba/F3 EGFR del19/T790M, Ba/F3 del19/T790M/C797S mutation cell lines were cultured in 37° C., 5% CO2 incubator by adding
puromycine 1 ug to RPMI containing 10% FBS, 1% penicillin-streptomycin. - The analysis of an EGFR inhibitory ability effect of the compound was carried out in accordance with the analysis reaction recipe below.
- 2500 cells/90 ul was cultured by passage in 96 well cell culture plate, and after 24 hours, treated with the compound represented by
Formula 1 in concentrations of 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 (μM). After the reaction of 72 hours, the plate treated with the compound was allowed to stand for 30 minutes at ambient temperature, and then, was further treated with 100 μl of the reagent, and was shaked for 10 minutes at ambient temperature. Finally, the ratio of fluorescence values at 570 nm was obtained by using the equipment and quantitatively measured, and the inhibitory ability of the compound was confirmed. The measurement values measured at the eight concentrations of the compound were analyzed by using the Prism program (version 5.01, Graphpad Software, Inc.), and IC50 value of the compound was calculated, which is an inhibitory ability indicator. -
TABLE 5 Ba/F3 Ba/F3 Ba/F3 Ba/F3 EGFR EGFR del19/ EGFR wt. EGFR del19 del19/T790M T790M/C797S Example IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) 1 >15 6.6 7.1 nd 2 2.8 3.8 1.8 2.4 3 4.1 1 1.2 1.6 5 2.4 0.26 0.57 0.79 6 >15 6.4 9 5.8 7 3.4 0.47 1.6 3.3 10 1 0.18 0.099 0.063 11 0.34 0.0047 0.031 0.038 12 0.32 0.33 0.38 0.08 13 4.4 0.98 0.65 1.5 14 0.75 0.5 0.54 0.11 16 >10 >10 2.3 >10 17 2.1 2.2 1.7 0.68 18 4.4 2.7 1.4 2 19 3.1 1.1 0.66 0.97 21 2.2 3.6 0.55 1.7 22 nd 0.9 0.39 1.3 24 >10 0.45 0.32 0.41 25 0.34 0.21 0.78 0.027 27 nd 1.1 0.94 >10 28 1.4 1.4 0.69 1.7 29 2.8 1.9 2.1 2.9 30 5.4 0.68 0.85 2.7 32 8 1.9 1.3 3.3 33 nd nd nd 0.12 34 nd nd nd 0.16 35 nd nd nd 0.084 36 nd nd nd 0.93 37 nd nd nd 0.099 38 nd nd nd 0.84 39 nd nd nd 0.68 40 nd nd nd 0.5 In Table 5 above, nd refers to no data. - As indicated in Table 5 above,
- it was confirmed that the example compounds according to the present invention showed a high inhibitory ability on EGFR mutation including EGFR del19/T790M/C797S, which is a triple mutation.
- In addition, it can be seen that the example compounds according to the present invention show a relatively weak activity inhibitory ability on wild-type EGFR in Ba/F3 cell line and a selectively high inhibitory ability on EGFR mutation including EGFR del19/T790M/C797S, which is a triple mutation.
- In order to confirm an inhibitory ability on FLT kinase, which is also well known as a kinase associated with hematologic malignancy, of the compound represented by
Formula 1 according to the present invention, the experiment was carried out as described below. The results are shown in Table 5 below. - The inhibitory activity on FLT kinase, such as wild-type FLT1, FLT3, FLT4, and FLT3 mutation forms, FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), FLT3(R834Q) was measured.
- The specific experiment method is as described below.
- FLT3 kinase inhibition was carried out by KINOMEscan method (DiscoverX Inc.). KINOMEscan method consists of the following processes. T7 bacteriophage labeled with FLT kinase was cultured by the infection to E. coli derived from BL21. After the infection of E. coli in the condition of 0.4 of MOI (multiplicity of infection), it was cultured for 90 to 150 minutes at 32° C. to lyse E. coli. The cell debris was removed by centrifugation and filtration, and the kinase protein present in the supernatant was secured. Additionally, the kinase protein was labeled with DNA for the qPCR measurement. The magnetic beads labeled with streptavidin were treated with the standard compound labeled with biotin and reacted for 30 minutes. The resulting beads were used as affinity beads for the measurement of a kinase activity. The binding reaction was initiated with mixing a kinase protein, the affinity beads bound with a ligand, and the compound. In this case, the used buffer solution was 20% SeaBlock, 0.17×PBS, 0.05
% Tween 20, 6 mM DTT. All the reactions were carried out in volume of 20 ul at a 384 well plate. After the reaction for 1 hour at ambient temperature, the beads were washed with the solution consisting of 1×PBS, 0.05 Tween 20. Finally, the kinase bound with the beads was eluted by using 1×PBS, 0.05 Tween 20, 0.5 uM standard compound unlabeled with biotin. The affinity of the compound to be tested was indirectly measured by quantifying the eluted kinase by qPCR. -
TABLE 6 Example Gene Symbol Modifier Kd (nM) 10 FLT1 > 10000 10 FLT3 = 3.7 10 FLT3(D835H) = 38 10 FLT3(D835V) = 0.29 10 FLT3(D835Y) = 4.2 10 FLT3(ITD) = 18 10 FLT3(ITD, D835V) = 0.32 10 FLT3(ITD, F691L) = 1.1 10 FLT3(K663Q) = 39 10 FLT3(N841I) = 6.5 10 FLT3(R834Q) = 33 10 FLT4 = 200 11 FLT1 = 910 11 FLT3 = 1.2 11 FLT3(D835H) = 1.8 11 FLT3(D835V) = 0.082 11 FLT3(D835Y) = 1.5 11 FLT3(ITD) = 4.2 11 FLT3(ITD, D835V) = 0.16 11 FLT3(ITD, F691L) = 0.27 11 FLT3(K663Q) = 20 11 FLT3(N841I) = 3.8 11 FLT3(R834Q) = 19 11 FLT4 = 81 - As indicated in Table 6 above,
- it was confirmed that the compounds of Examples 10 and 11 of the present invention showed a selectively superior inhibitory ability on
FLT 3 kinase in comparison withFLT 1 and FLT 4, and also showed a high inhibitory ability on wild-type FLT3, as well as, FLT3 mutation forms, such as FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), FLT3(R834Q). - In order to confirm a cell activity on Ba/F3 Del19/T790M/C797S cell line when administering the compound according to the present invention in combination with a conventional drug, cetuximab to be used in single therapy or combination therapy with anticancer chemotherapy in metastatic colorectal cancer, metastatic squamous epithelium head and neck cancer and the like was used to evaluate the cell activity according to the combination administration.
- Specifically, brigatinib was used as a control drug, and each of 30 nM of brigatinib, 30 nM of the compound of Example 10 according to the present invention, and 15 nM of the compound of Example 11 was administered to Ba/F3 Del19/T790M/C797S cell line in combination with 10 μg of cetuximab, which is a monoclonal antibody. The relative cell viability was measured and shown in
FIGS. 1 to 4 . - In addition, when administering each of brigatinib, the compounds of Examples 10 and 11 of the present invention in 30, 100, 300, 1000 nM alone or in combination with 10 μg of cetuximab, the sub-signal activity on a/F3 Del19/T790M/C797S cell line was evaluated and the results are shown in
FIGS. 5 to 7 . -
FIG. 1 is a graph showing a relative cell viability at the time of the administration of brigatinib in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 2 is a graph showing a relative cell viability at the time of the administration of the compound of Example 10 in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 3 is a graph showing a relative cell viability at the time of the administration of the compound of Example 11 in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 4 is a graph showing a relative cell viability at the time of the administration of only cetuximab alone to Ba/F3 Del19/T790M/C797S cell line (calculated by sigmaplot's t-test (**P<0.001, *P>0.01)). -
FIG. 5 shows a sub-signal activity at the time of the administration of brigatinib alone or in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line. -
FIG. 6 shows a sub-signal activity at the time of the administration of the compound of Example 10 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line. -
FIG. 7 shows a sub-signal activity at the time of the administration of the compound of Example 11 alone or in combination with cetuximab to Ba/F3 Del19/T790M/C797S cell line. - As shown in
FIGS. 1 to 4 , - it can be seen that the compounds of Examples 10 and 11 of the present invention show a lower cell viability by at least 30% on Ba/F3 Del19/T790M/C797S cell line when administered alone than cetuximab, and show a cell viability decreased by at least 50% when administered in combination with cetuximab than when administered alone, and thus, show a superior cancer cell apoptosis ability on a cell line with EGFR triple mutation even when administered alone, as well as, show a remarkably elevated anticancer effect when administered in combination with a conventional drug.
- In particular, it can be seen that the compounds of Examples 10 and 11 of the present invention show a cell viability decreased by at least 20% than when administering brigatinib, which is a conventional drug in use, in combination with cetuximab, and thus, show a superior anticancer effect than brigatinib.
- As shown in
FIGS. 5 to 6 , - it can be seen that the compounds of Examples 10 and 11 of the present invention show a concentration-dependent activity in pERK, pAKT, pS6, which is EGFR sub-signal, even when administered alone, as well as, show a superior activity when administered in combination with cetuximab.
- In particular, it can be seen that the compounds of Examples 10 and 11 of the present invention show a superior activity than when administering brigatinib, which is a conventional drug in use, in combination with cetuximab, and thus, show a superior anticancer effect than brigatinib.
- Therefore, the compound represented by
Formula 1 according to the present invention shows a high inhibitory ability on EGFR mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation, such as EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C797S, EGFR L858R, EGFR L858R/T790MS, EGFR L858R/T790M/C797S and the like. In particular, the compound represented byFormula 1 according to the present invention shows a remarkably superior inhibitory ability on EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S, which is a triple mutation, and thus, can be effectively used for the treatment of cancer with EGFR del19/T790M/C797S or EGFR L858R/T790M/C797S. - In addition, the compound represented by
Formula 1 according to the present invention shows a high inhibitory ability onFLT 3 and mutation thereof, such as FLT3(D 835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), or FLT3(R834Q), and thus, can be effectively used for the treatment of cancer associated with an activity ofFLT 3 or a mutation form ofFLT 3, particularly hematologic malignancy. - In addition, the compound represented by
Formula 1 according to the present invention shows a synergy effect when administered in combination with a conventional drug, and thus, can be effectively used when administered in combination with a conventional drug. -
-
Derivative represented by Formula 12 g Lactose 1 g - The powders were prepared by mixing the above ingredients and filling into an airtight bag.
-
-
Derivative represented by Formula 1100 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate 2 mg - The tablets were prepared by mixing the above ingredients and then tableting according to conventional methods for manufacturing tablets.
-
-
Derivative represented by Formula 1100 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate 2 mg - The capsules were prepared by mixing the above ingredients and then filling into gelatin capsules according to conventional methods for manufacturing capsules.
-
-
Derivative represented by Formula 1100 mg Mannitol 180 mg Na2HPO4 · 2H2O 26 mg Distilled water 2974 mg - The injections were prepared by containing the above ingredients in contents set forth above according to conventional methods for manufacturing injections.
-
-
Derivative represented by Formula 1500 ng Vitamin mixture q.s. Vitamin A acetate 70 mg Vitamin E 1.0 mg Vitamin 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 mg Vitamin C 10 mg Biotin 10 mg Nicotinamide 1.7 mg Folic acid 50 mg Calcium pantothenate 0.5 mg Mineral mixture q.s. Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium dihydrogen phosphate 15 mg Calcium hydrogen phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg - In regard to the composition ratio of the vitamin and mineral mixture, the ingredients relatively suitable for health foods were mixed according to the preferred examples, but the mixing ratio can be optionally modified in practice. According to conventional methods for manufacturing health foods, the above ingredients were mixed and then prepared into granules, and may be used in the preparation of health food compositions according to conventional methods.
-
-
Derivative represented by Formula 1500 ng Citric acid 1000 mg Oligosaccharide 100 g Japanese apricot concentrate 2 g Taurine 1 g Purified water added to a total of 900 ml - According to conventional methods for manufacturing health beverages, the above ingredients were mixed, then stirred and heated at 85° C. for about 1 hour, and then the resulting solution was filtered, obtained in a sterilized container, sealed, sterilized, then stored in a refrigerator, and used in the preparation of health beverage compositions.
- In regard to the composition ratio, the ingredients relatively suitable for favorite beverages were mixed according to the preferred examples, but the mixing ratio can be optionally modified in practice according to regional and ethnic preference, such as a demand class, demand country, purpose of use and the like.
- The N2,N4-diphenylpyrimidin-2,4-diamine derivative according to the present invention can be effectively used for the treatment of cancer, particularly cancer with EGFR mutation or cancer with FLT3 or a mutation thereof.
Claims (22)
1. A method of treating or preventing cancer, comprising administering to a subject in need thereof a compound represented by Formula 1:
in which,
R1 is CH3 or NH2,
R2 is hydrogen, halogen, methoxy, or methyl unsubstituted or substituted with one or more halogens;
R3 is hydrogen, halogen, or straight or branched C1-6alkyl;
R4 is straight or branched C1-6alkyl; and
is an unsubstituted or substituted 5- to 7-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of straight or branched C1-3alkyl, straight or branched hydroxyC1-3alkyl, acetyl, —NRaRb, morpholinyl, pyrrolidinyl, and unsubstituted or substituted piperidinyl or piperazinyl, wherein Ra and Rb are independently hydrogen, straight or branched C1-3alkyl, acetyl, straight or branched hydroxyC1-3alkyl, straight or branched C1-3alkoxyC1-2alkyl, or straight or branched diC1-3alkylaminoC1-2alkyl, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of straight or branched C1-3alkyl, straight or branched hydroxyC1-3alkyl, acetyl, and straight or branched C1-5alkoxycarbonyl,
an optical isomer thereof or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , characterized in that R1 is CH3.
3. The method of claim 1 , characterized in that R1 is NH2.
4. The method of claim 1 , characterized in that
R2 is hydrogen, F, Cl, Br, methoxy, or methyl unsubstituted or substituted with one or more fluoro;
R3 is hydrogen, F, Cl, or straight or branched C1-3alkyl; and
R4 is straight or branched C1-3alkyl.
5. The method of claim 1 , characterized in that
R2 is hydrogen, Cl, Br, methyl, CF3, or methoxy;
R3 is hydrogen or methyl; and
R4 is methyl.
6. The method of claim 1 , characterized in that
is an unsubstituted or substituted 5- or 6-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N, O, and S, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, —NRaRb, morpholinyl, pyrrolidinyl, and unsubstituted or substituted piperidinyl or piperazinyl, wherein Ra and Rb are independently hydrogen, straight or branched C1-3alkyl, acetyl, straight or branched hydroxyC1-3alkyl, straight or branched C1-3alkoxyC1-2alkyl, or straight or branched diC1-3alkylaminoC1-2alkyl, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of methyl, ethyl, hydroxymethyl, hydroxyethyl, acetyl, and tert-butoxycarbonyl.
7. The method of claim 1 , characterized in that
is an unsubstituted or substituted 5- or 6-membered heterocycloalkyl comprising one or more heteroatoms selected from the group consisting of N and O, wherein the substituted heterocycloalkyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, —NRaRb, morpholinyl, pyrrolidinyl, and unsubstituted or substituted piperidinyl or piperazinyl, wherein Ra and Rb are independently hydrogen, methyl, acetyl, hydroxyethyl, —(CH2)2OCH3, or —(CH2)2N(CH3)2, and the substituted piperidinyl or piperazinyl may be substituted with one or more substituents selected from the group consisting of methyl, hydroxyethyl, acetyl, and tert-butoxycarbonyl.
8. The method of claim 1 , characterized in that
wherein A1 is CH or N, and A2 is NH, O, CH—R5, or N—R5, with the proviso that if A1 is CH, then A2 is not CH—R5, wherein R5 is independently hydrogen, methyl, hydroxyethyl, acetyl, —NRaRb, morpholinyl, pyrrolidinyl,
9. The method of claim 1 , characterized in that
wherein R5 is independently hydrogen, methyl, hydroxyethyl, acetyl, —NH2, —NH(CH3), —NH(C═O)CH3, —NH(CH2)2OH, —NH(CH2)2OCH3, —NH(CH2)2N(CH3)2, —N(CH3)2, morpholinyl, pyrrolidinyl,
11. The method of claim 1 , characterized in that the compound represented by Formula 1 is any one selected from the group consisting of the following compounds:
<1> N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<2> N-(2-((5-chloro-2-((2-methoxy-5-methyl-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<3> N-(2-((5-bromo-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<4> N-(2-((5-methoxy-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<5> N-(2-((2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<6> 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine;
<7> 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidine;
<8> N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino))-5-methylpyrimidin-4-ylamino)phenyl)methanesulfonamide;
<9> N-(2-((2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<10> N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<11> N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<12> N-(2-((5-chloro-2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<13> N-(2-((5-chloro-2-((4-(1-(2-hydroxyethyl)piperidin-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<14> N-(2-((5-chloro-2-((4-(1′-(2-hydroxyethyl)[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<15> N-(2-((2-((4-(1-acetylpiperidin-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<16> N-(2-((2-((4-([1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<17> N-(2-((5-chloro-2-((2-methoxy-4-(1′-methyl-[1,4′-bipiperidin]-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<18> N-(2-((2-((4-(1′-acetyl-[1,4′-bipiperidin]-4-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<19> N-(2-((2-((4-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<20> tert-butyl 4-(1-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate;
<21> N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<22> N-(2-((5-chloro-2-((4-(4-(4-(2-hydroxyethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<23> N-(2-((5-chloro-2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<24> N-(2-((2-((4-(4-(1-acetylpiperidin-4-yl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<25> N-(2-((5-chloro-2-((2-methoxy-4-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<26> tert-butyl 4-(4-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)piperidine-1-carboxylate;
<27> N-(2-((5-chloro-2-((2-methoxy-4-(4-(piperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<28> N-(2-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<29> 4-(4-((5-chloro-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine;
<30> 4-(4-((5-bromo-4-((2-(sulfamoylamino)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine;
<31> N-(2-((2-((2-methoxy-4-(piperazin-4-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<32> N-(2-((5-chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<33> N-(2-((5-chloro-2-((4-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<34> N-(2-((5-chloro-2-((2-methoxy-4-(4-morpholinopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<35> N-(2-((5-chloro-2-((2-methoxy-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<36> (N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate;
<37> (N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)sulfamoyl)carbamate;
<38> N-(2-((2-((4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<39> N-(1-(4-((5-chloro-4-((2-(methylsulfonamido)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)acetamide;
<40> N-(2-((5-chloro-2-((2-methoxy-4-(4-(methylamino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<41> N-(2-((5-chloro-2-((4-(4-((2-hydroxyethyl)amino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide;
<42> N-(2-((5-chloro-2-((2-methoxy-4-(4-((2-methoxyethyl)amino)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide; and
<43> N-(2-((5-chloro-2-((4-(4-((2-(dimethylamino)ethyl)amino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide.
12. (canceled)
13. (canceled)
14. The method of claim 1 , wherein one or more of an EGFR (epidermal growth factor receptor) mutation, FLT3, and FLT3 mutation are inhibited.
15. The method of claim 14 , wherein the EGFR mutation is one or more selected from the group consisting of EGFR del19, EGFR del19/T790M, EGFR del19/T790M/C797S, EGFR L858R, EGFR L858R/T790MS, and EGFR L858R/T790M/C797S.
16. The method of claim 14 , wherein characterized in that the FLT3 mutation is one or more selected from the group consisting of FLT3(D835H), FLT3(D835V), FLT3(D835Y), FLT3(ITD), FLT3(ITD,D835V), FLT3(ITD,F691L), FLT3(K663Q), FLT3(N841I), and FLT3(R834Q).
17. The method of claim 1 , wherein characterized in that the cancer has a mutation expressed on one or more selected from the group consisting of EGFR, ALK, FAK, FLT3, JAK3, KIT, and PLK4.
18. The method of claim 1 , characterized in that the cancer is one or more selected from the group consisting of pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testis cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, epithelial ovarian cancer, ovarian seminoma, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, cholangiocarcinoma, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullar of vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal and paranasal cavity cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, renal cancer, heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal tumor, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsillar cancer, squamous cell cancer, adenocarcinoma of lung, lung cancer, squamous cell lung cancer, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleura cancer, hematologic malignancy, and thymic cancer.
19. The method of claim 1 , further comprising administering an anticancer agent in combination with the compound of Formula 1.
20. (canceled)
21. The method of claim 19 , wherein the anticancer agent is cetuximab.
22. The method of claim 21 , wherein the compound of Formula 1 is:
N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide; or
N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/675,917 US20220249482A1 (en) | 2017-06-13 | 2022-02-18 | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0073907 | 2017-06-13 | ||
KR20170073907 | 2017-06-13 | ||
KR10-2017-0146241 | 2017-11-03 | ||
KR1020170146241A KR20180135781A (en) | 2017-06-13 | 2017-11-03 | N2,N4-diphenylpyrimidine-2,4-diamine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient |
PCT/KR2018/006644 WO2018230934A1 (en) | 2017-06-13 | 2018-06-12 | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
US201916622057A | 2019-12-12 | 2019-12-12 | |
US17/675,917 US20220249482A1 (en) | 2017-06-13 | 2022-02-18 | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/622,057 Continuation US11253516B2 (en) | 2017-06-13 | 2018-06-12 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
PCT/KR2018/006644 Continuation WO2018230934A1 (en) | 2017-06-13 | 2018-06-12 | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220249482A1 true US20220249482A1 (en) | 2022-08-11 |
Family
ID=70972831
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/622,057 Active 2038-06-18 US11253516B2 (en) | 2017-06-13 | 2018-06-12 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
US17/675,917 Pending US20220249482A1 (en) | 2017-06-13 | 2022-02-18 | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/622,057 Active 2038-06-18 US11253516B2 (en) | 2017-06-13 | 2018-06-12 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Country Status (19)
Country | Link |
---|---|
US (2) | US11253516B2 (en) |
EP (1) | EP3640246B1 (en) |
JP (1) | JP6945015B2 (en) |
KR (2) | KR20180135781A (en) |
CN (1) | CN110740999A (en) |
AU (1) | AU2018286361B2 (en) |
BR (1) | BR112019026253A2 (en) |
CA (1) | CA3066083C (en) |
CL (1) | CL2019003589A1 (en) |
EA (1) | EA201992722A1 (en) |
ES (1) | ES2969701T3 (en) |
IL (1) | IL271291B2 (en) |
JO (1) | JOP20190281A1 (en) |
MX (1) | MX2019014548A (en) |
NZ (1) | NZ760089A (en) |
PL (1) | PL3640246T3 (en) |
SA (1) | SA519410722B1 (en) |
WO (1) | WO2018230934A1 (en) |
ZA (1) | ZA201908241B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101992621B1 (en) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | Novel pyrimidine derivative showing growth inhibition of cancer cell and pharmaceutical composition comprising the same |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
AU2020296620B2 (en) * | 2019-06-20 | 2023-07-13 | Oncobix Co.Ltd. | Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof |
WO2020257385A1 (en) * | 2019-06-20 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of src tyrosine kinase |
KR20220028075A (en) | 2019-07-03 | 2022-03-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
WO2021125758A1 (en) * | 2019-12-16 | 2021-06-24 | 주식회사 온코빅스 | Novel deuterium-substituted pyrimidine derivative and pharmaceutical composition comprising same |
CN113896744B (en) * | 2020-07-06 | 2024-04-16 | 成都先导药物开发股份有限公司 | Selective EGFR inhibitor |
CN112390760B (en) * | 2020-10-15 | 2022-07-29 | 北京师范大学 | FAK-targeting compound and preparation method and application thereof |
CN112239422B (en) * | 2020-10-16 | 2022-07-22 | 河北化工医药职业技术学院 | Bugatinib intermediate, salt thereof, preparation method thereof and preparation method of brigatinib |
EP4274567A1 (en) * | 2021-01-05 | 2023-11-15 | Sumitomo Pharma Oncology, Inc. | Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor |
US20240051940A1 (en) * | 2021-02-08 | 2024-02-15 | Accutar Biotechnology Inc. | Sulfonamides with egfr inhibition activities and their use thereof |
EP4286376A1 (en) * | 2021-04-01 | 2023-12-06 | Therapex Co., Ltd. | Pyrimidine derivative having protein kinase inhibitory activity, and therapeutic pharmaceutical composition comprising same |
EP4371983A1 (en) * | 2021-07-13 | 2024-05-22 | Korea Research Institute of Chemical Technology | Novel pyrimidine-2,4-diamine derivatives, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
WO2023201024A1 (en) * | 2022-04-15 | 2023-10-19 | Bridge Biotherapeutics, Inc. | Composition and treatment for cancer with mutations |
WO2024106979A1 (en) * | 2022-11-17 | 2024-05-23 | (주)팜캐드 | Piperidine derivative, salt of same, and pharmaceutical composition containing same as active ingredient |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4607879B2 (en) * | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 2,4-Pyrimidinediamine useful for the treatment of neoplastic diseases, inflammation and immune disorders |
EA019966B1 (en) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Compounds and compositions as protein kinase inhibitors |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
MX2010012703A (en) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Phosphorous derivatives as kinase inhibitors. |
CN104284584B (en) * | 2012-03-15 | 2019-06-04 | 西建卡尔有限责任公司 | The salt of epidermal growth factor receptor kinase inhibitor |
KR101656382B1 (en) | 2014-02-28 | 2016-09-09 | 한국화학연구원 | pyrimidine-2,4-diamine derivatives and pharmaceutical composition for anti cancer containing the same as an active ingredient |
WO2015176010A1 (en) * | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
KR101733733B1 (en) | 2014-06-17 | 2017-05-11 | 한국화학연구원 | pyrimidine-2,4-diamine derivatives and pharmaceutical composition for anti cancer containing the same as an active ingredient |
BR112017003186A2 (en) | 2014-08-22 | 2017-11-28 | Fujifilm Corp | pharmaceutical composition for treatment of positive cancer for mutation in flt3, mutant flt3 inhibitor and uses thereof |
KR101789934B1 (en) | 2015-07-31 | 2017-10-26 | 중앙대학교 산학협력단 | Novel compound having tumor diagnosis or tumor growth inhibitory activity on EGFR mutant and medical uses comprising the same |
-
2017
- 2017-06-16 JO JOP/2019/0281A patent/JOP20190281A1/en unknown
- 2017-11-03 KR KR1020170146241A patent/KR20180135781A/en active Search and Examination
-
2018
- 2018-06-12 NZ NZ760089A patent/NZ760089A/en unknown
- 2018-06-12 CA CA3066083A patent/CA3066083C/en active Active
- 2018-06-12 EA EA201992722A patent/EA201992722A1/en unknown
- 2018-06-12 AU AU2018286361A patent/AU2018286361B2/en active Active
- 2018-06-12 JP JP2019568682A patent/JP6945015B2/en active Active
- 2018-06-12 WO PCT/KR2018/006644 patent/WO2018230934A1/en unknown
- 2018-06-12 MX MX2019014548A patent/MX2019014548A/en unknown
- 2018-06-12 US US16/622,057 patent/US11253516B2/en active Active
- 2018-06-12 BR BR112019026253-9A patent/BR112019026253A2/en not_active Application Discontinuation
- 2018-06-12 EP EP18816671.4A patent/EP3640246B1/en active Active
- 2018-06-12 ES ES18816671T patent/ES2969701T3/en active Active
- 2018-06-12 CN CN201880039329.5A patent/CN110740999A/en active Pending
- 2018-06-12 KR KR1020180067349A patent/KR102023156B1/en active IP Right Grant
- 2018-06-12 PL PL18816671.4T patent/PL3640246T3/en unknown
-
2019
- 2019-12-03 SA SA519410722A patent/SA519410722B1/en unknown
- 2019-12-06 CL CL2019003589A patent/CL2019003589A1/en unknown
- 2019-12-09 IL IL271291A patent/IL271291B2/en unknown
- 2019-12-11 ZA ZA2019/08241A patent/ZA201908241B/en unknown
-
2022
- 2022-02-18 US US17/675,917 patent/US20220249482A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201908241B (en) | 2021-04-28 |
MX2019014548A (en) | 2020-02-07 |
SA519410722B1 (en) | 2023-03-15 |
JOP20190281A1 (en) | 2019-12-02 |
KR20180135815A (en) | 2018-12-21 |
EP3640246A4 (en) | 2020-08-05 |
KR20180135781A (en) | 2018-12-21 |
AU2018286361A1 (en) | 2020-01-16 |
ES2969701T3 (en) | 2024-05-22 |
IL271291A (en) | 2020-01-30 |
WO2018230934A1 (en) | 2018-12-20 |
CL2019003589A1 (en) | 2020-07-03 |
NZ760089A (en) | 2022-10-28 |
CA3066083C (en) | 2021-11-30 |
KR102023156B1 (en) | 2019-09-19 |
IL271291B2 (en) | 2023-02-01 |
EP3640246A1 (en) | 2020-04-22 |
JP2020523360A (en) | 2020-08-06 |
CN110740999A (en) | 2020-01-31 |
EP3640246C0 (en) | 2023-11-01 |
CA3066083A1 (en) | 2018-12-20 |
BR112019026253A2 (en) | 2020-06-23 |
EP3640246B1 (en) | 2023-11-01 |
JP6945015B2 (en) | 2021-10-06 |
PL3640246T3 (en) | 2024-04-22 |
US20200179384A1 (en) | 2020-06-11 |
IL271291B (en) | 2022-10-01 |
EA201992722A1 (en) | 2020-04-02 |
AU2018286361B2 (en) | 2020-11-19 |
US11253516B2 (en) | 2022-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220249482A1 (en) | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | |
US11504375B2 (en) | ErbB/BTK inhibitors | |
US8314234B2 (en) | Bicyclic pyrimidine kinase inhibitors | |
KR102383200B1 (en) | pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
EP2595964A1 (en) | Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them | |
KR102267662B1 (en) | Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
JP2024527599A (en) | Novel pyrimidine-2,4-diamine derivatives, their preparation process, and pharmaceutical compositions containing them as active ingredients for preventing or treating cancer | |
AU2018224359B2 (en) | 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as IKKE, TBK1 and/or SIK2 kinases inhibitors | |
EP4382514A1 (en) | Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | |
CA3211588A1 (en) | Novel pyrimidine derivative showing inhibition effect on growth of cancer cells | |
NZ793115A (en) | N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | |
EA041822B1 (en) | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF CANCER | |
KR102568168B1 (en) | Novel pyrimidine-2,4-diamine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
US20220324874A1 (en) | N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer | |
US20230293535A1 (en) | Erbb/btk inhibitors | |
US20220289733A1 (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
KR20230022393A (en) | Pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
CN117794914A (en) | Pyrimidine-2, 4-diamine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, KWANGHO;SHIN, INJI;CHOI, GILDON;AND OTHERS;REEL/FRAME:060948/0033 Effective date: 20191128 |